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“Dream is not what you see in sleep. It is the thing which does       
  not let you sleep.”  Dr. A. P. J. Abdul Kalam  
 
Abstract 
 
B. Dulla, PhD thesis (2013)  
 
Abstract: 
The majority of pharmaceuticals and biologically active agrochemicals are heterocyclic 
compounds; it represents their immense importance in serving mankind. The purpose of this 
thesis was to investigate feasibility of making potential biological active noval heterocyclic 
compounds designed based on lead molecules. The work accomplished in this thesis includes 
five different chapters to explain importance, achieve simple and fused-ring heteropolicyclic 
systems having potential pharmacological properties. 
  
The first chapter briefly explains importance of heterocyclic compounds and research 
objective.  
 
The second chapter of thesis concerns with target-oriented synthesis to access complex 
dehydro shikimate analogues containing a pyridine/isoquinoline unit with antitubercular 
activities with MIC: 4-10µM. Third chapter deals with study of novel synthetic approach to 
the one pot synthesis of 2H-benzo[b] [1,4]oxazines with anti inflammatory activites.  
 
In the fourth chapter is presented as a series of functionalized phenyl oxazole derivatives 
were designed, synthesized and screened in vitro for their activities against LSD1 and for 
effects on viability of cervical and breast cancer cells (IC50: 1-10 nM), and in vivo for effects 
using zebrafish embryos. Indeed it also explains the designing and cost effective route to 
synthesis of LSD1 inhibitors. Finally, fifth one is related to the intramolecular 1,3-dipolar 
cycloaddition of isovanillin derived N-aryl hydroxylamines possessing ortho-allylic 
dipolarophiles affords novel benzo analogues of tricyclic isoxazolidines that can be readily 
transformed into functionalized lactams, γ-aminoalcohols and oxazepines. The corresponding 
N-unsubstituted hydroxylamines give rise to tetrahydroisoquinolines. Anxiogenic properties 
of these compounds were tested in zebrafish.   
 
Moreover, in all chapters in silico docking studies were performed to predict binding 
interactions of the most potent scaffolds synthesized and reported inhibitors with the selected 
targets. At the end of each chapter are drawn a series of conclusions, concerning the 
investigations performed and the results obtained. Prof. Dr. Oliver Reiser (advisor), Prof. Dr. 
Javed Iqbal (advisor), Prof. Joachim Wegener, Prof. Dr. Robert Wolf (Committee Members).
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List of Abbreviations 
 
Abs  absolute 
AIDS                 acquired immunodeficiency syndrome  
aq  aqueous 
Bn  benzyl 
Bz  benzoyl 
Bu  butyl 
CCDC                cambridge crystallographic 
                           data centre 
calcd  calculated 
cat  catalytic 
CI  chemical ionization (MS) 
d  day(s) 
DCM  dichloromethane 
DMAP  4-dimethylaminopyridine 
DMF  dimethylformamide 
DMSO  dimethyl sulfoxide 
dr  diastereomeric ratio 
EI  electron impact (MS) 
ent  enantiomer 
equiv  equivalent(s) 
ESI  electrospray ionization (MS) 
Et  ethyl  
EtOAc  ethyl acetate 
GC  gas chromatography 
h  hour(s) 
HPLC  high-pressure liquid  
                          chromatogaphy 
HRMS  high resolution mass  
                           spectrometry 
Hz  hertz 
HIV                   human immunodeficiency virus 
i  iso 
IR  infra red spectroscopy 
LAH  lithium aluminium hydride 
LSD1                 lysine specific demethylase1 
LORA               low oxygen recovery assay                                
 
M  molar / metal 
Me  methyl 
µM                     micro molar 
min  minute(s) 
mp  melting point 
MS  mass spectroscopy 
Mtb                    mycobacterium tuberculosis 
NMR  nuclear magnetic resonance 
nd  not determined 
no  number 
NOE  nuclear Overhauser effect 
Nu  nucleophile 
ORTEP              oak ridge thermal ellipsoid   
                           plot  
PDE4B               cAMP-specific 3',5'-cyclic  
                           phosphodiesterase 4B 
PE  hexanes 
ppm  parts per million 
Ph                      phenyl 
PDB                   protein data bank 
quant  quantitative 
rac  racemic 
rt  room temperature 
t  tert 
SDH                  shikimate dehydrogenase 
TBAF  tetra-n-butylammonium 
                          fluoride 
TBS  tert-butyldimethylsilyl 
TBSCl  tert-butyldimethylsilyl  
                          chloride 
TFA  trifluoroacetic acid 
THF  tetrahydrofuran 
TLC  thin layer chromatography 
TNF-α               tumor necrosis factor alpha   
Ts  tosyl 
wt  weight 
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2. Design, synthesis & pharmacological evolution of dehydro 
shikimate analogues as potential antitubercular agents 
 
1 Introduction: 
1.1 Definition:  
Tuberculosis is an infectious disease characterized by the growth of nodules (tubercles) in 
the tissues, especially in the lungs. Bacillus Mycobacterium tuberculosis is the etiological 
agent of TB belonging to the genus Mycobacterium, which is presumed to have originated 
more than 150 million years ago. Tuberculosis (TB) is one of the leading causes of death 
due to a single infectious organism in the world. It typically affects the lungs (pulmonary 
TB) but can affect other sites as well (extrapulmonary TB).1 The probability of developing 
TB is much higher among people infected with the Human Immunodeficiency Virus 
(HIV).   
1.2  Pathogenesis of tuberculosis 
The primary mode of transmission of M. tuberculosis (Mtb) is through the air in an 
aerosolized form, most commonly when pulmonary TB bacteria are expelled via a cough 
or sneeze from people who are sick with TB.2 The infective droplet nuclei trapped in 
nasopharynx and the upper respiratory tract enters the alveoli, whereby they are ingested 
by the alveolar macrophages through the process of phagocytosis. In this early stage of the 
infection, Mtb is able to replicate within non-activated macrophages.3 However the body 
subsequently mounts a cell-mediated immune response to the growing mycobacterium via 
the activation of macrophages with interferon-γ which controls Mtb infection, but not 
wiped out the bacteria from the host.3, 4 In fact, the remaining mycobacterium will enter 
into the non-replicating persistence phase (latent stage of the infection). Mtb can reside in 
alveolar macrophages, avoiding the host immune response for an indefinite period of time. 
Such latent mycobacterium can get activated anytime later, especially when the host has 
immune deficiency.  
  1.3 Overview of TB infection and host defence: 
 There are three potential outcomes of infection of the human host in M. tuberculosis.  
    a) The frequency of spontaneous healing is unknown, but is assumed to be rare. 
    b) Disease progression immediately after infection in the immunocompromised host.  
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    c) In the majority of cases, mycobacteria are initially contained and the disease    
        progresses later due to reactivation.  
 
Figure 1: Overview of TB infection and host defence. 
The granuloma is the major site of infection, which develops from infected    macrophages a n d  becomes 
surrounded by lymphocytes. Effector T cells (CD4+CD8+ T cells, and double-negative or CD4/CD8 single-
positive T cells that recognize antigen presented by CD1) and macrophages participate in the control of TB. 
Crucial macrophage activators interferon-γ  (IFN-γ)  and  tumor-necrosis   factor-α   (TNF-α)   are  produced  
by  T  cell  and  macrophages  respectively. Macrophage activation permits phagosomal maturation and the 
production of antimicrobial molecules such as reactive nitrogen intermediates (RNI) and reactive oxygen 
intermediates (ROI). E x t r a c t e d  f r o m  N a t u r e  R e v i e w s  I m m u n o l o g y  1 ,  2 0 - 3 0  ( O c t o b e r  2 0 0 1 )  
w i t h  l i c e n c e .  
1.4 Epidemiology of tuberculosis  
The burden of disease caused by TB can be measured in terms of incidence, prevalence, 
and mortality. Globally, the absolute number of incident TB cases per year has been 
falling since 2006, if these trends are sustained; the MDG (Millennium Development 
Goals) target that TB incidence should be falling by 2015 will be achieved. 
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1.5 Structure and Mechanism of action of anti tubercular drugs 
The available chemotherapies for M. tuberculosis are mainly relies on drugs which inhibit 
bacterial metabolism with a special significance on inhibitors of the cell wall synthesis.  
 
Table 1:  Example of anti TB drugs and their mode of action  
Drug Drug mechanism of action 
Isoniazid (INH) (1952) 
 
 
 
Ethionamide (ETH) (1956) 
 
 
 
 
Ethambutol (EMB) (1961) 
 
 
 
 
 
Rifampicin (RIF) (1966) 
 
 
 
 
 
 
Pyrazinamide (PYR) (1952) 
 
 
 
 
Streptomycin  (STREP) (1944) 
 
 
 
 
 
Inhibition of mycolic acid biosynthesis and other 
multiple effects on DNA, lipids, carbohydrates and 
NAD metabolism 
 
Inhibition of mycolic acid biosynthesis 
 
 
Inhibition of cell wall arabinogalactan (AG) 
biosynthesis 
 
                                                                                
 
 
Inhibition of transcription 
 
 
 
Acidification of cytoplasm and de- energising the   
membrane 
 
 
Inhibition of protein synthesis 
 
The currently available first and second line TB drugs can be grouped as cell wall 
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inhibitors (isonizid (INH), ethambutol, ethionamide), nucleic acid synthesis inhibitors 
(rifampicin (RIF), quinolones), protein synthesis inhibitors (streptomycin, kanamycin) and 
inhibitors of membrane energy metabolism (pyrazinamide). 
 
1.6  Classification of antitubercular drugs: 
Tuberculosis treatment includes three basic concepts which are as follows: (1) Regimens 
must contain multiple drugs to which the organism is susceptible. (2) Drugs must be taken 
regularly. (3) Drug therapy must continue for a sufficient time. Traditionally, 
antituberculosis drugs are classified as first line drugs are superior in efficacy and posses an 
acceptable degree of toxicity. If the M. tuberculosis organisms are resistant to the first line 
drugs, second-line drugs will be preferred which are more toxic and less effective and they 
are indicated only agents. 
  Table 2:  Examples of 1st line and 2nd line drugs with characteristics 
 Characteristics Drugs 
First line drugs 
(Essential anti TB drugs) 
High anti TB effect, 
acceptable degree of 
toxicity, used routinely 
Isoniazid, Ethambutol, 
Rifampicin, Pyrazinamide, 
Streptomycin   
Second line drugs 
(Reserved anti TB drugs) 
Low anti TBeffect, high 
degree of toxicity, used in 
special circumstances 
PAS, Amikacin, 
Capreomycin, Ethionamide, 
Kanamycin, Cycloserine 
 
The common side effects to these antituberculosis drugs include hepatitis, cutaneous 
reactions, gastrointestinal intolerance, haematological reactions and renal failure which must 
be adverse effects must be recognised early, to reduce associated morbidity and mortality. 
 
1.3  TB Drug resistance                    
This disease is complicated by the human immunodeficiency virus (HIV), TB turns out to be 
most opportunistic co-infection which is growing at an alarming rate with the increase of 
world human population.5,6 The disease poses a major threat to the human life with the recent 
emergence of multidrug-resistant (MDR) and extensively drug resistant (XDR)-TB. Because 
of its increasing prevalence MDR-TB is now subdivided into ‘basic’ MDR-TB, with 
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resistance only to rifampicin and isoniazid, and ‘MDR-TB-plus’, with a similar resistance 
pattern but with resistance to one or more additional first- and/or second-line drugs. The 
most effective drug regimen is endorsed by the WHO and is called Directly Observed 
Treatment, Short-course (DOTS), developed to fully supervise those patients deemed high-
risk for non-drug adherence.7 Since this disease poses a major threat to the human life it 
requires an immediate attention for the identification and development of novel antitubercular 
drugs.8 
 
2. Shikimate pathway:  
The shikimate pathway plays a pivotal role in the biosynthesis of   precursors for aromatic 
amino acids, vitamins, quinones, and a variety of other aromatic compounds in bacteria, 
plants, fungi, and apicomplexa parasites.9 The end product of the shikimate pathway is 
chorismate, which is converted to precursors of a host of secondary metabolities essential 
for the survival of these organisms. (Figure 2) Shikimate is the first intermediate identified, 
isolated from fruit of Illicium religiosum (commonly known as the Japanese star anise, 
shikimi) which gave the name to this pathway.10  
 
 
 
 
 
 
 
 
Figure 2: Shikimate pathway 2 (self drawn) 
1st step: The  shikimate  pathway  begins  with  the  aldol condensation  of two  
phosphorylated  'household  metabolites',  phospho enolpyruvate (PEP) and  D-erythrose 4-
phosphate (E4P) catalyzed by 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP) 
synthase. Based on sequence similarity, DAHP synthases are classified into two types. Type 
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II DAHP synthases are found in plants and some microbes (e.g., Mycobacterium 
tuberculosis). 
2nd step: 3-Deoxy-D-arabino-heptulosonate-7-phosphate undergoes five consecutive 
chemical reactions: alcohol oxidation, β-elimination of inorganic phosphate, carbonyl 
reduction, ring opening, and intramolecular aldol condensation performed by 3-dehydro 
quinate synthase (DHQS) in one active site  using a divalent cation (e.g., Co2+) and NAD+ 
cofactors to form 3-dehydro quinate.                                                                        
3rd step: The third enzymatic reaction include the dehydration of 3-dehydroquinate to 3-
dehydroshikimate to introduce the first double bond by 3-dehydro dehydratase (DHD).         
4th step: Shikimate dehydrogenase plays an important role in catalyzing the fourth step in 
the shikimate pathway involving the reversible conversion of 3-dehydro shikimate (DHS) 
and NADPH to yield shikimate, a 3,4,5-trihydroxycyclohexene-1-carboxylic acid and 
NADP+.   
5th step: Shikimate kinase (SK) phosphorylates the C3 hydroxyl group of Shikimate using 
ATP as a co substrate to yield shikimate 3-phosphate.    
6th step: 5-Enolpyruvylshikimate-3-phosphate synthase (EPSP) catalyzes the penultimate 
step of the shikimate pathway, the addition of enolpyruvyl moiety of phospho enolpyruvate 
(PEP)   to the 5-hydroxyl group of shikimate-3-phosphate.   
7th step:   The last step of the synthesis  of  aromatic  amino  acids, vitamins and quinones 
catalyzed  by  chorismate  synthase  (CS) involves  a  1,4-trans  elimination  of  phosphoric 
acid  from  5-enolpyruvylshikimate  3-phosphate introducing the second double bond in 
the ring to produce chorismate.11 
Importantly the shikimate pathway has been shown to be essential for the viability of 
Mycobacterium tuberculosis.12 The absence of the shikimate pathway in humans and its 
indispensible importance in algae, higher plants, bacteria, and fungi makes it a potential 
target for the development of novel antitubercular agents.13  
3. Design of new and potential antitubercular agents from known DHS analogues: 
Shikimate dehydrogenase was chosen as the target since it occurs early in the pathway and 
also due to easy accessibility of its synthetic analogue. 
a. In 1961, D. Balinsky. et al.  reported studies on shikimate dehydrogenase inhibition 
with a variety of substituted phenols. They disclosed that both dehydroshikimic acid (1) 
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and shikimic acid (2) (figure 3) bind to the enzyme by means of the –COOH and OH 
groups at C4, C5 respectively. 14 
O
OH
COOH
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4
5
6
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OH
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3
4
5
6
1 2   
Figure 3: Structures of dehydro shikimic acid, shikimic acid 
b. In 1972, A. C Baillie. et al. reported active site directed inhibitors based on D. Balinsky. 
et al results. They have designed a novel dehydroshikimate analogue 1, 6-dihydroxy-2-
oxoinicotinic acid (3; R =H) [a tautomeric form of citrazinic acid 1-oxide (4)] (figure 4) 
in which the amide carbonyl should be less susceptible to enzyme reduction than the 
keto carbonyl of the natural substrate.  
NO
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aryl  
Figure 4: Structures of dehydro shikimate analogues 
They found that a hydrophobic area exists near the active site of the enzyme, since a 
series of 6-O-alkyl derivatives of compound 3 bound almost similarly like the parent 
compound 1. Maximum binding was obtained with the isopropyl ether. 15   
c.  In 1972, Floss et al. demonstrated that the substituent on C-6 of 3-dehydro quinate (5) 
are not directly involved in any reaction until chorismate synthase step. This was further 
supported by S. Bornemann. et al. in 1995,                                                              
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Figure 5: Synthesis of 6-fluoro chorismic acid 
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through enzymatic conversion of 6α-fluoro-5-enolpyruvylshikimate-3-phosphate (6) to 
6-fluorochorismic acid (7) at 0.3% rate with the normal substrate.16 
d. In 1988, A. B. Chris. et al. discussed about the specificity of shikimate dehydrogenase 
towards analogues of 3-dehydroshikimc acid. Treatment of (8) with DHS (Shikimate 
dehydrogenase) and NADPH rapidly gave (3R, 4S)-3, 4-dihydroxycyclohex-1-
enecarboxylic acid (9). 17 
O
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6
HO
OH
COOH
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2
3
4
5
6DHS, NADPH
8 9  
Figure 6:  Synthesis of (3R, 4S)-3, 4-dihydroxycyclohex-1-enecarboxylic acid 
Moreover, the results  indicate  that  for  the  C-5  hydroxyl group  the  apparent  binding  
energy  (∆Gapp)  is  1.8 kJ  mol-1, whereas  for  the  C-4  hydroxyl  group  ∆Gapp=  29 kJ  
mol-1.  This  demonstrates  that  removal  of the  C-5  hydroxyl  group  has  little  effect  
on  specificity,  but  removal  of the  C-4  hydroxyl  group  is  very  significant.  The  
observed  loss  of  specificity  on  removal  of  the  C-4  hydroxyl group  suggests  
removal  of  a  hydrogen  bonding  interaction  between  substrate  and a charged  group  
at the  enzyme  active  site. 
Prompted by these observations and due to our continuing interest in the identification of 
novel small molecules as potential antitubercular agents we became interested in evaluating 
1, 6-dihydroxy-2-oxoinicotinic acid (A) and a series of pyridine-4-carboxylic acid 
derivatives (B and C, Figure 7) for their potential antitubercular properties.  
N
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N
COY
O
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C
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X = Cl, OR3
Y = OH, OR3, NHNH2
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Figure 7: Design pyridine-4-carboxylic acid derivatives from a known DHS analogue A 
The target compounds were achieved by introducing a fused ring with or without any 
substituent at C-5 and C-6 positions into the 2-pyridone moiety of A and/or converting the 
carboxylate group into an ester or carbohydrazide moiety (Figure 7). 
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4. Results and discussion:  
4.1 Chemistry: The synthesis of our target molecules based on B and C primarily consisting 
of three different classes of protocols known in literature. 
4.11. Synthesis of substituted 3-cyano-2-pyridone derivatives from appropriate methyl 
ketones followed by converting them into corresponding 1-hydroxy-2-pyridone 
derivatives via 5 steps. 
4.1.2 Synthesis of 2-oxo-1, 2-dihydroquinoline-4-carboxylic acids from appropriate 
indoline-2, 3-diones were converted to the corresponding 1-hydroxy-2-oxo-1, 2-
dihydroquinoline-4-carboxylic acid derivatives in 3 steps. 
4.1.3 Construction of 1-hydroxy 2-pyridone 4-carboxylic acid ring fused with different 
substituted uracil derivatives in 5 steps. 
 
4.1.1 Synthesis of 1-hydroxy-2-oxo-1,2-dihydropyridine-4-carboxylic acid derivatives 
The 3-cyano-2-pyridone derivatives  prepared by treating appropriate ketones with 
cyanoacetamide in the presence of  NaOEt, were converted to 2-pyridonecarboxylic acids and 
subsequently to 2-chloro ester derivatives (Scheme 1).18 The acid (12a) was also converted to 
the corresponding ester (13e) (synthesized to explore chemistry at C5-C6 double bond like 
cyclopropanation, epoxidation, which was however unsuccessful) as shown in Scheme 1.19 
Treating the compounds (13a-d) with m-CPBA provided the corresponding N-oxides 14a-d 
that were converted to 1-hydroxy-2-pyridone derivative 15a or 2-ethoxy pyridine N-oxides 
15b-c depending on the reaction conditions employed.20, 21 Finally, the ester 15a was 
hydrolyzed to the corresponding acid 16a and the acids 15b-c was transformed into the 
corresponding 1-hydroxy 2-pyridone derivatives 17a-b. 22, 23 
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Scheme 1. Synthesis of 1-Hydroxy-2-oxo-1,2-dihydropyridine-4-carboxylic acid derivatives 
(B) 
The dehydro shikimate analogue A (or 21) was prepared according to a known method as 
shown in Scheme 2. Initially the N-oxide 19 was synthesized from 18 using m-CPBA, DCM 
at rt for 36 h affords 40% of yields. Similarly substitution of chlorides in 19 with NaOEt 
(commercially available) affording 20 in 35% yield according to the literature protocols22  
Yields 
 however did not exceed 30% even after 5 times repeatition of experiments using above 
protocols which could be improved to 66% by following the reaction protocol of Zhu et. al.  
24
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   Scheme 2.  Synthesis of 1, 6-dihydroxy-2-oxoisonicotinic acid A (11).22 
4.1.2 Synthesis of 1-hydroxy-2-oxo-1, 2-dihydroquinoline-4-carboxylic acid derivatives 
The synthesis of other target molecules based on B is shown in Scheme 3. The 2-oxo-1,2-
dihydroquinoline-4-carboxylic acid derivatives (23a-d) 25a prepared from appropriate 
indoline-2, 3-diones (22a-d) were converted to the corresponding 2-chloro ester derivatives 
(24a-d).25b Treating these compounds with H2O2 provided the corresponding N-oxides (25a-
c) that were converted to the desired 1-hydroxy-2-oxo-1,2-dihydroquinoline-4-
carboxylicacidderivatives (26a-c).22  
Results & discussion – Chapter 2 
 
B.Dulla, PhD thesis (2013) Page 15 
 
N
H
R
O
O
R = H, 22a
CH3, 22b
F, 22c
NO2, 22d
CH2(CO2H)2
AcOH
Reflux
12 h
N
H
COOH
O
R
R = H, 23a
CH3, 23b
F, 23c
NO2, 23d
1.POCl3
Reflux
3 h
2.SOCl2
Reflux, 2 h
ROH, Et3N
Reflux, 2 h
N
COOR1
Cl
R
R = H, 24a
CH3, 24b
F, 24c
NO2, 24d
Na2CO3,
1.5 H2O2
CH3CN
Tf2O, 0°C, 1h
rt, 16 h
R1= CH3, C2H5
68-80 %
65-70 %
70 - 75 %
N
COOR1
Cl
O
R Na, R1OH
100°C;2 h
0 °C, HCl,1 h
60-68%
NO
COOH
OH
R
R = H, 25a
CH3, 25b
F, 25c
R = H, 26a
CH3, 26b
F, 26c
 
Scheme 3. Synthesis of 1-hydroxy-2-oxo-1, 2-dihydroquinoline-4-carboxylic acid derivatives 
 
Synthesis of 2-chloro acid derivatives  
2-chloro acid derivatives (27a-d), (28a-c) were synthesized from precursors 14a-d, 25a-c 
respectively as shown in Scheme 4. The reactions were carried out in the presence of 
LiOH•H2O in these cases. 23 
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Scheme 4.  Synthesis of 2-chloro acid derivatives (16) 
Synthesis of 2-oxo-1, 2-dihydropyridine/quinoline-4-carbohydrazide derivatives: 
The ethyl-2-oxo-1, 2-dihydropyridine-4-carboxylate derivatives (29a-c and 31a-d) 26 were 
prepared from the appropriate 2-oxo-1, 2-dihydroquinoline-4-carboxylic acid derivatives 
(12b-d and 23a-d). The resulting ethyl esters were treated with hydrazine hydrate to afford 2-
oxo-1, 2-dihydropyridine-4-carbohydrazide derivatives (30a-b and 32a-d).27 
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Scheme 5. Synthesis of 2-oxo-1, 2-dihydroquinoline-4-carbohydrazide derivatives  
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Scheme 6. Synthesis of 2-oxo-1, 2-dihydropyridine-4-carbohydrazide derivatives  
 
4.1.3 Synthesis of 7-chloro-2, 4-dioxo-1-propyl-1, 2, 3, 4-tetrahydropyrido [2, 3-d] 
pyrimidine derivatives  
The 4-methylcarboxylate-2-pyridone derivatives (34a, 34b) were synthesized by refluxing 
uracil derivatives  with dimethyl acetylenedicarboxylate in MeOH 28 which were on 
hydrolysis converted to 2-pyridone carboxylic acids (35a, 35b) and subsequently to 2-
chloro ester derivatives (36a, 36b) (Scheme 7). Treating the compounds 36a, 36b with 
several per acids did not provide the corresponding N-oxides. Hydrolysis of 36a with 
LiOH•H2O provided the compound 36c.                                              
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O
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= n-propyl 37b
 
Scheme 7.  Synthesis of 7-chloro-2,4-dioxo-1-propyl-1, 2, 3, 4-tetrahydropyrido[2, 3-d] 
pyrimidine derivatives. 
 
ORTEP diagrams: 
While all the compounds synthesized were characterized by spectral (NMR, IR and MS) data 
the molecular structure of few representative compounds for example, 13e, 15a, and 15b 
were confirmed unambiguously by single crystal X-ray diffraction (Fig 8, 9 and 10). 
HN COOC3H7
O  
Figure 8: ORTEP representation of the 13e (C10H13NO3). (Thermal ellipsoids are drawn at 
50% probability level). 
N
O
HO
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Figure 9: ORTEP representation of the 15a (C8H9NO4). (Thermal ellipsoids are drawn at 
50% probability level). 
N
O
COOH
O
 
Figure 10: ORTEP representation of the 15b (C11H13NO4.H2O). (Thermal ellipsoids are 
drawn at 50% probability level). 
4.2 Pharmacology: 
Pharmacological testing was performed at the Institute for Tuberculosis Research, College of 
Pharmacy, in the group of Prof. Scott G. Franzblau, University of Illinois at Chicago. 
All the compounds synthesized initially were tested for their activity against M. tuberculosis 
H37Rv, which was determined by using fluorescence readout in the Microplate Alamar Blue 
Assay (MABA).29 The compounds found promising in this assay were then tested for their 
activity against non-replicating M. tuberculosis, which was determined by using the Low-
Oxygen Recovery Assay (LORA).30
 
The well-known agents such as rifampicin 
(asemisynthetic bactericidal antibiotic drug), isoniazide (or isonicotinylhydrazine, an 
antitubercular agent) and moxifloxacin (a fluoroquinolone antibacterial agent) were used as 
reference compounds in these assays. Finally, the cytotoxicity assay31 of the most active 
compound was carried out using Vero cells.  
Among all the compounds tested quinoline-1-oxides i.e. 25a, 25b, and 25c were found to be 
promising in MABA assay (Table 3). Indeed, compound 25b showed the lowest MIC i.e. 
4.33 µg/mL among them. This compound also showed the lowest MIC i.e. 3.65 µg/mL in 
LORA assay (Table 3). Finally, this compound showed IC50 value < 8.0 µg/mL in the 
cytotoxicity assay in Vero cells. Among the other compounds 12a-d, 16, 15a-c, and 23a-d 
showed MIC ~ 50 µg/mL whereas rest of the compounds showed MIC ~ 100 µg/mL (see 
Results & discussion – Chapter 2 
 
B.Dulla, PhD thesis (2013) Page 19 
 
page 35) when tested in MABA assay. Notably, MIC of the known inhibitor of shikimate 
dehydrogenase 2122 and citrazinic acid were found to be >50 and100 µg /mL, respectively, 
in the same assay.  
Table 3. In vitro assay results of selected compounds. 
Compound   
MIC (µg/mL)a,c IC50 (µg/mL) b, 
MABA  LORA  Vero Cell  
25a             
          9.2 
 
         7.3              n.d. 
          25b 
  
4.33 
 
3.65 
 
         < 8.0 (96%) 
        25c    
           
        21                                                   
  
         10.9 
        
         > 50 
 
        13.1 
         
        n.d. 
 
n.d. 
 
n.d. 
Citrazinic acid 
   
  > 100 
 
 n.d.     n.d. 
Rifampicin  0.05 1.47 n.d. 
Isoniazide   0.33 > 128 
(84%) 
n.d. 
Moxifloxacin 0.39 15.93 n.d. 
 n.d. = not determined. a MIC value obtained was defined as the lowest concentration inhibiting recovery of 
luciferase signal, greater or equal to 90% relative to bacteria-only controls. b IC50 represent the concentration of 
compound that causes a 50% growth inhibition to untreated cells using the MABA assay.  
Nevertheless, the compound 25b though found to be less effective than the reference 
compounds employed in MABA assay but was comparable or better than rifampicin, 
isoniazide and moxifloxacin in LORA assay. Overall, the compound 25b appeared as 
attractive new chemical entity due to its interesting and novel structural features. 
4.2 Molecular docking studies   
Molecular docking studies were done by K. Ravi Kumar at Institute of Life Sciences, India. 
 To understand the nature of interactions of these molecules with the shikimate 
dehydrogenase protein of Mycobacterium tuberculosis (SDHmt), in silico docking studies 
were performed using compounds 25a–c along with the known inhibitor of shikimate 
dehydrogenase 22 21. An SDHmt protein homology model was developed and used for this 
purpose. The dock scores obtained after docking these molecules into the SDHmt protein are 
summarized in Table 4. It is evident from Table 4 that in compared to compound 21 these 
molecules (25a–c) bind better with SDHmt the compound 25b being the best among them. 
The ligand interaction and binding pose of compound 25a–c with SDHmt protein is shown in 
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Figs. 12–14. All these molecules were found to interact with the SDHmt protein through H-
bonding. For example, compound 25a with Arg 29 or 25b with Lys69 or 25c with Arg29 
residue of the protein used. Additionally, the fused ring (introduced by drug design approach, 
see Figure 14) that is, the benzene ring fused with the pyridine moiety participated well in 
hydrophobic interactions in all these cases.  
 
 
Figure 11: (a) Interaction mode of compound 25a with SHMDt showing H-bonding (pink dotted 
line) with Arg 29. (b) Binding pose of compound 25a in SHMDt protein represented in electrostatic 
potential solid surface. (c) 2D interaction diagram of compound 25a with SHMDt protein 
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Figure 12:  (a) Interaction mode of compound 25b with SHMDt showing H-bonding (pink 
dottedline) with Arg 29. (b) Binding pose of compound 25b in SHMDt protein represented in 
electrostatic potential solid surface. (c) 2D interaction diagram of compound 25b with SHMDt 
protein 
 
Figure 13: (a) Interaction mode of compound 25c with SHMDt showing H-bonding (pink dotted 
line) with Arg 29. (b) Binding pose of compound 25c in SHMDt protein represented in electrostatic 
potential solid surface. (c) 2D interaction diagram of compound 25c with SHMDt protein 
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Overall, the docking studies indicated that the present N-oxides 29 25a–c could be potential 
inhibitors of shikimate dehydrogenase and are of further interest.  
 
Docking study 
The molecular docking simulation was performed using Chemical Computing Group’s 
Molecular Operating Environment (MOE) software 2008.10 Version, ”DOCK” application 
Module. The molecules 25a, 25b and 25c were docked into the Shikimate Dehydrogenase 
Protein of Mycobacterium tuberculosis (SDHmt) and their respective docking scores (Table 
1) and interactions were observed. 
 
 
 
 
 
Table 4. Dock scores obtained after docking the molecules into the SDHmt protein 
 
 
 
 
 
The purpose of the dock application was to search for favorable binding configurations in 
macromolecular target, which is usually a protein. For each ligand, a number of 
configurations called poses were generated and scored in an effort to determine favorable 
binding modes. For all scoring functions, lower scores indicated more favorable poses. 
 
5. Summary 
Based on the reported assay results of a novel DHS analogue i.e. 1, 6-dihydroxy-2-
oxoisonicotinic acid against shikimate dehydrogenase a series of fused and functionalized 
pyridine derivatives were designed, synthesized and tested for their potential antitubercular 
properties. All these pyridine based compounds were prepared by using multistep methods 
involving the construction of pyridine ring as a key synthetic step followed by further 
functionalization reactions. The single crystal X-ray diffraction study was used to confirm the 
Molecules MOE Dock score (K.cal/mol) 
25a -10.03 
25b -12.84 
25c -10.93 
21 -8.87 
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molecular structure of three representative compounds unambiguously. To the best of our 
knowledge synthesis of the class of designed compounds was not known in the literature. 
Few of these compounds were found to be interesting when tested in vitro. Based on in vivo 
(LORA assay) studies indicated that 25b better than rifampicin, isoniazide and moxifloxacin. 
Overall, compound 25b appeared as an attractive and potential antitubercular agent and its 
strong binding with SDHmt protein was supported by docking studies.   
 
6. Experimental section 
6.1 Chemistry - General methods 
All reactions were carried out in oven dried glassware under atmospheric conditions unless 
otherwise stated. Commercially available chemicals were used as received, without any 
further purification. The following solvents and reagents were purified prior to use: 
Dichloromethane (DCM) was distilled from CaCl2 and stored over molecular sieves (4 Å). 
Dimethylformamide (DMF) dried with CaH2, distilled and stored over molecular sieves (4 
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Å). Ethyl acetate (EA) and hexanes (PE) for chromatographic separations were distilled prior 
to use.  
Chromatography 
Analytical thin layer chromatography was performed on Merck TLC aluminium sheets silica 
gel 60 F254. Visualization was accomplished with UV light (λ = 254 nm). Vaniline, ninhydrin, 
mostain and permanganate solutions followed by heating or iodine were used for staining. 
Liquid chromatography was performed using Merck silica gel 60 (0.063 - 0.200 mm) and 
flash silica gel 60 (0.040 - 0.063 mm). 
 
NMR-Spectroscopy  
1H- and 13C-NMR spectra were recorded on a Bruker Avance 300 (300 MHz for 1H, 75 MHz 
for 13C), Bruker Avance III 400 “Nanobay” (400 MHz for 1H, 101 MHz for 13C) or Avance 
III 600 (600 MHz for 1H, 151 MHz for 13C) FT-NMR-Spectrometer at ambient temperature. 
Data are given  as follows for 1H-NMR: Chemical shift in ppm from internal CHCl3 (7.27 
ppm) or CH3OH (3.31 ppm) as standard on the δ scale, multiplicity (br = broad, s = singlet, d 
= doublet, t = triplet, q = quartet, dd = doublet of doublet, ddd = doublet of doublet of 
doublet, dt = doublet of triplet, qd = quartet of doublet, sept = septet and m = multiplet), 
integration and coupling constant (Hz). Data are as follows for 13C-NMR: Chemical shift in 
ppm from internal CHCl3 (77 ppm) or CH3OH (49 ppm) as standard on the δ scale.  
 
Mass spectrometry & IR spectroscopy and melting points 
Mass spectrometry was performed using Varian MAT 311A, Finnigan MAT 95, 
Thermoquest Finnigan TSQ 7000 or Agilent Technologies 6540 UHD Accurate-Mass Q-TOF 
LC/MS at the analytical department of the University of Regensburg. The percentage set in 
brackets gives the peak intensity related to the basic peak (I = 100%). High resolution mass 
spectrometry (HRMS): The molecular formula was proven by the calculated precise mass. 
ATR-IR spectroscopy was carried out on a Biorad Excalibur FTS 3000 spectrometer, 
equipped with a Specac Golden Gate Diamond Single Reflection ATR-System.The melting 
points were measured on a Büchi SMP-20 apparatus in a silicon oil bath. Values thus 
obtained were not corrected. 
Syntheses of literature-known compounds and reagents 
Methyl 2-chloro-6-methyl isonicotinate (13a)18,  Methyl 2-chloro-6,7-dihydro-5H-cyclopenta 
[b] pyridine-4-carboxylate (13b)19, Methyl 2-chloro-5,6,7,8-tetrahydroquinoline-4carboxylate  
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N
H
O
COOH
(13c)20,Methyl-2, 6-dichloroisonicotinate (18)22, Ethyl 2-chloroquinoline-4-carboxylate 
(24a)13, Ethyl 2-chloro-6-methylquinoline-4-carboxylate (24b)13,  Ethyl 2-chloro-6-
nitroquinoline-4-carboxylate(24d)13,14, 2-Oxo-1,2-dihydroquinoline-4-carbohydrazide 
(32a)19,10,  6-Methyl-2-oxo-1,2-dihydroquinoline-4-carbohydrazide (32b) 19,10, 6-Nitro-2-oxo-
1,2-dihydroquinoline-4-carbohydrazide (32d)19,18, 2,4,7-Trioxo-1-propyl-1,2,3,4,7,8-
hexahydropyrido [2,3-d] pyrimidine-5-carboxylicacid (35a)15, Methyl-2,4,7-trioxo-1,3-
dipropyl-1,2,3,4,7,8-hexahydropyrido[2,3-d]pyrimidine-5-carboxylate(35b)15. These 
compounds physical data matching with the literature reports and used as precursors for 
synthesis of the targeted molecules. 
6.2 Syntheses 
Ethyl-3-cyano-2-oxo-1,2,5,6,7,8,9,10-octahydrocycloocta[b]pyridine-4-carboxylate (11d):                
The compound was prepared in 75% yield according to reported procedure for methyl 2-
chloro-6-methyl isonicotinate (13a)18. Mp 278 °C, Rf: (silica gel, 6% 
MeOH in CH2Cl2): 0.60; IR (cm-1): 3444, 2858, 2228 (CN), 1740 (CO 
ester), 1656 (CO amide), 1247; 1H NMR (300 MHz, CDCl3) δ 1.29 -
1.36 (m, 7H), 1.54 -1.67 (m, 4H), 2.44-2.45 (m, 2H), 2.72-2.76 (m, 
2H), 4.41 (q, 2H), 12.85 (s, 1H); 13C NMR (75 MHz, CD3OD) δ 11.6, 23.9, 24.1, 24.3, 28.0, 
28.2, 29.2, 60.2, 114.2, 114.8, 121.68, 145.4, 147.6, 162.2, 165.2; MS (EI, 70ev) :  m/z (%) 
[M]+.   274.2 (27.56), 245.1 (100%); HRMS [M] + Calcd. for C15H18N3O3 274.1313; Found: 
274:1313. 
2-Oxo-1,2,5,6,7,8,9,10-octahydrocycloocta[b]pyridine-4-carboxylic acid (12d): 
The title compound was prepared in 75% yield according to the 
procedure described for Methyl 2-chloro-6-methyl isonicotinate 
(13a)18; Rf: 0.6 (CH2Cl2/ MeOH 1:1), mp 250 °C; IR (cm-1): 3388, 
2995, 2915, 1715 (CO acid), 1625 (CO amide), 1442, 1228; 1H NMR 
(300 MHz, DMSO-d6) δ 1.30-1.60 (m. 8H), 2.55-2.65 (m, 4H), 6.37 (s, 1H), 12.50 (bs, 1H), 
13.00 (bs, 1H); 13C NMR (75MHz, CD3OD) δ 23.9, 24.1, 24.3, 28.2, 29.2, 116.8, 118.4, 
134.3, 136.8, 163.2, 166.3; MS (EI, 70ev):  m/z (%) [M+H]+. 266.6 (100).  
Methyl2-chloro-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine-4-
carboxylate (13d):  
The title compound was prepared in 70% yield according to the general 
N
H
O
COOC2H5
NC
NCl
COOCH2CH3
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procedure as described above for Methyl 2-chloro-6-methyl isonicotinate (13a)18; Rf: 0.8 
(CH2Cl2), mp150 °C; IR (cm-1): 3050, 2944, 1721 (CO ester), 1557, 1458, 1273, 1200; 1H 
NMR (300MHz, CDCl3) δ   1.28 -1.47(m, 7H), 1.73 -1.84 (m, 4H), 3.00 (t, J = 6.4 Hz, 4H), 
3.91 (s, 3H), 4.38 (q, J = 4.6 Hz, 2H), 7.46 (s, 1H); 13C NMR (75MHz, CDCl3) δ 14.2, 25.8, 
26.48, 27.1, 30.7, 31.0, 35.4, 61.9, 121.5, 133.7, 140.8, 148.2, 164.5, 165.9; MS (EI, 70ev):  
m/z (%) [M]+ . 253.1 (100), 238.1 (88.95); HRMS [M]+ calcd. for C13H16ClNO2 253.0870; 
found: 253. 087. 
2-Chloro-4 (methoxycarbonyl)-6-methylpyridine-1- oxides (14a): 
A mixture of (0.5g, 2.7mmol) of 3-chloro-1-methylisoquinoline (12a), 
(0.8 g, 4.6mmol) of m-chloro per benzoic acid, and benzene (8 mL) was 
stirred until a solution formed and was allowed to stand at room 
temperature for 2 days. Treatment of the reaction mixture with sodium 
carbonate solution followed by extraction with dichloromethane 
afforded 0.35 g (60% yield) of crude product. Rf: 0.4 (30% EtOAc in Petroleum Ether), mp 
120 °C; IR (cm-1):  3066, 2928, 1716 (CO ester), 1527, 1439, 1235(N-O), 1176, 935(N-O); 
1H NMR (300 MHz, CDCl3) δ 2.50 (s, 3H), 3.87 (s, 3H), 7.73 (d, J = 2.4 Hz, 1H), 7.93 (d, J 
= 2.4 Hz, 1H) ; 13C NMR (75 MHz, CDCl3) δ 18.7, 52.9, 124.0, 124.6, 125.1, 142.4, 151.0, 
163.6; MS (EI, 70ev):  m/z (%) [M]+. 201(98.75), 184 (100). 
2-Chloro-4-(methoxycarbonyl)-6,7-dihydro-5H-cyclopenta[b]pyridine1-oxide(14b):          
The title compound was prepared in 70% yield according to the 
general procedure as described for (14a); Rf: 0.38 (30% EtOAc in 
Petroleum Ether), mp 180 °C; IR (cm-1): 3072, 2958, 1718 (CO ester), 
1536, 1439, 1225(N-O), 1136, 940 (N-O); 1H NMR (300 MHz, 
CDCl3) δ 2.16-2.27 (m, 2H), 3.19 (t, J = 7.8 Hz, 2H), 3.35 (t, J = 7.8 
Hz, 2H), 3.92 (s, 1H), 7.92 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 22.0, 30.4, 32.9, 52.6, 
123.1, 125.4, 140.0, 141.2, 155.5, 164.0; MS (EI, 70ev) :  m/z ( % ) [M]+ .  227.03(100). 
2-Chloro-4-(methoxycarbonyl)-5,6,7,8-tetrahydroquinoline 1-oxide (14c):  
The title compound was prepared in 75% yield according to the 
general procedure as described for (14a); Rf: 0.35 (30% EtOAc in 
Petroleum Ether), mp 123 °C; IR (cm-1): 3082, 2968, 1720 (CO 
ester), 1526, 1429, 1238 (N-O), 1166, 936 (N-O); 1H NMR (300 
MHz, CDCl3) δ 1.73 -1.77 (m. 2H), 1.86 -1.89 (m. 2H), 2.97 (t, J = 
NCl
COOCH3
O
NCl
COOCH3
O
NCl
COOCH3
O
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6.8 Hz, 2H), 3.09 (t, J = 6.9 Hz, 2H), 3.90 (s, 3H), 7.92 (s, 1H); 13C NMR (75 MHz, CDCl3) 
δ 21.1, 21.4, 26.4, 27.2, 52.6, 124.4, 125.1, 135.7, 138.9, 151.7, 164.5; MS (EI, 70ev): m/z 
(%) [M]+. 241.1(37.85), 192.1 (100). 
2-Chloro-4-(methoxycarbonyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine1-oxide(14d):              
The title compound was prepared in 72% yield according to the general procedure as 
described for (14a);  Rf: 0.4 (30% Et OAc in petroleum ether), mp 
110 °C; IR (cm-1): 3076, 2966, 1717 (CO ester), 1546, 1419, 1240(N-
O), 1166, 948 (N-O); 1H NMR (300MHz, CDCl3) δ 1.32 -1.47 (m. 
4H), 1.81 -1.85 (m, 4H), 3.12-3.30 (m, 4H), 3.90 (s, 3H), 7.88 (s, 
1H); 13C NMR (75MHz, CDCl3) δ 26.0, 26.7, 26.8, 26.9, 28.3, 30.9, 
52.7, 125.1, 138.7, 145.8, 155.0, 158.6, 164.8; MS (EI, 70ev):  m/z (%) [M]+. 269.1(22.96), 
252.1 (194.87), 220.1(100); HRMS [M]+ calcd. for C13H16ClNO3  269.081, found:  269.0816. 
 Methyl-1-hydroxy-6-methyl-2-oxo-1,2-dihydropyridine-4-carboxylate (15a):  
To a solution of (50 mg, 2.17 mmol) of sodium metal dissolved in 
Methanol (5 ml) was added (200 mg, 0.99mol) of Methyl 1-hydroxy-
6-methyl-2-oxo-1, 2-dihydropyridine-4-carboxylate. The solution was 
heated at reflux for 3 h. The solution was cooled and diluted with Con 
HCl. Filtered the solid; concentrate the filtrate followed by triturate 
the filtrate with ether. 100 mg (60 % yield) product obtained. Rf: 0.5 (10% MeOH in EtOAc); 
1H NMR (300 Hz, CDCl3) δ 2.53 (s, 3H), 3.90 (s, 3H), 6.75 (s, 1H), 7.20 (s, 1H); 13C NMR 
(75Hz, CDCl3) δ 22.7, 52.9, 105.5, 114.1, 137.4, 142.4, 157.5, 164.8; MS (EI, 70ev): m/z (%) 
[M]+. 183.05 (100); HRMS [M]+ calcd. for C8H9NO4 183.0532, found:  183.0530. 
4-Carboxy-2-ethoxy-6,7-dihydro-5H-cyclopenta[b]pyridine 1-oxide (15b): 
The title compound was prepared in 72% yield according to the 
general procedure as described for (15a);  Rf: 0.4 (50% MeOH in 
EtOAc); 1H NMR  (250 Hz, CD3OD) δ 1.57 (t, J = 6.5 Hz, 3H), 
2.24-2.35 (m, 2H), 3.35 (t, J =7.8 Hz, 4H), 4.55 (q, J = 6.5 Hz, 2H), 
7.65 (s, 1H); 13C NMR (75Hz, CD3OD) δ 14.5, 23.4, 31.5, 33.3, 
70.2, 109.6, 136.4, 137.6, 157.8, 158.1, 165.8; MS (EI, 70ev) : m/z 
( % ) [M]+. 223.08. 
 
NCl
COOCH3
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4-Carboxy-2-ethoxy-5,6,7,8-tetrahydroquinoline 1-oxide (15c): 6  
The title compound was prepared in 66% yield according to the general 
procedure as described for (15a); Rf: 0.4 (50% MeOH in EtOAc); 1H 
NMR (300 MHz, CDCl3) δ 1.57 (t, J = 6.5 Hz, 3H), 1.70-1.89 (m. 4H), 
2.9-2.93 (m, 4H), 4.55 (q, J = 6.5 Hz, 2H), 7.10 (s, 1H), 11.30 (bs, 1H); 
13C NMR (75 MHz, CD3OD) δ 14.2, 20.52, 20.9, 26.2, 68.9, 107.7, 
128.1, 142.7, 152.6, 156.3, 165.1;  MS (EI, 70ev):  m/z (%) [M]+. 223.08 
1-Hydroxy-6-methyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid (16): 
To a solution of 1-hydroxy-6-methyl-2-oxo-1,2-dihydropyridine-4-
carboxylic acid (15a) (100 mg, 0.54 mmol) in THF (2.5 mL) was added a 
solution of LiOH.H2O (26 mg, 1.08 mmol) in H2O (7.5 mL) at 0 °C. The 
reaction was stirred at 23 °C for 2.5 h. After completion of the reaction, 
solvent was removed under a low vacuum. The solution was cooled in an 
ice bath and neutralized with HCl (aq). The excess of HCl was distilled off and CH3CN was 
added. The CH3CN layer was collected and concentrated to give the gel like product (58 mg, 
63 % yield). Rf: 0.38 (50% MeOH in EtOAc); IR (cm-1): 3414, 3080, 2956, 1730 (CO acid), 
1650 (CO amide), 1556, 1429, 1230(N-O), 1168; 1H NMR (300MHz, CD3OD) δ 2.49 (s, 
3H), 6.80 (s, 1H), 7.07 (s, 1H); 13C NMR (75MHz, CD3OD) δ 17.6, 107.2, 111.3, 136.4, 
146.6, 154.0, 167.2; MS (EI, 70ev): m/z (%) [M]+. 169.03(100); HRMS [M]+ calcd. for 
C7H7NO4 169.0380, found:  169.0380. 
1-Hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b] pyridine-4-carboxylic acid (17a):  
1-Hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridine-4-
carboxylic acid (200 mg, 0.9 m mol) was taken in HCl (8 mL of 10% 
HCl) and refluxed for 10 h. After completion of the reaction, the excess 
of HCl was distilled off. The residue was washed with CHCl3 and dried 
under high vacuum to give the desired product (100 mg, 57 % yield) as a 
gel like material. R f: 0.28 (50% MeOH in EtOAc); 1H NMR (300MHz, CD3OD) δ 2.14-2.21 
(m, 2H), 3.06-3.13 (m, J = 7.8 Hz, 4H), 6.95 (s, 1H); 13C NMR (75MHz, CD3OD) δ 23.5, 
31.0, 32.5, 116.7, 122.0, 139.8, 147.0, 151.1, 168.6; MS (EI, 70ev):  m/z (%) [M+H]+.  196.03 
(14.54); HRMS [M]+ calcd. for C8H9NO4 195.0532, Found:  195.0532. 
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1-Hydroxy-2-oxo-1,2,5,6,7,8-hexahydroquinoline-4-carboxylic acid (17b): 
The title compound was prepared in 60% yield according to the general 
procedure as described above for 17a; R f: 0.3 (50% MeOH in EtOAc); 
1H NMR (300MHz, CD3OD) δ 1.72 -1.82 (m, 4H), 2.75-2.85 (m, 4H), 
6.86 (s, 1H); 13C NMR (75MHz, CD3OD) δ 22.1, 22.7, 26.0, 26.5, 
115.1, 117.7, 143.4, 146.3, 158.5, 168.3; MS (EI, 70ev):  m/z (%) [M-
H]-  208.1(10); HRMS [M]+ calcd. for C10H11NO4 209.0632, Found:  209.0631. 
2, 6-Dichloro-4-(methoxycarbonyl) pyridine 1-oxide (19):                                                       
A mixture of methyl 2,6-dichloroisonicotinate  (200 mg, 1.0 mmol), 
sodium per carbonate (157 mg, 1.0 equiv)  and anhydrous CH3CN (5 
mL) was cooled to -10 °C and trifluoromethanesulfonic anhydride 
(0.339 ml, 2 equiv) was added drop wise to it. The formations of 
bubbles were observed during addition. The mixture was stirred at the 
same temperature for 1 h, then at room temperature for 14 h. Most of the sodium per 
carbonate disappeared after 4h. The reaction mixture was poured onto mixture of crushed ice 
and saturated sodium carbonate. After stirred for 1 h the mixture was extracted with EtOAc. 
The organic layers were collected, combined, washed with 10% Na2S2O5 and dried over 
anhydrous Na2SO4 to give the title compound (180 mg, 81% yield).1H NMR (300MHz, 
CDCl3) δ 3.90 (s, 3H), 7.98 (s, 2H); 13C NMR (75MHz, CDCl3) δ 53.3, 124.9, 125.4, 143.7, 
162.6; MS (EI, 70ev):  m/z (%) [M-H]-  220.9 (100). 
4-Carboxy-2,6-diethoxypyridine 1-oxide (20):  
The title compound was prepared in 66% yield according to the 
general procedure as described above for 15a. R f: 0.3 (50% 
MeOH in EtOAc); 1H NMR (300MHz, CD3OD) δ 1.58 (t, J = 
7.0 Hz, 6H), 4.62 (q, J = 7.0 Hz, 4H), 7.47(s, 2H); 13C NMR 
(75MHz, CD3OD) δ 14.5, 71.0, 101.9, 146.5, 159.2, 164.7; MS 
(EI, 70ev):  m/z (%) [M]+. 228(100). 
1,6-Dihydroxy-2-oxo-1,2-dihydropyridine-4-carboxylic acid (21): 
The title compound was prepared in 65% yield according to the 
general procedure as described for 1-hydroxy-2-oxo-2,5,6,7-
tetrahydro-1H-cyclopenta[b]pyridine-4-carboxylic acid (17a). 1H 
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NMR (300 MHz, CD3OD) δ 6.71(s, 1H), 12.92 (bs, 3H); 13C NMR (75 MHz, CD3OD) δ 
130.5, 141.7, 168.4, 169.2, 173.9; MS (EI, 70ev):  m/z (%) 171.07 (M+H). 
Methyl 2-chloro-6-fluoroquinoline-4-carboxylate (24c): 
The title compound was prepared in 75% yield according to the 
literature procedure for (24a). Rf: 0.9 (CH2Cl2), mp 120 °C; IR (cm-1): 
3090, 2914, 2842, 1710 (CO ester), 1567, 1468, 1243, 1210; 1H NMR 
(300 MHz, CDCl3) δ 1.47 (t, J = 7.2 Hz, 3H), 4.5 (q, J = 7.2 Hz, 2H), 
7.52-7.59 (m, 1H), 7.98 (s, 1H), 8.05- 8.09 (dd, J1 =5.4 Hz, J 2 = 9.3 Hz, 1H), 8.47- 8.52 (dd, 
J1 =2.7 Hz, J 2=10.4Hz, 1H); 13C NMR (75MHz, CDCl3) δ 14.3, 62.3, 111.5, 120.6, 122.8, 
126.9, 128.0, 137.0, 140.3, 161.7, and 163.5, 164.4; MS (EI, 70ev):  m/z (%) [M]+. 239.1 
(100). 
2-Chloro-4 (ethoxycarbonyl) quinoline 1- oxides (25a): 
The title compound was prepared in 75% yield according to the general 
procedure as described for 2,6-dichloro-4-(methoxycarbonyl) pyridine-
1-oxide (19). Rf: 0.5 (10% EtOAc in petroleum ether), mp 170 °C; IR 
(cm-1): 3072, 2968, 1720 (CO ester), 1526, 1429, 1230(N-O), 1166, 930 
(N-O); 1H NMR  (300 MHz, CDCl3) δ  1.46 (t, J = 7.2 Hz, 3H),  4.50 (q, J = 7.2 Hz, 2H), 
7.7-7.83 (m, 2H),   8.17 (s, 1H), 8.76 (dd,  J1 =1.1 Hz,  J2 = 8.7 Hz,  1H), 9.03 (dd, J1 = 1.1 
Hz, J2 =8.7 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ  14.3, 62.1, 119.9, 123.3, 125.7, 126.5, 
127.0, 129.9, 131.1, 137.4, and 143.2, 163.9; MS (EI, 70ev):  m/z (%) [M]+. 249.1 (100). 
2-Chloro-4 (ethoxycarbonyl)-6-methylquinoline 1-oxides (25b): 
The title compound was prepared in 72% yield according to the 
general procedure as described for 2,6-dichloro-4-(methoxycarbonyl) 
pyridine-1-oxide (19). Rf: 0.48 (10% EtOAc in Petroleum Ether), mp 
135 °C; IR (cm-1):  3082, 2968, 1720 (CO ester), 1526, 1429, 1238 
(N-O), 1166, 936 (N-O); 1H NMR (300MHz, CDCl3) δ 1.46 (t, J = 
7.2 Hz, 3H), 2.56 (s, 1H), 4.48 (q, J = 7.2 Hz, 2H), 7.64 (d, J = 8.8 Hz, 1H), 8.13(s, 1H), 8.63 
(d, J = 8.8 Hz, 1H), 8.79(s, 1H); 13C NMR (75Hz, CDCl3) δ  14.3, 22.9, 62.0, 119.7, 122.8, 
125.6, 125.9, 126.6, 133.1, 140.5, 141.7, 164.0;  MS (EI, 70ev):  m/z (%) [M]+.    265.1  (100). 
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2-Chloro-6-fluoro-4-(ethoxycarbonyl) quinoline 1-oxide (25c): 
The title compound was prepared in 70% yield according to the 
general procedure as described for 2, 6-dichloro-4-(methoxycarbonyl) 
pyridine-1-oxide (19). Rf: 0.6 (10% EtOAc in Petroleum Ether), mp 
120 °C; IR (cm-1): 3086, 2988, 1717 (CO ester), 1546, 1447, 1291, 
1211(N-O), 1136, 933 (N-O); 1H NMR (300MHz, CDCl3) δ 1.47 (t, J 
= 7.2 Hz, 3H), 4.50 (q, J = 7.2 Hz, 2H), 7.51-7.58 (m, 1H), 8.25(s, 1H), 8.75- 8.80(m, 2H); 
13C NMR (75MHz, CDCl3) δ 14.3, 62.3, 111.5, 120.6, 122.2, 122.8, 123.0, 126.9, 128.1, 
137.0, 140.3, 161.0, 163.5; MS (EI, 70ev): m/z (%) [M]+. 255 (46.72), 239.1(100). 
1-Hydroxy-2-oxo-1,2-dihydroquinoline-4-carboxylic acid (26a): 
The title compound was prepared in 68% yield according to the general 
procedure as described for 1-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-4-carboxylic acid (17a); Rf: 0.4 (50% MeOH in 
EtOAc); IR (cm-1): 3424, 3090, 2966, 1732 (CO acid), 1645 (CO amide), 
1546, 1419, 1240 (N-O), 1178; 1H NMR (300 MHz, CD3OD) δ 7.25 (s, 1H), 7.35 (t, J = 7.5 
Hz, 1H), 7.7 (t, J =7.5 Hz, 1H), 7.89 (d, J = 8.2 Hz, 1H), 8.45 (d, J = 8.2 Hz, 1H); 13C NMR 
(75 MHz, CD3OD) δ 114.2, 118.3, 123.6, 124.6, 128.1, 132.8, 140.0, 159.1, 167.8; MS (EI):  
m/z (%) [M]+. 205.1(100); HRMS [M]+ calcd. for C10H7NO4 205.0375, found:  205.0374. 
1-Hydroxy-6-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylic acid (26b):  
The title compound was prepared in 60% yield according to the general 
procedure as described for 1-hydroxy-2-oxo-2, 5, 6, 7-tetrahydro-1H-
cyclopenta[b]pyridine-4-carboxylic acid (17a). Rf: 0.4 (50% MeOH in 
EtOAc); 1H NMR (300MHz, CD3OD) δ 2.42 (s, 3H), 7.21 (s, 1H), 
7.65(d, 2H), 8.22 (s, 1H); 13C NMR (250 Hz, CD3OD) δ 21.5, 114.1, 118.3, 123.4, 127.5, 
134.1, 134.6, 145.8, 158.8, 167.9; MS (EI, 70ev): m/z (%) [M]+. 219.1 (100); HRMS [M]+ 
calcd. For C11H9NO4 219.0526, found  219.0532. 
6-Fluoro-1-hydroxy-2-oxo-1,2-dihydroquinoline-4-carboxylic acid (26c):  
The title compound was prepared in, 60% yield according to the 
general procedure as described for 1-hydroxy-2-oxo-2,5,6,7-
tetrahydro-1H-cyclopenta[b]pyridine-4-carboxylic acid (17a); Rf: 0.4 
(50% MeOH in EtOAc), mp 266 °C; 1H NMR (300MHz, CD3OD) δ 
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N
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7.25(s, 1H), 7.59-7.65 (m, 1H), 7.79-7.84 (dd, J1 =5.4 Hz, J 2= 9.3 Hz, 1H), 8.16-8.2 (dd, J1 = 
2.7 Hz, J 2 = 10.4 Hz, 1H); 13C NMR (75MHz, CD3OD) δ 113.1, 116.4, 120.6, 121.0, 126.0, 
136.9, 138.4, 147.5, 158.6, 161.6, 167.2; MS (EI, Offline,70ev) :  m/z ( % ) [M]+. 223.1(100); 
HRMS [M]+ calcd. for C10H6FNO4  223.0277, found:  223.028. 
4-Carboxy-2-chloro-6-methylpyridine 1-oxide (27a):  
The title compound was prepared in 60% yield according to the general 
procedure as described for 1-hydroxy-6-methyl-2-oxo-1, 2-
dihydropyridine-4-carboxylic acid (16); mp 215 °C; IR (cm-1):  3390, 
3076, 2968, 1737 (CO acid), 1546, 1447, 1291, 1221(N-O), 1136, 940 
(N-O); 1H NMR (300MHz, DMSO-d6) δ 2.45 (s, 3H), 7.95(d, J = 2.0 Hz, 
1H), 7.99 (d, J = 2.0 Hz, 1H); 13C NMR (75Hz, DMSO-d6) δ 17.9, 124.3, 124.3, 125.7, 
140.6, 150.4, 164.2; MS (EI, 70ev):  m/z (%), 229([M+H]+. + CH3CN, 100), 188 (MH+, 35); 
HRMS [M]+ calcd. for  C7H6ClNO3 187.0036, Found:  187.0038. 
4-Carboxy-2-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine 1-oxide (27b):  
           The title compound was prepared in 80% yield according to the general 
procedure as described for 1-hydroxy-6-methyl-2-oxo-1, 2-    
dihydropyridine-4-  carboxylic acid (16); mp 140 °C; IR: (cm-1): 3440, 
3090, 2968, 1737 (CO acid), 1556, 1437, 1281, 1241 (N-O), 1136, 918 (N-O); 1H 
NMR  (300MHz, CD3OD) δ 2.23 (t, J = 7.8 Hz , 2H), 3.15 (t, J = 7.8 Hz , 2H), 3.37 (t, J = 
7.8 Hz, 2H), 7.98 (s, 1H); 13C NMR (75 MHz, CD3OD) δ 23.1, 31., 33.9, 126.9, 128.7, 140.8, 
143.4, 157.4, 166.5; MS (EI, 70ev):  m/z (%) [M]+. 213.1(100); HRMS [M]+ calcd. for 
C9H8ClNO3 213.0193, Found:  213.0196. 
4-Carboxy-2-chloro-5,6,7,8-tetrahydroquinoline 1-oxide (27c):  
The title compound was prepared in 70% yield according to the general 
procedure as described for 1-hydroxy-6-methyl-2-oxo-1, 2-
dihydropyridine-4-carboxylic acid (16); mp 190 °C; IR: (cm-1):  3380, 
3086, 2958, 1727 (CO acid), 1546, 1437, 1291, 1231(N-O), 1136, 928 
(N-O); 1H NMR (300Hz, DMSO-d6) δ  1.62-1.82 (m. 4H), 2.77(t, J = 
6.8 Hz, 2H), 2.99 (t, J = 6.8 Hz, 2H), 7.5(s, 1H), 13.57(s, 1H); 13C NMR (75MHz, DMSO-d6) 
δ 20.5, 20.7, 25.9, 26.6, 123.9, 125.8, 134.9, 137.2, 150.5, 165.4; EI Mass: 227.03 (M+, 49).  
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4-Carboxy-2-chloro-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine 1-oxide (27d): 
The title compound was prepared in 68% yield according to the 
general procedure as described for 1-hydroxy-6-methyl-2-oxo-1, 2-
dihydropyridine-4-carboxylic acid (16); mp 219 °C; IR: (cm-1): 
3400, 3056, 2960, 1740 (CO acid), 1566, 1437, 1281, 1241(N-O), 
1126, 945 (N-O); 1H NMR (300 MHz, CD3OD) δ 1.35 -1.49 (m, 
4H), 1.77 -1.87 (m, 4H), 3.19-3.34 (m, 4H), 8.00(s, 1H); 13C NMR (75 MHz, CD3OD) δ 27.1, 
27.7, 27.9, 28.1, 29.1, 32.1, 126.5, 130.6, 136.4, 140.22, 156.5, 167.2; MS (EI, 70ev):  m/z 
(%), 255.1([M] +. 102.88), 238.1(85.97), 196.1(100); HRMS [M]+ calcd. for  C12H14ClNO3  
255.0662, Found: 255.0655.   
4-Carboxy-2-chloroquinoline 1-oxide (28a): 
The title compound was prepared in 72% yield according to the general 
procedure as described for 1-hydroxy-6-methyl-2-oxo-1,2-
dihydropyridine-4-carboxylic acid (6); mp 197 °C; IR: (cm-1): 3414, 
3056, 1730 (CO acid), 1556, 1427, 1281, 1231(N-O), 1126, 935 (N-O); 
1H NMR (300MHz, DMSO-d6) δ 7.83-7.93 (m, 2H), 8.24(s, 1H), 8.57-
8.60 (dd, J1 =1.1Hz, J 2 = 7.3 Hz, 1H), 8.97-8.90 (dd, J1 =2.1Hz, J2= 
7.3 Hz, 1H), 13.95 (s, 1H); 13C NMR (75MHz, DMSO-d6) δ  119.2, 123.7, 125.7, 126.2, 
126.9, 129.9, 131.2, 136.6, 142.4, 165.3; MS (EI, 70ev):  m/z (%) [M]+. 223.1(100); HRMS 
[M]+ calcd. for C10H6ClNO3 223.0036, found:  223.0032. 
4-Carboxy-2-chloro-6-methylquinoline 1-oxide (28b): 
The title compound was prepared in 80% yield according to the 
general procedure as described for 1-hydroxy-6-methyl-2-oxo-1,2-
dihydropyridine-4-carboxylic acid (6); mp 172 °C; IR: (cm-1): 3414, 
3086, 1736 (CO acid), 1536, 1437, 1271, 1238(N-O), 1126, 929 (N-
O) ; 1H NMR (300 MHz, DMSO-d6) δ 2.47 (s, 3H), 7.7- 7.74 (d, J = 
9 Hz, 1H), 8.18 (s, 1H), 8.46(d, J = 9 Hz, 1H), 8.74 (s, 1H), 13.75 (s, 1H); 13C NMR (75Hz, 
DMSO-d6) δ  21.4, 119.1, 123.18, 125.6, 125.7, 126.2, 132.9, 135.7, 139.9, 141.0, 165.4; MS 
(EI, 70ev):  m/z (%) [M]+. 237.1(23.52), 221.1(68.33); HRMS [M]+ calcd. for C11H8ClNO3 
237.019, found:  237.0187. 
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4-Carboxy-2-chloro-6-fluoroquinoline 1-oxide (28c): 
The title compound was prepared in 70% yield according to the 
general procedure as described for 1-hydroxy-6-methyl-2-oxo-1,2-
dihydropyridine-4-carboxylic acid (6); mp 222 °C; IR: (cm-1):  3394, 
3076, 1728 (CO acid), 1576, 1467, 1261, 1234(N-O), 1116, 937 (N-
O); 1H NMR (300MHz, DMSO-d6) δ 7.79-7.84 (m, 1H), 8.29 (s, 
1H), 8.61-8.65 (dd, J1 = 2.9Hz, J 2 = 10.2Hz, 1H), 8.73-8.77 (dd, J1 = 2.9Hz, J 2 = 10.2Hz, 
1H); 13C NMR (75Hz, DMSO-d6) δ   111.1, 120.5, 122.6, 127.0, 127.7,136.3, 139.8, 160.5, 
162.9, 165.1; MS (EI, 70ev):  m/z (%) [M]+. 241.1(100); HRMS [M]+ calcd. for 
C10H5FClNO3 240.9942, Found:  240.9943. 
Ethyl 2-oxo-1,2,5,6,7,8-hexahydroquinoline-4-carboxylate (29a): 
Acetyl chloride (2mL) was added slowly to ethanol (10 mL) at room 
temperature, stirred it for 10 minutes. To this was added 2-oxo-
1,2,5,6,7,8-hexahydroquinoline-4-carboxylic acid (695 mg, 3.59 mmol) 
and the reaction mixture was heated to reflux for overnight. The 
reaction mixture was cooled to room temperature and extracted with CHCl3. The organic 
layer was collected, washed with 5% NaHCO3, dried over anhydrous Na2SO4, filtered and 
concentrated under low vacuum to give the titled product (650 mg, 82 % yield). 1H NMR 
(300 MHz, DMSO-d6) δ 1.27 (t, J = 7.1 Hz, 3H), 1.63-1.67 (m, 4H), 2.43-2.49 (m, 4H), 4.25 
(q, J = 7.1 Hz, 2H), 6.37 (s, 1H), 11.9 (bs, 1H); 13C NMR (75 MHz, DMSO-d6) δ 13.8, 20.7, 
21.9, 23.7, 61.2, 111.9, 116.9, 133.8, 144.5, 161.2, 165.9; MS (EI, 70ev):  m/z (%) [M]+. 
221.1 (41.08), 192.1(100).   
2-Oxo-1,2,5,6,7,8-hexahydroquinoline-4-carbohydrazide (30a): 
A mixture of  ethyl 2-oxo-1,2,5,6,7,8-hexahydroquinoline-4-
carboxylate (71 mg, 0.32 mmol) and N2H4.H2O (0.1 mL) in ethanol (10 
mL) was refluxed for 10 h. after completion of the reaction most of the 
solvent was evaporated. The solid separated was filtered, washed with 
ether and dried to afford 2-oxo-1,2,5,6,7,8-hexahydroquinoline-4-carbohydrazide (50m g, 
75% yield) as a pale yellow solid; mp 258 °C; IR (cm-1): 3348, 2985, 2865, 1685 (CO 
amide), 1645 (CO amide), 1442, 1228. 1H NMR (300 MHz, CD3OD) δ 1.73-1.82 (m, 4H), 
2.49-2.53 (t, J = 5.9 Hz, 2H), 2.6-2.64 (t, J = 5.9 Hz, 2H), 6.35 (s, 1H); 13C NMR (75Hz, 
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CD3OD) δ 22.6, 23.3, 24.8, 25.2, 113.7, 116.1, 146.0, 151.1, 163.8, 164.8, 166.1;  MS (EI, 
70ev):  m/z (%) [M]+. 207.1(100). 
Ethyl 6-fluoro-2-oxo-1,2-dihydroquinoline-4-carboxylate (31c): 
The title compound was prepared in 72% yield according to the 
general procedure as described for ethyl 2-oxo-1,2,5,6,7,8-
hexahydroquinoline-4-carboxylate (29a). mp 222 °C; IR: (cm-1):  
3394, 3076, 1728 (CO acid), 1576, 1467, 1261, 1234(N-O), 1116, 
937 (N-O); 1H NMR (300MHz, DMSO-d6) δ 1.35(t, J = 7.2 Hz, 3H), 4.40 (q, J = 7.2 Hz, 
2H), 7.02(s, 1H), 7.38-7.50 (m, 2H), 7.9-7.95(dd, J1 =2.7 Hz, J 2= 7.7 Hz, 1H), 12.4 (bs, 1H); 
13C NMR (75Hz, DMSO-d6) δ 13.8, 61.9, 111.1, 116.5, 117.6, 119.1, 136.2, 139.3, 158.6, 
160.6, 166.2; MS (EI, 70ev):  m/z (%) [M]+. 241.1(100); HRMS [M]+ calcd. for 
C10H5FClNO3 240.9942, found:  240.9943. 
6-Fluoro-2-oxo-1,2-dihydroquinoline-4-carbohydrazide (32c):  
The title compound was prepared according to the general procedure 
as described in 2-Oxo-1,2,5,6,7,8-hexahydroquinoline-4-
carbohydrazide (30a) in 70% yield. The physical properties of this 
material are consistent with previously reported data. mp 321°C; IR 
(cm-1): 3407, 3265, 3164, 2865, 1661 (CO amide), 1641 (CO amide), 
1430, 1252;  1H NMR (300 MHz, DMSO-d6) δ 4.62 (s, 2H), 7.34 - 7.57 (m, 4H), 9.90 (s, 
1H), 12.03 (s, 1H) ; 13C NMR (75MHz, DMSO-d6) δ 110.7, 116.8, 117.4, 119.1, 121.4, 
135.8, 143.8, 155.3, 160.8, 164.6; MS (EI, 70ev): m/z (%) [M]+. 221.1(72.88), 134.1(100); 
HRMS [M]+ calcd. for C10H8FN3O2 221.0601, found:  221.0596. 
2,4,7-Trioxo-1-propyl-1,2,3,4,7,8-hexahydropyrido[2,3-d]pyrimidine-5-carboxylicacid 
(35a):  
A mixture of methyl-2,4,7-trioxo-1-propyl-1,2,3,4,7,8-
hexahydropyrido[2,3-d]pyrimidine-5-carboxylate (22b) (100 mg, 
0.36 mmol) and 1N NaOH (3mL) was refluxed for 2 h. After 
completion of the reaction the mixture was cooled to 0 °C and 
acidified with 6N HCl. The solid separated was filtered, washed with 
cold water and dried to give the desired product (75 mg, 79%). mp 284 °C; IR (cm-1): 3404, 
3097, 2962, 2853, 1710 (CO Acid), 1640 (CO amide), 1209; 1H NMR (300MHz, DMSO-d6) 
δ 0.89 (t, J = 7.3 Hz, 3H), 1.59-1.67 (m, 2H), 4.03 (t, J = 7.8 Hz, 2H), 6.4 (s, 1H), 11.50 (s, 
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1H), 12.31 (s, 1H), 13.45 (s, 1H); 13C NMR (75MHz, DMSO-d6) δ 10.9, 20.5, 42.5, 102.3, 
115.6, 147.7, 150.2, 152.2, 159.5, 166.5, 167.8; MS (EI, 70ev): m/z (%) [M+H]+. 266(100);  
HRMS [M]+ calcd. for C11H11N3O5  265.0699, Found:  265.0700. 
Methyl-7-chloro-2,4-dioxo-1-propyl-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-5-
carboxylate (36a):    The title compound was prepared in 60% yield according to the general 
procedure as described for methyl-2-chloro-6-methyl isonicotinate 
(3a). Rf: 0.7 (50% EtOAc in Petroleum Ether); mp 217 °C; IR (cm-1): 
3234, 2945, 28513, 1720 (CO ester), 1665 (CO amide), 1550, 1420, 
1303, 1258, 1166; 1H NMR (300 MHz, DMSO-d6) δ 0.89 (t, J = 7.3 
Hz, 3H), 1.57-1.67 (m, 2H), 3.85 (s, 3H), 4.03 (t, J = 7.8Hz, 2H), 7.53 
(s, 1H), 11.93(s, 1H); 13C NMR (75 MHz, DMSO-d6) δ  10.9, 20.3, 40.3, 52.5, 106.4, 115.8, 
145.4, 149.8, 152.2, 153.9, 165.7; MS (EI, 70ev): m/z (%) [M+H]+. 298(100).   
7-Chloro-2,4-dioxo-1-propyl-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-5-carboxylic 
acid (36c): 
The title compound was prepared in 60% yield according to the general 
procedure as described for methyl-2-chloro-6-methyl isonicotinate (6). 
Rf: 0.7 (50% EtOAc in Petroleum Ether). mp 217 °C; IR (cm-1): 3234, 
2945, 28513, 1720 (CO ester), 1665(CO amide), 1550, 1420, 1303, 
1258, 1166; 1H NMR (300MHz, DMSO-d6) δ 0.86 (t, J = 7.3 Hz, 3H), 
1.50-1.60 (m, 2H), 4. 20 (t, J = 7.3 Hz, 2H), 7.50 (s, 1H), 11.00 (s, 
1H); 13C NMR (75MHz, DMSO-d6) δ 10.9, 20.2, 30, 42.5, 112.3, 115.6, 147.7, 150.2, 152.2, 
159.5, 166.5, 167.8; MS (EI, 70ev): m/z (%) [M+H]+. 284.04 (100); HRMS [M]+ calcd. for 
C11H10ClN3O4 283.114, Found:  283.104. 
1-Ethyl-2,4,7-trioxo-3-propyl-1,2,3,4,7,8-hexahydropyrido[2,3-d]pyrimidine-5-
carboxylic acid (35b): 
The title compound was prepared in 60% yield according to the 
procedure as described for  2,4,7-trioxo-1-propyl-1,2,3,4,7,8-
hexahydropyrido[2,3-d]pyrimidine-5-carboxylic acid.  
mp 226 °C; IR (cm-1):3414, 3047, 2972, 2803, 1698 (CO Acid), 1610 
(CO amide), 1209; 1H NMR (300MHz, DMSO-d6) δ 0.83-0.91 (m, 6H), 1.52-1.67 (m, 4H), 
3.81 (t, J = 7.4 Hz, 2H), 4.10 (t, J = 7.8 Hz, 2H), 6.51 (s, 1H), 12.53 (s, 1H), 13.46 (s, 1H); 
HN
N NO
COOCH3
Cl
O
N
N N
H
O
COOH
O
O
HN
N NO
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13C NMR (75 Hz, DMSO-d6) δ 10.9, 11.2, 20.5, 20.5, 42.2, 43.3, 106.5, 117.7, 142.7, 150.3, 
158.7, 166.7, 167.9; MS (EI, 70ev):  m/z (%) [M+H]+. 294.1 (100). 
6.3. Single crystal X-ray data for compound 13e, 15a and 15b. 
Single crystals suitable for X-ray diffraction of 13e and 15a, 15b, were grown from 8:2 
hexane-ethylacetate and the compound 15b from MeOH. The crystals were chosen using a 
stereo zoom microscope supported by a rotatable polarizing stage. The data was collected at 
room temperature on CrysAlisPro, Oxford Diffraction Ltd, Version 1.171.33.55 with graphite 
monochromated Cu-Kα radiation (1.54814 Å). The crystals were glued to a thin glass fibre 
using FOMBLIN immersion oil and mounted on the diffractometer. The crystal structure was 
solved by direct methods using SHELXS-97 and the data was refined by full matrix least-
squares refinement on F2 with anisotropic displacement parameters for non-H atoms, using 
SHELXL-97.32 
Crystal data of 13e: Molecular formula = C10H13NO3, Formula weight = 195.21, Crystal 
system = Monoclinic, space group = P2(1)/n, a = 8.918 (11) Å, b = 7.969 (7)Å, c = 14.721 
(18)Å, V = 1009.73 (2)Å3, T = 296 K, Z = 4, Dc = 1.284  Mg m–3, µ(Mo-Kα) = 0.79 mm–1, 
5081  reflections measured, 1808 independent reflections, 1612 observed reflections [I > 2.0 
σ (I)], R1_obs = 0.009, Goodness of fit =1.081. Crystallographic data (excluding structure 
factors) for 13e have been deposited with the Cambridge Crystallographic Data Center as 
supplementary publication number CCDC 871206. 
Crystal data of 15a: Molecular formula = C8H9NO4, Formula weight = 183.16, Crystal 
system = Orthorhombic, space group = Pna21, a = 23.033 (6) Å, b = 4.038 (10)Å, c = 18.018 
(5)Å, V = 1676.2 (8)Å3, T = 296 K, Z = 8, Dc = 1.456 Mg m–3, µ(Mo-Kα) = 1.01 mm–1, 5768 
reflections measured, 2506 independent reflections, 2371 observed reflections [I > 2.0 σ (I)], 
R1_obs = 0.026, Goodness of fit = 1.05. Crystallographic data (excluding structure factors) 
for 15a have been deposited with the Cambridge Crystallographic Data Center as 
supplementary publication number CCDC 871207. 
Crystal data of 15b: Molecular formula = C11H13NO4,H2O, Formula weight = 241.24, 
Crystal system = Monoclinic, space group = P2(1)/n, a = 10.413 (19) Å, b = 19.895 (3)Å, c = 
11.164 (2)Å, V = 2256.54 (7)Å3, T = 296 K, Z = 8, Dc = 1.387 Mg m–3, µ(Mo-Kα) = 0.95 
mm–1, 17064 reflections measured, 4439 independent reflections, 3792 observed reflections 
[I > 2.0 σ (I)], R1_obs = 0.031, Goodness of fit = 1.05. Crystallographic data (excluding 
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structure factors) for 15b have been deposited with the Cambridge Crystallographic Data 
Center as supplementary publication number CCDC 871209. 
6.4 Pharmacology methods                            
MABA and LORA assay:  
Activity against replicating M. tuberculosis H37Rv (ATCC 27294, American Type Culture 
Collection, Rockville, MD) was determined using a fluorescence readout in the Microplate 
Alamar Blue Assay (MABA) following incubation for one week with test compounds in 
glycerol-alanine-salts medium (GAS) as well as in medium without added iron but with Tween 
80 (GAST). The MIC was defined as the minimum concentration inhibiting fluorescence by 
90% relative to bacteria-only controls. Activity against non-replicating M. tuberculosis was 
determined using the Low-Oxygen Recovery Assay (LORA) by exposing low-oxygen adapted 
M. tuberculosis containing a luciferase gene to test compounds under anaerobic conditions for 
10 days. After a 28 h recovery in air, the luciferase signal was measured. MIC was defined as 
the lowest concentration inhibiting recovery of luciferase signal, greater or equal to 90% 
relative to bacteria-only controls. 
 
Briefly, the test compound MICs against TB were assessed by the MABA using INH, 
Moxifloxacin and SM as positive controls. Compound stock solutions were prepared in 
DMSO at a concentration of 12.8 mM, and the final test concentrations ranged from 100 to 
0.5 µM. 2-fold dilutions of compounds were prepared in Middlebrook 7H12 medium (7H9 
broth containing 0.1% w/v casitone, 5.6 µg/mL palmitic acid, 5 mg/mL bovine serum 
albumin, 4 mg/mL catalase, filter-sterilized) in a volume of 100 µL in 96-well microplates 
(black viewplates). Mtb H37RV (100 µL inoculum of 2 × 105 cfu/mL) was added, yielding a 
final testing volume of 200 µL. The plates were incubated at 37 °C. On the 7th day of 
incubation 12.5 µL of 20% Tween 80 and 20 µL of Alamar Blue (Trek Diagnostic, Westlake, 
OH) were added to the test plate. After incubation at 37 °C for 16–24 h, fluorescence of the 
wells was measured (ex 530, em 590 nm). The MICs ware defined as the lowest 
concentration effecting a reduction in fluorescence of ≥90% relative to the mean of replicate 
bacteria-only controls. 
Cytotoxicity assay:  
Vero cells (ATCC CRL-1586) were cultured in 10% fetal bovine serum (FBS) in minimum 
essential medium Eagle. J774A.1 cells were cultured in 10% FBS in Dulbecco’s modified 
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Eagle’s medium (DMEM). The cells were incubated at 37 °C under 5% CO2 until confluent 
and then diluted with phosphate-buffered saline to 106 cells/mL. In a transparent 96-well 
plate (Falcon Microtest 96), threefold serial dilutions of the macrolide stock solutions 
resulted in final concentrations of 102.4 to 0.42 µM in a final volume of 200 µL. After 
incubation at 37 °C for 72 h, medium was removed and monolayers were washed twice with 
100 µL of warm Hanks’ balanced salt solution (HBSS). One hundred microliters of warm 
medium and 20 µl of freshly made MTS-PMS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2-tetrazolium and phenylmethasulfazone] 
(100:20) (Promega) were added to each well, plates were incubated for 3 h, and absorbance 
was determined at 490 nm. 
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R
 
 
Foot note: In vitro data generated for all the compounds using Microplate Alamar Blue 
Assay (MABA) with 50µg/mL, 100 µg/mL concentrations of the compounds. Percentage of 
inhibition was mentioned in brackets. For potent active molecules MIC values were 
calculated. 
6.5 Docking procedure: The SDHmt Protein Homology Model was used as the receptor for 
docking. SDHmt Protein was protonated (Addition of Hydrogen atoms) with protonation 3D 
application in MOE, Connolly Molecular surface was generated around the ligand site of the 
protein, Gasteiger Partial charges was added to the protein and finally energy minimization 
was performed to relieve the bad crystallographic contacts. “Active site finder” function of 
the MOE software was used to denote potential docking pockets within the protein crystal 
structure. All the molecules were placed in the active site pocket of the protein by the 
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“Triangle Matcher” method, which generates poses by aligning the ligand triplet of atoms 
with the triplet of alpha spheres in cavities of tight atomic packing. The dock scoring was 
performed with London dG method and then finally retaining and scoring the best 10 poses 
of molecules. The preparation of ligands for docking simulation involved the energy 
minimization with Molecular Mechanics Force-field MMFF94x (Merck Molecular Force 
Field ) and then molecules were subjected to conformational search in MOE using the 
Conformations Stochastic search module to find the lowest Energy Conformers.The docking 
results were appear as docking score in which the docking poses were ranked by the 
Molecular Mechanics and Generalized Born solvation model (MM/GBVI) binding free 
energy. RMSD of the docking pose compares the docking poses to the ligand in the co-
crystallized structure. 33, 34, 35  
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3. Novel synthesis of 2H-benzo[b][1,4]oxazines via sequential C-N    
and C-O bond formation in single pot & their pharmacological      
evaluation as anti inflammatory agents 
 
3.1 Introduction 
             1,4-Benzoxazine is a heterocyclic scaffold of paramount importance to human race. 
Several 1,4-Benzoxazine derivatives isolated from natural resources or prepared synthetically 
are significant with respect to medicinal chemistry and biomedical use. Indeed, 1,4-
Benzoxazines have been part of molecular skeletons for the design of biologically active 
compounds, ranging from herbicides and fungicides to therapeutically usable drugs (Figure 
1).1 A literature survey provided/identified several 1,4-benzoxazine compounds (Fig. 1) in the 
development phase as potential new drugs. Novel 1,4-benzoxazine derivative 12 possesses 
peroxisome proliferator activated receptor α (PPAR α) and PPAR γ agonist activity and could 
be used in treating diabetes, hyperlipidemia and other diabetic complications. French 
investigators recently introduced new 8-arylalkylamino-1,4-benzoxazine neuro-protectants 2, 
3 and 4.3 Schering has disclosed 1,4-benzoxazines 5 4 and 6 5 as inhibitors of nitric oxide 
synthase (NOS) which are potential drugs for treating neurodegenerative, inflammatory, 
autoimmune and cardio-vascular disorders. 1,4-Benzoxazine 7 6 inhibits the coagulation 
serine proteases factor Xa. 2H-benzo[b] [1,4] oxazine 8 7 as hypoxia targeted compounds for 
cancer therapeutics.7  
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The research results suggested that 1,4-Benzoxazine and related compounds are a plentiful 
source of potential anti-cancer, anti diabetic, anti inflammatory drugs deserving further study. 
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Figure 1: Therapeutically usable drugs with 1,4-benzoxazine core structures 
    3.2  Literature reports for synthesis of 1,4-benzoxazines 
Substituted 2-aminophenols are classical starting compounds for the synthesis of 3, 4-
dihydro-2H-1,4-benzoxazines. 
J. Y. Me´rour et al. described an environmentally friendly and highly efficient 
procedure for the synthesis of substituted 3,4-dihydro-2H-1,4-benzoxazines as shown in 
Scheme 1. The reaction of substituted 2-aminophenols 9 with ethyl 2,3-dibromopropionate 
(10) affords, depending on the substituent’s on the aromatic ring, ethyl 3,4-dihydro-2H-1,4-
benzoxazine-2-carboxylates (11) as the main, and ethyl 3,4-dihydro-2H-1,4-benzoxazine-3-
carboxylates (12) as the minor, isomers. In the case of the unsubstituted 2-aminophenol, the 
ratio between the isomers is 20:1.8 
OH
NH2
R1 +
Br
Br
O
OEt K2CO3, acetone
Reflux
O
N
H
R1
COOEt
O
N
H
R1
9 10 11 12
COOEt
Scheme 1 
J. Y. Merour et al. demonstrated that 2-cyano-3,4-dihydro-2H-1,4-benzoxazines 149 
can be obtained by a ring-closure reaction following the pathway presented in Scheme 2. 
The reaction of substituted 2-aminophenols 9 and 2-chloroacrylonitrile (13) under reflux 
in acetonitrile for 18 h in the presence of K2CO3 provided 2-cyano-3,4-dihydro-2H-1,4-
benzoxazine derivatives (14) in good yield.9 
OH
NH2
R1 +
Cl CN
K2CO3, MeCN
Ref lux, 75-90%
O
N
H
R1
CN
9 13 14
 
Scheme 2 
M. Varasi et al. reported synthesis of integrin receptor antagonists; the key 
intermediate 1710 was prepared in a reaction of methyl (2E)-4-bromobut-2-enoate (16)  
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Scheme 3 
with 2-amino-phenol 15 via an intramolecular Michael addition (Scheme 3). 
In the recent times several 2-Nitro Phenols have been successfully used for ring closure to 3, 
4-dihydro-2H-1,4-benzoxazines by a reductive amination reaction.11  
T. Fujikura et al. reported that, 2-bromo-2-methylpropanal (19) can be used for O-
alkylation of 2-nitrophenols (18) to give the phenolic ethers (20) which are reduced, with 
concomitant intermolecular reductive amination, yielding 3,4-dihydro-2H-1,4-benzoxazines 
21 (Scheme 4).11 
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rt, 12h, 90%
OH
NO2
+
18
R2 Br
Me Me
CHO
19
O
NO2
20
R2
Me
CHO
Me Ra Ni,
EtOH, 36%
O
N
H21
R2
Me
Me
 
Scheme 4 
1-(3,4-Dihydro-2H-1,4-benzoxazin-3-yl) methanamine 25 is used as intermediate in 
the synthesis of pyrazino [2,1-c]-1,4-benzoxazines, ligands for the α1-adrenergic receptor 
reported by Minneman, K. P and co-workers.12 Epoxide 22 is opened by Pthallimide 23, 
giving the alcohol, which is oxidized by the Dess–Martin reagent to the ketone 24. Reduction 
of the nitro group of 24 and concomitant cyclization by reductive amination subsequently 
deprotection by hydrazinolysis to afford the amine 25 (Scheme 5). 
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Scheme 5 
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           A novel synthesis of 2-phenoxymethyl-3,4-dihydro-2H-1,4-benzoxazine (29; R3 = Bn, 
Ph), through formation of the C–O and C–N bonds, involves ring-opening of glycidol 27 with 
the N-nucleophile formed from 2-fluoro-N-tosylaniline (26) under phase-transfer catalysis, 
and subsequent intramolecular nucleophilic substitution of fluoride promoted by a non-
nucleophilic strong base. Cleavage of the N-tosyl protecting group of 28 with 
sodium/naphthalene in dimethyl ether (DME) affords the 2-substituted 1,4-benzoxazines 29 
(Scheme 6).13 
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26 27 28 29
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N
H
O
OR3
R3 = Ph, Bn
Scheme 6 
 
G. E. Zurenko and co workers disclosed that O-alkylation of the 2,5-diaminophenol 
derivative (30) with 1-chloroacetone affords the phenoxyacetate as intermediate in which the 
protecting groups are removed by hydrazinolysis and the obtained phenylenediamine 
intermediate undergoes cyclization, yielding the 2H-1,4-benzoxazine derivative (31), which 
was reduced to 3-methyl-3, 4-dihydro-2H-1,4-benzoxazin-7-amine (32), an intermediate in 
the synthesis of antibacterial agents.14 
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Scheme 7 
 
More recently, the formation of aryl C-X bonds (X = N, O, S, etc) by metal mediated 
coupling was successfully extended to the preparation of many such heterocycles.  
S. L. Buchwald and co workers demonstrated Pd-mediated synthesis of 2H-1,4-
benzoxazines. 3,4-Dihydro-2H-1,4-benzoxazines (34)14 were synthesized by intramolecular 
C–O bond formation using palladium-catalyzed intramolecular etherification of aryl halides 
(33) employing di-tert-butyl phospho biaryl ligands (L) and palladium (II) acetate(Scheme 8).  
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Scheme 8 
 
Y. Fort. et al. reported that Nickel-mediated intramolecular amination of aryl 
chlorides 35 yields 3,4-dihydro-2H-1,4-benzoxazines 36 as shown in Scheme 9 by the in situ-
generated Ni (0) catalyst associated with 2,2’-bipyridine.15 
 
O 5 mol% Ni(0), 15mol% 2,2'-biPy,
10 mol% NaOtBu, 95 mol% NaH,
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O
R6
35 36
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Cl
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Scheme 9 
 
 
A series of functionalized 2,3-dihydro-1,4-benzoxazines were obtained in moderate to 
excellent yields via domino [5 + 1] annulations. 
     W. D. Zhu and co workers revealed the domino [5 + 1] annulations of imines 37 with 2-
halo-1,3-dicarbonyl compounds 38 under mild conditions (scheme 10). They have applied 
this method in the synthesis of bioactive analogues, such as functionalized tetracyclic-1,4-
benzoxazines (39) which contain two new heterocyclic rings and quaternary carbon centers 
has also been developed. 16 
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     3.3  Dearomatization of arenes 
Despite the high resonance energy of the benzene ring, a number of examples of     
dearomatization by microorganisms either through oxidation (oxygenases) or reduction 
(reductases) exist in nature. 17  
 
Figure 2: Back ground of dearomatization reactions 
 
          Upon dearomatization of aromatic and heteroaromatic derivatives, highly reactive 
intermediates are generally produced leading to facile formation of carbon–carbon and 
carbon–heteroatom bonds, spontaneous cycloadditions, and cascade reactions. As shown in 
figure 2, a number of strategies for dearomatization have been utilized by organic chemists 
during the course of complex total syntheses. 
          Myers and co-workers applied a chemo enzymatic method for arene dearomatization 
by the dihydroxylation of benzoic acid (40) using the bacterium A. eutrophus affording 1, 2-
dihydroxycyclohexadiene (41) with high enantioselectivity (Scheme 11).18 The simple, 
dearomatized dihydroxycyclohexadiene (41) was parlayed into a number of useful chiral 
building blocks (e.g. 42 and 43) for use in total synthesis and demonstrates the utility of 
enzymatic dearomatization. 
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Schultz and co-workers, pioneers of the diastereoselective Birch reduction/alkylative 
dearomatization process, reported the first enantioselective synthesis of the alkaloid (+) -
Cepharamine (47; scheme 12).19 Their route employed a diastereoselective Birch reduction of 
chiral benzamide 44 to access a chiral enolate intermediate which was alkylated in situ with 
iodide 45 to afford 1, 4-cyclohexadiene 46 in 95% yield as a single diastereomer. 
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Scheme 12 
M J. Gaunt et al discussed a process that directly converts a para-substituted phenol (48) to 
a highly functionalized chiral molecule via oxidative dearomatization and amine-catalyzed 
enantioselective desymmetrizing Michael reaction (Scheme 13). This one-step transformation 
reveals a complex structure (49) formed with control of three new stereogenic centers and an 
array of exploitable orthogonal functionality directly from a flat molecule that is devoid of 
architectural complexity.20 
OH
O
H
N
H
Ar
Ar
OTMS
(10 mol%)
PhI(OAc)2 (100 mol%)
MeOH
O
MeO
H O
H
y: 75% 99% ee >20/1 dr
48 49
 
Scheme 13 
F. Christopher Pigge and co workers reported about the transition metal mediated 
dearomatization reactions dearomatization through η6 coordination. Gratifyingly, treatment 
of 50 in THF (or DMF) with excess NaH at room temperature for 30 min followed by 
addition of aldehyde afforded the desired azaspirocyclic ruthenium complexes. Deprotonation 
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of the activated methylene group in the arene ruthenium side chain presumably leads to rapid 
spirocyclization with nucleophilic aromatic addition occurring exclusively from the face 
opposite the RuCp fragment.21 
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Scheme 14 
Danishefsky and co-workers employed a dearomatization strategy involving an ortho-
Claisen rearrangement (Scheme 15). The rearrangement was conducted using the reverse O-
prenylated derivative 53 to furnish the desired dearomatized cyclohexadienone 54, a 
precursor of the natural product of tricycloillicinone (55).22 
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Scheme 15 
            Finally, an impressive example of pyridinium dearomatization was reported in the 
early 1990s by Magnus and co-workers in their total synthesis of the pentacyclic alkaloid 
nirurine (58; scheme 16).23 Synthesis of the azabicyclo-[2.2.2] octane (isoquinuclidine) core 
of 58 commenced with the alkylative dearomatization at the C2 position of an acylpyridinium 
derived from pyridine 56 to introduce an allyl side chain.24 Further desilylation generated 
allenoate intermediate 57 which participated in intramolecular [4+2] cyclo-addition to furnish 
the nirurine core structure in two steps as shown in Scheme 16.  
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Oxidative dearomatization has been previously adapted to nitrogen-tethered ortho-
quinol acetates (60) from biphenyl 59 for azacyclization reactions (Scheme 17) for the 
synthesis of Phenanthridine Alkaloid Motifs (61). 25 
 
Scheme 17 
Prompted by above observations it is evident that, oxidative dearomatization of 
phenols has been long perceived as an attractive tactic in the design of the syntheses of 
complex natural products of various kinds. Nevertheless, several previous reports highlighted 
dearomatization as a powerful strategy for the total synthesis of architecturally complex 
molecules wherein planar, aromatic scaffolds are converted to three dimensional molecular 
architectures.26 
 
3.4.1 Our approach for synthesis of 2H-benzo[b][1,4]oxazines via one pot sequential C-N,  
C-O bond formation: 
                 In the light of above classical and elaborated examples, the present report puts forward an 
application of oxidative dearomatization of 2,5-dihydroxy carbonyl compounds using silver 
oxide 27 for synthesis of 2H-benzo[b][1,4]oxazines that provides an easy access to nitrogen–
carbon (N–Cx) and Oxygen–carbon (O-Cy) strategic bonds in a single operation.  
      In an experiment designed to synthesize the napththoxazine cycloadduct 64 by 
intramolecular Diels-Alder cyclisation from an imine precursor of 2,5-dihydroxy 
benzaldehyde (62) and O-allyl serine ester derivative (63), we observed that 2H-benzo[b][1, 
4]oxazine  65 was obtained as the only product, in good yields  (Scheme 18). 
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Scheme 18: Noval approach for synthesis of  2H-benzo[b][1,4]oxazines 
      
This new finding lead us to apply the similar reaction conditions to esters of other natural 
amino acids (66) which contain a β-aryl substituent like phenylalanine and tryptophan esters. 
We were pleased to obtain 2H-benzo[b][1,4] oxazines in good to excellent yields in all the 
cases (Table 1).  
 
 
Scheme 19: Generalised scheme for synthesis of  2H-benzo[b][1,4] oxazines 
 
However tyrosine ester did not cyclize to a similar product (entry 1, Table 2). We have 
attributed this observation to oxidation of hydroxyl moiety in tyrosine in presence of silver 
oxide. Thus we chose to prepare different derivatives of tyrosine with an electron-releasing 
and electron withdrawing groups and apply the same reaction conditions. Quantitative yields 
of 2H-benzo[b][1,4]oxazines were obtained from aminoester derivatives possessing electron 
donating groups (entry 2, Table 2) and no such product was  observed with the electron 
withdrawing counterparts (entry 3, Table 2).  Therefore we presumed that the reaction 
mechanism is influenced by the electronic factors of the β-aryl ring which merits further 
validation.  
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Table 1. Synthesis of 1,4- benzoxazines from quinol and natural amino acid derivatives 
 
 
Table 2. Synthesis 2H-benzo[b][1,4]oxazine from quinol and tyrosine derivatives 
 
a
 No reaction in acetonitrile, methanol and  10% yield in THF with 4 equiv silver oxide; product obtained in  
70% yield with THF and 2 equiv silver oxide.  b  NR: No Reaction 
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The initial cyclization studies using 4 equiv of silver oxide and dichloromethane as solvent 
provided the 2H-benzo[b][1,4]oxazines in good yields. We then attempted further 
optimization of the reaction conditions using 2 equivalents of silver oxide and CH2Cl2, which 
failed to afford products, except in the case of phenyl alanine (footnote, Table 1). Further, 
methanol, acetonitrile and THF too have either decreased the yield drastically or  failed to 
afford products. Therefore, we continued using 2 equivalents of silver oxide for the synthesis 
of 2H-benzo[b][1,4]oxazines. 
         We then attempted further optimization of the reaction conditions using 2 equivalents of 
silver oxide and CH2Cl2, which failed to afford products, except in the case of phenyl alanine 
(footnote, Table 1). Further, methanol, acetonitrile and THF too have either decreased the 
yield drastically or  failed to afford products. Therefore, we continued using 2 equivalents of 
silver oxide for the synthesis of 2H-benzo[b][1,4]oxazines. After these optimization studies, 
we now set out to validate our results using esters of  amino acids having withdrawing 
groupshave been synthesized using the method described in Aldrich.28 These unnatural 
aminoesters were also subjected to similar reaction conditions and the results are summarized 
in Table 3. 
 
The observations demonstrated a striking influence of electronic factors in aryl moiety on this 
transformation. 1,4-benzoxazines were obtained in good yields from aminoesters containing 
electron-donating moieties (entries 9-14, Table 3). Aminoesters with p-CF3 and p-NO2 
substituents on phenyl did not afford the desired 1,4-benzoxazines, thus validating our 
assumption. We have further observed that 4'-azaphenylalanine ester too did not result in 1,4-
benzoxazine formation (footnote, Table 3). 
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Table 3. Synthesis of 2H-benzo[b][1,4]oxazines from unnatural amino acid derivatives 
 
 
          c 2 equiv  silver oxide in CH2Cl2 resulted in only 10% yield, d no Reaction   
 
3.4.2 Plausible mechanism: 
   The most plausible mechanistic pathway delineated for the reaction to account for the 
formation of the product, is shown in Figure 3. The initial event may be considered as the 
nucleophilic attack of amine (66) in a Michael fashion on the transient enone to generate an 
intermediate 79.  The intermediate 79 may undergo benzylic oxidation leading to 81 which on 
dearomatisation provides enone 82 and subsequent electrocyclization of the latter and eventual 
re-aromatisation leads to 83 via 82 which further undergoes oxidation to final product 84 
(Figure 3).  
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Figure 3. Plausible mechanism for oxidative-dehydrogenation, C-N and C-O bond generation 
 
 
An electron-rich aryl group can significantly enhance the yield of 2H-benzo[b][1,4] 
oxazines by an apparent stabilization of benzylic cation (80) that may be destabilized by 
electron-withdrawing substituents on R8. The mechanism (formation of  81) further supported 
by formation of racemic compounds which is evidenced from the optical rotation [α] value of 
one of the derivative i.e, 69 found to be zero. 
 
  3.4.3 The single crystal X-ray study of 2H-benzo[b][1,4] oxazine 69 : 
While all the eleven noval 2H-benzo[b][1,4] oxazines synthesized were characterized by 
spectral (NMR, IR, MS and HRMS) data the molecular structure of one of the 2H-
benzo[b][1,4]oxazines 69 was isolated as bright yellow solid that crystallized well, whose  
structure was solved by single crystal X-ray diffraction studies (Figure 4).  
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Figure 4. The ORTEP diagram of 2H-benzo[b][1,4]oxazine 69 
 
  3.4.4 Pharmacology: 
 
Pharmacological testing was performed at the Institute of Life Sciences, in the group of Dr. 
Kishore V.L. Parsa, University of Hyderabad, India. 
All the compounds synthesized were tested for their PDE4B inhibitory activity in vitro. 13 In 
inflammatory and immune cells, the inhibition of cellular responses, including the production 
and/or release of proinflammatory mediators, cytokines, and active oxygen species, is 
associated with elevated levels of cAMP. Since PDE4 (that exists in four different isoforms 
e.g., PDE4A, B, C and D) plays a key role in the hydrolysis of cAMP to AMP 29 hence 
inhibition of PDE4 should result in elevated levels of cAMP in the air-way tissues and cells 
thereby suppressing inflammatory cell function. This is supported by the fact that PDE4 
inhibitors have been found to be beneficial for the treatment of inflammatory and 
immunological diseases including asthma and chronic obstructive pulmonary disease 
(COPD). 
Notably, rolipram 30 the first-generation PDE4 inhibitor showed adverse effects such as 
nausea and vomiting. More recently, cardiovascular effects of PDE4 inhibitors have been 
reported. 31 While these dose-limiting side effects were reduced by second generation 
inhibitors like cilomilast 32 (Ariflo) and roflumilast, their therapeutic index has delayed 
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market launch so far. It is therefore necessary to devote a continuing effort in exploring new 
class of compounds for their PDE4 inhibitory potential.  
Moreover, identification of novel small molecules possessing balanced inhibitory properties 
could be useful in minimizing the adverse side effects.  Accordingly, our compounds were 
evaluated against PDE4B by using PDE4B enzyme isolated from Sf9 cells. Rolipram, a well 
known inhibitor of PDE4 was used as a reference compound. 33 Among all compounds 74 
showed significant inhibition of PDE4B in compared to other molecules when tested at 30 
µM (Table 4).  
 
Table 4:  % of inhibition of PDE4B by compounds at 30 µM 
Compound (30 µ M) Exp1 Exp2 Exp3 Average % Luciferase Inhibition
68 47.53 58.50 30.25 45.42 11.64
69 76.72 70.65 73.68 34.52 28.07
70 70.48 58.70 32.25 53.81 16.13
71 51.87 43.34 47.60 47.58 17.04
72 43.92 78.69 32.37 51.66 13.61
74 65.49 65.64 65.56 65.56 13.55
% PDE4B Inhibition
 
  
 
3.4. 5 Molecular docking studies   
 
Molecular docking studies were done by D. Giridhar Singh at Institute of Life Sciences, 
India. The docking studies were performed to predict the interactions and binding mode of 
synthesized molecules with the binding site of human Phosphodiesterase (PDB ID: 3O0J) 
enzyme. The docking results obtained after docking of these molecules with PDE4B protein 
is summarized in Table 5 which clearly suggests that these molecules bind well with PDE4B.  
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Table 5: Glide XP-Parameter contribution to docking score. 
Molecule GScore LipophilicEvdW HBond Electro PhobEn LowMW 
69 -7.1 -3.9 -0.7 -0.9 -1.3 -0.3 
71 -7.0 -4.2 -0.9 -0.6 -1.0 -0.4 
74 -7.1 -4.3 -0.9 -0.5 -1.2 -0.2 
 
 
                 
Figure 11: (a) Interaction mode of compound 69 at the binding site of human Phosphodiesterase enzyme 
showing H-bonding (pink dotted line) with threonine-345. (b) 2D interaction diagram of compound 69 with 
PDE4B. (c) Binding pose of compound 69 at the binding site of PDE4B protein represented in ribbon form. 
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Figure 12: (a) Interaction mode of compound 71 at the binding site of human Phosphodiesterase enzyme 
showing H-bonding (pink dotted line) with tyrosine-233. (b) 2D interaction diagram of compound 71 with 
PDE4B. (c) Binding pose of compound 71 at the binding site of PDE4B protein represented in ribbon form 
 
 
Figure 13: (a) Interaction mode of compound 74 at the binding site of human Phosphodiesterase enzyme 
showing H-bonding (pink dotted line) with tyrosine-233. (b) 2D interaction diagram of compound 74 with 
PDE4B. (c) Binding pose of compound 74 at the binding site of  PDE4B protein represented in ribbon form. 
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       In case of 69 hydroxyl group of 2H-1,4-benzoxazine ring is making perfect H-Bonding 
with threonine-345 (figure 11). In both the molecules (71 and 74) oxygen atom of carbonyl-
group is well interacting by H-Bonding with tyrosine-233 and histidine-234 (figure 12 and 
13). We also docked the S-isomers of 69, 71and 74 and the glide docking score (GScore) was 
found to be -6.9, -6.4 and -5.0, respectively. 
 3.5 Summary 
 In conclusion we have demonstrated a facile synthesis of 2H-benzo[b][1,4]oxazines by  
sequential generation of  C-N, C-O bonds in a single pot via  oxidative dearomatization of 
quinols in presence of functionalized amino ester derivatives. Further mechanistic studies of 
this reaction  are underway. All the compounds synthesized were tested for PDE4B inhibitory 
properties in vitro and many of them showed significant inhibition. The docking results 
suggested that these mole-cules interact well with PDE4B protein where the ester moiety 
played a key role in all cases, while the OH of 69 was extended into a hydrophobic pocket.       
 Overall, noval method for synthesis of 2H-benzo[b][1,4]oxazines has been identified and 
further 2H-benzo[b][1,4]oxazines proved as a new template for the identification of small 
molecule based novel inhibitors of PDE4B. 
 
3.6. Experimental section 
3.6.1 Chemistry - General methods  
All reactions were carried out under an inert atmosphere with dry solvents, unless otherwise 
stated. Reactions were monitored by thin layer chromatography (TLC) on silica gel plates (60 
F254), using UV light detection.  Visualization of the spots on TLC plates was achieved 
either by UV light or by staining the plates in 2, 4 Dinitro phenyl hydrazine and Ninhydrin 
stains charring on hot plate. Flash chromatography was performed on silica gel (230-400 
mesh) using distilled hexane, ethyl acetate, dichloromethane.  
NMR-Spectroscopy  
1H NMR and 13C NMR spectra were recorded in CDCl3 or acetone-d6 solution by using 
VARIAN 400 MHz spectrometers. Deuterium exchange studies were done in CD3OD, 
DMSO-d6 and D2O. Chemical shifts are reported as δ values relative to internal CDCl3 δ 7.26 
or TMS δ 0.0 DMSO-d6 δ 2.50 and CD3OD δ 3.34 for 1H NMR and CDCl3 δ 77.0 and 
CD3OD δ 49.05 for 13C NMR.  1H NMR data was recorded as follows: chemical shift 
[multiplicity, coupling constant(s) J (Hz), relative integral] where multiplicity is defined as: s 
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(singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublet), m (multiplet), bs (broad 
singlet).  
IR spectroscopy, mass spectrometry and melting points  
FTIR spectra were recorded on Bruker (Alpha) spectrometer. Mass spectra were recorded on 
Micro Mass VG-7070H mass spectrometer for ESI and are given in mass units (m/z). High 
resolution mass spectra (HRMS) [ESI+] were obtained using either a TOF or a double 
focusing spectrometer. Melting points were determined by using a Buchi melting point B-540 
apparatus. Values thus obtained were not corrected. 
3.6.2 Syntheses 
Typical experimental procedure for synthesis of 2H-Benzo [b][1,4]oxazines:  
R8= phenyl, p-BrC6H4, p-FC6H4, p-CH3C6H4, p-CH3(CHCH3)C6H4, p-OCH3C6H4,
p-OCOPhC6H4, OCH2PhC6H4, O-allyl, 3'-indolyl, 1-naphthyl
CHO
OH
OH
Ag2O, MgSO4, CH2Cl2,
12h, rt
H2N
R8
COOR9
N
O R8
CHO
HO COOR9
66
62 67
 
 
A suspension of 66 (0.179 g, 1 mmol) in anhydrous dichloromethane is cooled in ice bath 
to 0 °C and neutralised with 1 equiv. triethylamine (if amino acid is HCl salt) (0.15mL, 1 
mmol) under constant stirring. 2, 5 dihydroxy benzaldehye (62) (0.138 g, 1 mmol) and 
Ag2O (0.924 g, 4 mmol) and anhydrous MgSO4 (0.120g, 1 mmol), were added 
consecutively, and stirred at rt for 12h. The mixture was filtered through celite and 
washed with CH2Cl2. Removal of the solvent under reduced pressure followed by column 
chromatography (10% EtOAc/Hexane) yielded pure 2H-benzo[b][1,4]oxazines. 
 
2) SPECTRAL DATA FOR NEW COMPOUNDS:  
Methyl5-formyl-6-hydroxy-2-phenyl-2H-benzo[b][1,4]oxazine-3-carboxylate (68):   
 Yellow oil, Yield(75%), Rf = 0.5 (10% EtOAc/Hexane); 1H 
NMR (400 MHz, CDCl3): δ 3.93 (s, 3H), 6.31 (s, 1H), 6.89 (d, 
J = 8.8Hz, 1H), 7.09 (d, J = 9Hz, 1H), 7.29-7.33 (m,  5H), 
10.81(s, 1H), 11.46 (s, 1H); 13C NMR (100 MHz, CDCl3): δ 
53.24, 71.87, 114.29, 121.10, 126.10, 127.25, 128.98, 129.58, 
N
O
COOCH3HO
CHO
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131.59, 134.66, 137.31, 152.88, 157.53, 162.95, 195.87. IR (neat, cm-1): 3426, 2952, 2925, 
2855, 1742, 1644, 1251, 1024. Mass (ES) m/z 334.06 (M+Na, 100%); HRMS (ESI): calcd 
for C17H13NO5Na (M+Na) + 334.0691 found 334.0679. 
Methyl 5-formyl-6-hydroxy-2-(1H-indol-3-yl)-2H-benzo[b][1,4]oxazine-3-carboxylate 
(69):  
Light yellow solid (mp: 186 0 °C), Yield (70%), Rf = 0.48 
(10% EtOAc/Hexane); 1H NMR (400 MHz, CDCl3): δ 3.90 
(s, 3H), 6.71 (s, 1H), 6.81 (s, 1H), 6.83 (s, 1H), 6.95 (d, J = 
2.4Hz, 1H), 7.09 (d, J = 8Hz, 1H), 7.22 (d, J = 2.4Hz, 1H), 
7.32 (d, J = 2.4Hz, 1H), 7.87 (d, J = 2.4Hz, 1H), 8.15 (bs, 1H), 10.88 (s, 1H), 11.46 (s, 1H);  
13C NMR (100 MHz, CDCl3): δ  53.22, 65.67, 111.48, 119.24, 120.58, 123.17, 124.97, 
126.73, 132.23, 136.57, 152.68, 157.46, 162.34, 195.97. IR (neat, cm-1): 3402, 3049, 2923, 
2851, 1737, 1649, 1262, 1021. Mass (ES) m/z 373.07 (M+Na, 100%); HRMS (ESI): calcd 
for C19H14N2O5Na (M+Na) + 373.0800 found 373.0788.  
Methyl 2-(allyloxy)-5-formyl-6-hydroxy-2H-benzo[b][1,4]oxazine-3-carboxylate (70):   
Colorless oil, Yield (52%), Rf  = 0.42 (10% 
EtOAc/Hexane); 1H NMR (400 MHz, CDCl3): δ 3.98 (s, 
3H), 4.28 (d, J = 5.6 Hz, 2H), 5.24-5.33 (m, 2H), 5.81-
5.91(m, 1H), 6.04 (s, 1H), 7.04 (d, J=8.8Hz, 1H), 7.3 (d, 
J=8.8Hz, 1H), 10.83 (s, 1H), 11.59 (s, 1H);  13C NMR (100 MHz, CDCl3): δ  53.19, 69.83, 
118.97, 121.27, 126.19, 131.75, 132.74, 136.19, 147.49, 158.11, 162.68, 195.85. IR (neat, 
cm-1): 3421, 3078, 2923, 2854, 1723, 1654, 1294, 1063. Mass (ES) m/z 292.08 (M+H, 
100%); HRMS (ESI): calcd for C14H14NO6 (M+H) + 292.0821, found 292.0818. 
Methyl 5-formyl-6-hydroxy-2-(4-methoxyphenyl)-2H-benzo[b][1,4]oxazine-3-
carboxylate (71):  
Colorless resin, Yield (92%), Rf  = 0.46 (10% 
EtOAc/Hexane); 1H NMR (400 MHz, CDCl3): δ 3.76 
(s, 3H), 3.9 (s, 3H), 6.24 (s, 1H), 6.88 (d, J = 9.2Hz, 
2H), 6.91 (d, J = 9Hz, 1H), 7.06 (d, J = 9Hz, 1H), 7.20 
(d, J = 10Hz, 2H), 10.83 (s, 1H), 11.46 (s, 1H);  13C 
NMR (100 MHz, CDCl3): δ  53.22, 55.23, 71.72, 114.39, 120.98, 126.24, 128.97, 131.65, 
137.30, 153.05, 157.48, 160.61, 162.91, 195.91. IR (neat, cm-1): 3398, 2924, 2855, 1711, 
1649, 1291, 1012. Mass (ES) m/z 364.07 (M+Na, 100%); HRMS (ESI): calcd for 
C18H15NO6Na (M+Na) + 364.0797, found 364.0796. 
N
O
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Methyl 2-(4-(benzyloxy) phenyl)-5-formyl-6-hydroxy-2H-benzo[b][1,4] oxazine-3-
carboxylate (72): 
Light brown resin, Yield (10%), Rf  = 0.4 (15% 
EtOAc/Hexane); 1H NMR (400 MHz, CDCl3): δ 4.2 (s, 
3H), 5.05 (s, 2H), 6.94 (d, J = 8.4Hz, 2H), 7.13 (d, J = 
9.2Hz, 1H), 7.3-7.4 (m, 9H), 10.84 (s, 1H), 11.82 (s, 
1H);  13C NMR (100 MHz, CDCl3): δ  39.81, 70.02, 
115.08, 115.13, 121.08, 125.14, 126.93, 127.44, 127.96, 
128.57, 130.74, 131.98, 136.87, 138.82, 152.28, 158.56, 
159.99, 195.63. IR (neat, cm-1): 3441, 2924, 2855, 1734, 1649, 1601, 1257, 1018. Mass (ES) 
m/z 418.14 (M+H, 100%). 
Methyl2-(4-(benzoyloxy)-phenyl)-5-formyl-6-hydroxy-2H-benzo[b][1,4]oxazine-3-
carboxylate (73): 
Colorless resin, Yield (50%), Rf  = 0.5 (10% 
EtOAc/Hexane); 1H NMR (400 MHz, CDCl3): δ 3.9 (s, 
3H), 6.34 (s, 1H), 7.14-7.2 (m, 1H), 7.35-7.65 (m, 8H), 
8.17(m, 2H), 10.85 (s, 1H), 11.48 (s, 1H);  13C NMR (100 
MHz, CDCl3): δ  54.47, 69.96, 115.50, 121.08, 125.05, 
127.50, 128.03, 128.57, 128.62, 130.38, 136.65, 148.61, 
158.61, 164.47, 169.31, 191.63. IR (neat, cm-1): 3433, 3070, 2943, 2844, 1723, 1654, 1620, 
1284, 1080. Mass (ES) m/z: 432.10 (M+H, 100%); HRMS (ESI): calcd for C24H18NO7 
(M+H) + 432.1083, found 432.1065. 
Methyl 2-(4-bromophenyl)-5-formyl-6-hydroxy-2H-benzo[b][1,4]oxazine-3-carboxylate 
(74): 
 Light brown oil, Yield (66%), Rf  = 0.48 (10% 
EtOAc/Hexane); 1H NMR (CDCl3):  δ 1H NMR (400 MHz, 
CDCl3):  δ 3.95 (s, 3H), 6.26 (s, 1H), 6.91 (d, J = 9.2 Hz, 1H), 
7.1 (d, J = 9.2 Hz, 1H), 7.15 (d, J = 7.6 Hz, 2H), 7.46 (d, J = 8 
Hz, 2H), 10.79 (s, 1H), 11.47 (s, 1H); 13C NMR (100 MHz, 
CDCl3): δ  53.35, 71.18, 121.39, 123.91, 126.02, 128.87, 132.20, 132.40, 133.68, 138.72, 
152.24, 157.70, 162.85, 195.71.  IR (neat, cm-1): 3364, 2957, 2860, 1722, 1684, 1641, 1311, 
1285, 1123. Mass (ES) m/z: 389.99 (M+H, 100%); HRMS (ESI): calcd for C17H13NO5Br 
(M+H) + 389.9977, found 389.9964. 
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Methyl2-(4-fluorophenyl)-5-formyl-6-hydroxy-2H-benzo[b][1,4]oxazine-3-carboxylate 
(75):  
Light yellow oil, Yield (58%), Rf = 0.46 (10% 
EtOAc/Hexane); 1H NMR (400 MHz, CDCl3):  δ 3.93 (s, 
3H), 6.27 (s, 1H), 6.9 (d, J = 9.2 Hz, 1H), 7.08 (m, 2H), 7.11 
(d, J = 9.2 Hz, 1H), 7.28 (dd, J = 7.46, 4.19 Hz, 2H), 10.81 (s, 
1H), 11.47 (s, 1H). 13C NMR (100 MHz, CDCl3): δ 53.30, 
71.20, 115.97, 116.18, 117.53, 119.12, 121.28, 126.08, 129.25, 129.35, 135.65, 137.02, 
152.57, 157.63, 162.85, 164.56, 195.76. IR (neat, cm-1): 3430, 2924, 2856, 1718, 1648, 1289, 
1010. Mass (ES) m/z 352.05 (M+Na, 100%); HRMS (ESI): calcd for C17H12NO5FNa 
(M+Na) + 352.0597, found 352.0587. 
Ethyl 5-formyl-6-hydroxy-2-p-tolyl-2H-benzo[b][1,4]oxazine-3-carboxylate (76):  
 Colourless oil, Yield (47%), Rf  = 0.5 (10% 
EtOAc/Hexane): 1H NMR (400 MHz, CDCl3): δ 1.36 (t, J 
= 7.12 Hz , 3H), 2.3 (s, 3H),  4.37 (q, J = 7.12 Hz, 2H), 
6.26 (s, 1H), 6.87 (d, J = 9.09 Hz, 1H), 7.18-7.06 (m, 5H), 
10.83 (s, 1H), 11.45 (s, 1H). 13C NMR (100 MHz, CDCl3): 
δ 14.03, 21.19, 62.56, 71.92, 114.31, 120.82, 126.11, 127.28, 129.65, 131.73, 137.34, 139.66, 
153.48, 157.44, 162.47, 196.04. IR (neat, cm-1): 2954, 2854, 1729, 1651, 1641, 1261, 1123. 
Mass (ES) m/z: 340.11 (M+H, 100%); HRMS (ESI): calcd for C19H18NO5 (M+H) +340.1184, 
found 340.1182. 
 
Methyl5-formyl-6-hydroxy-2-(naphthalen-2-yl)-2H-benzo[b][1,4]oxazine-3-carboxylate 
(77):  
Colourless resin, Yield (70%), Rf  = 0.5 (20% 
EtOAc/Hexane); 1H NMR (400 MHz, CDCl3): δ 3.90 (s, 
3H), 6.84-6.69 (m, 1H), 6.92 (d, J = 9.11 Hz, 1H), 7.09 
(s,1H), 7.15 (s, J = 7.2 Hz, 1H), 7.36-7.21 (m, 1H), 7.58 (t, 
J = 7.2 Hz, 1H ), 7.69 (t, J = 7.2 Hz, 1H), 7.87 (dd, J = 16.19, 8.21 Hz, 2H), 8.47 (d, J = 8.53 
Hz, 1H), 10.92 (s, 1H), 11.46 (s, 1H). 13C NMR (100 MHz, CDCl3): δ 53.30, 68.97, 117.55, 
119.14, 120.87, 123.92 124.76, 125.91, 126.31, 127.19, 128.47, 128.89, 130.85, 131.99, 
134.35, 137.07, 152.90, 157.63, 162.78, 195.87. IR (neat, cm-1); 3636, 3053, 2922, 2853, 
1724, 1652, 1287, 1051.  Mass (ES) m/z 384.08 (M+Na, 100%); HRMS (ESI): calcd for 
C21H15NO5Na (M+Na) + 384.0847, found 384.0847. 
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Ethyl5-formyl-6-hydroxy-2-(4-isopropylphenyl)-2H-benzo[b][1,4]oxazine-3-carboxylate 
(78): 
Yellow resin, Yield (72%), Rf  = 0.5 (10% 
EtOAc/Hexane); 1H NMR (400 MHz, CDCl3 ppm): δ 
1.18(d, J = 6.8Hz, 6H), 1.37 (t, J = 7.2Hz, 3H), 2.90-2.79 
(m, 1H), 4.37 (q, J = 7.2 Hz, 2H), 6.27 (s, 1H), 6.9-6.86 
(m, 1H), 7. 2-7.15 (m, 2H), 7.45 (t, J = 8 Hz, 1H), 7.84 
(d, J = 7.90 Hz, 1H), 10.75 (s, 1H), 11.45 (s, 1H). 13C 
NMR (100 MHz, CDCl3): δ 14.03, 23.72, 33.82, 62.55, 71.91, 120.80, 126.13, 127.05, 
127.28, 131.70, 132.10, 137.43, 150.40, 153.45, 157.42, 162.53, 196.06. IR (neat, cm-1): 
3311, 2960, 2863, 1722, 1652, 1254, 1020. Mass (ES) m/z: 368.14 (M+H, 100%); HRMS 
(ESI): calcd for C21H22NO5 (M+H) + 368.1497, found 368.1512. 
 
3) EXPERIMENTAL PROCEDURE FOR SYNTHESIS OF UNNATURAL AMINOACID 
ESTERS  
Ethyl 2-amino-3-(4-isopropylphenyl) propanoate (82) 
Benzophenone (79) (29.0 g, 0.16 mol), glycine ethyl ester hydrochloride (80) (11.0g, 0.08 
mol) and toluene (50 mL) were charged in a 250 mL, 2-necked round bottomed flask 
equipped with a Dean-Stark apparatus, heated to reflux for 30 min. DIEA (28 mL, 0.159 mol) 
was added drop wise over three hours using a dropping funnel at same temperature. Solution 
was refluxed the pale yellow color solution until it turns to brownish color (3h). After 
completion of reaction, the mixture was cooled to room temperature followed by addition of 
water. The layers were separated and the organic solution was washed with water (50 mL) 
and concentrated in vacuum at 45-50 °C to give (Benzhydrylideneamino)-acetic acid ethyl 
ester (40g). 
A solution of N-(diphenylmethylene) glycine ethyl ester (0.800g, 3 mmol) in dimethyl 
sulfoxide (5 mL) was cooled to 0 °C, potassium hydroxide (0.505g, 9 mmol) was added and  
stirred for 5 min then treated with p-isopropyl benzyl halide (0.636g, 3 mmol) at 0 °C and 
stirred for 60 min at room temperature. The reaction mixture was neutralized with 1 N 
hydrochloric acid and extracted with EtOAc several times. The combined organic layers were 
washed with water and brine, dried over MgSO4, filtered and concentrated to obtain 81.  
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     A solution of above imine 81 (1 mmol) in tetrahydrofuran (10mL) was adjusted to pH 
~ 4 with 10mL 4N hydrochloric acid and stirred for 2h. DCM was added to remove 
benzophenone, neutralize with 1N sodium hydroxide solution and extracted with ethyl acetate 
several times. The combined organic layers were washed with water and brine, dried over 
MgSO4, filtered and concentrated to afford 82 as racemic amino ester.4 The amino esters 83, 
84, 85 and 86 were obtained by similar procedure from the corresponding suitably substituted 
benzyl halides.  
N COOC2H5
ClH . H2N COOC2H5
O 1. Toluene, reflux
30 min, DIPEA,
3h, reflux THF, 4N HCl,0 °C, 1N NaOH
1hr
+ H2N COOC2H5
82
2. DMSO, 0 °C
3. KOH, 4 - Isopropyl
Benzyl Bromide
0 °C, 60min 81
79
80
 
 
Ethyl 2-(diphenyl methylene amino)-3-(4-isopropylphenyl) propanoate (81):  
  Colorless  resin, Yield (80%), Rf  = 0.8 (10% 
EtOAc/Hexane); 1H NMR (400 MHz, CDCl3) :  δ  1.25 (m, 
9H), 2.84 (Septet, 1H), 3.18 (dd, J = 13.33, 6.73 Hz, 1H), 
3.28 (dd, J = 13.33, 6.73 Hz, 1H), 4.2 (q, J = 7.16 Hz, 1H), 
6.94 (d, J = 7.6 Hz, 2H), 7.25 (m, 2H), 7.599 (m, 4H), 7.81 
(d, J = 7.37 Hz, 4H). 
 
Ethyl 2-amino-3-(4-isopropylphenyl) propanoate (82): 
Light brown resin, Yield (80%), Rf = 0.4 (40% EtOAc/Hexane); 1H 
NMR (400 MHz, CDCl3):  δ 1.24 (m, 9H), 2.61 (bs, 1H), 2.83 (m, 
1H), 3.03-3.08 (m, 1H), 3.74 (m, 1H), 4.17 (q, J = 7.16 Hz, 2H), 7.1-
7.22 (m, 4H). 
 
Ethyl 2-amino-3-p-tolylpropanoate (83): 
The title compound was synthesized as colourless resin in 88% yield 
according to general procedure as described above for 82, Rf  = 0.5 
(40% EtOAc/Hexane); 1H NMR (400 MHz, CDCl3):  δ 1.19 (t, J = 
7.08 Hz , 3H), 2.30 (s, 3H), 2.73-2.64 (m, 1H), 3.02-3.06 (m, 1H), 3.66-3.7 (m, 1H), 4.16 (q, 
J = 7.16 Hz, 2H), 7.1-7.19 (m,4H). 
H2N COOC2H5
N COOC2H5
H2N COOCH2CH3
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Ethyl 2-amino-3-(4-nitrophenyl) propanoate (84):  
 The title compound was synthesized as light yellow resin in 70% 
yield according to general procedure as described above for 82, Rf  = 
0.4 (30% EtOAc/Hexane);  1H NMR (400 MHz, CDCl3): δ 1.25 (t, J = 
7.08 Hz, 3H), 2.98 (dd, J = 13.61, 7.78 Hz, 1H), 3.17 (dd, J = 13.63, 
5.45 Hz, 1H), 3.74 (dd, J = 7.59, 5.69 Hz, 1H), 4.18 (q, J = 7.16 Hz, 2H), 7.47-7.08 (m, 2H), 
8.17 (d, J = 8.43 Hz, 2H). 
 
Ethyl 2-amino-3-(4-(trifluoromethyl) phenyl) propanoate (85):  
 The title compound was synthesized as yellow oil in 80% yield 
according to general procedure as described above for 82, Rf  = 0.4 
(40% EtOAc/Hexane); 1H NMR (400 MHz, CDCl3): δ  1.24 (t, J = 
7.13 Hz, 3H), 2.07 (bs, 2H), 2.95 (dd, J = 13.59 , 7.6 Hz, 1H), 3.14 
(dd, J = 13.53, 7.6 Hz, 1H), 3.75 (m, 1H), 4.17 (q, J = 7.13 Hz, 2H), 7.33 (d, J = 8.4Hz, 2H), 
7.565 (d, J = 8.2 Hz, 2H). 
 
Ethyl 2-amino-3-(pyridin-4-yl) propanoate (86): 
The title compound was synthesized as colourless oil in 70% yield 
according to general procedure as described above for 82, Rf  = 0.35 
(40% EtOAc/Hexane); 1H NMR (400 MHz, CDCl3): δ 1.24 (t, J = 
7.13 Hz, 3H), 2.86 (dd, J = 13.8 , 7.6 Hz, 1H), 3.08 (dd, J = 13.8, 
7.6 Hz, 1H), 3.73 (m, 1H), 4.17 (q, J = 7.13 Hz, 2H), 7.15 (d, J = 
5.6 Hz, 2H), 8.52(d, J = 6 Hz, 2H). 
 
The following amino ester derivatives have been prepared from tyrosine by methods reported 
in literature.34 
Methyl 2-amino-3-(4-hydroxyphenyl) propanoate hydrochloride (87), 4-(2-Amino-3-
methoxy-3-oxopropyl) phenyl benzoate (88), Methyl 2-amino-3-(4-methoxyphenyl) 
propanoate (23), Methyl 2-amino-3-(4-(benzyloxy) phenyl) propanoate (89). The following 
amino ester derivatives have been prepared by simple esterification from the corresponding 
commercially available amino acids.34 Ethyl 2-amino-3-(4-bromophenyl) propanoate (90), 
Ethyl2-amino-3-(4-fluorophenyl) propanoate (91), Methyl 2-amino-3-(4-(naphthalen-1-yl) 
phenyl) propanoate (92). 
N
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3.6.3 Single crystal X-ray data for compound 69 
Single crystals suitable for X-ray diffraction of 69 were grown from 2:8 hexane-ethylacetate. 
The crystals were carefully chosen using a stereo zoom microscope supported by a rotatable 
polarizing stage. X-ray data was collected at room temperature using a Bruker Smart Apex 
CCD diffractometer with graphite monochromated MoKα radiation (λ=0.71073Å) with ω-
scan method.1 Integration and scaling of intensity data were accomplished using SAINT 
program.35 The structures were solved by Direct Methods using SHELXS9736  and refinement 
was carried out by full-matrix least-squares technique using SHELXL97.  
Formula C19H14N2O5, M = 350.32, monoclinic, space group P21/c, a = 9.0334(6) Å, b 
= 7.3253(5) Å, c = 23.9981(15) Å, β = 99.161(1) °, V = 1567.76(18) Å3, Z = 4, Dc = 1.484 g 
cm-3, µ(Mo K) = 0.109 mm-1, F(000) = 728, T = 294(2)  K,  R1(I> 2σ(I)) = 0.0335, wR2(all 
data) = 0.0937 for 2535 independent reflections with a goodness-of-fit of 1.058. 
 
3.6.4 Pharmacology methods: 
Materials and Methods 
Cells and Reagents: HEK 293 and Sf9 cells were obtained from ATCC (Washington D.C., 
USA). HEK 293 cells were cultured in DMEM supplemented with 10% fetal bovine serum 
(Invitrogen Inc., San Diego, CA, USA). Sf9 cells were routinely maintained in Grace’s 
supplemented medium (Invitrogen) with 10% FBS. RAW 264.7 cells (murine macrophage 
cell line) were obtained from ATCC and routinely cultured in RPMI 1640 medium with 10% 
fetal bovine serum (Invitrogen Inc.). cAMP was purchased from SISCO Research 
Laboratories (Mumbai, India). PDElight HTS cAMP phosphodiesterase assay kit was 
procured from Lonza (Basel, Switzerland). PDElight HTS cAMP phosphodiesterase assay kit 
was procured from Lonza (Basel, Switzerland). PDE4B1, PDE4A4 and PDE4D3 cDNA 
clones were from OriGene Technologies (Rockville, MD, USA). PDE4D2 enzyme was 
purchased from BPS Bioscience (San Diego, CA, USA). Lipopolysaccharide (LPS) was from 
Escherichia coli strain 0127:B8 obtained from Sigma (St. Louis, MO, USA).  Mouse TNF-α 
ELISA kit was procured from R&D Systems (Minneapolis, MN, USA). 
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PDE4B protein production and purification 
PDE4B cDNA was sub-cloned into pFAST Bac HTB vector (Invitrogen) and transformed 
into DH10Bac (Invitrogen) competent cells. Recombinant bacmids were tested for integration 
by PCR analysis. Sf9 cells were transfected with bacmid using Lipofectamine 2000 
(Invitrogen) according to manufacturer’s instructions. Subsequently, P3 viral titer was 
amplified, cells were infected and 48 h post infection cells were lysed in lysis buffer (50 mM 
Tris-HCl pH 8.5, 10 mM 2-Mercaptoethanol, 1 % protease inhibitor cocktail (Roche), 1 % 
NP40). Recombinant His-tagged PDE4B protein was purified as previously described 
elsewhere (Wang et al., 1997). Briefly, lysate was centrifuged at 10,000 rpm for 10 min at 4 
ºC and supernatant was collected. Supernatant was mixed with Ni-NTA resin (GE Life 
Sciences) in a ratio of 4:1 (v/v) and equilibrated with binding buffer (20 mM Tris-HCl pH 
8.0, 500 mM-KCl, 5 mM imidazole, 10 mM 2-mercaptoethanol and 10 % glycerol) in a ratio 
of 2:1 (v/v) and mixed gently on rotary shaker for 1 hour at 4˚C. After incubation, lysate-Ni-
NTA mixture was centrifuged at 4,500 rpm for 5 min at 4˚C and the supernatant was 
collected as the flow-through fraction. Resin was washed twice with wash buffer (20 mM 
Tris-HCl pH 8.5, 1 M KCl, 10 mM 2-Mercaptoethanol and 10% glycerol). Protein was eluted 
sequentially twice using elution buffers (Buffer I: 20 mM Tris-HCl pH 8.5, 100 mM KCl, 
250 mM imidazole, 10 mM 2-mercaptoethanol, 10% glycerol, Buffer II: 20 mM Tris-HCl pH 
8.5, 100 mM KCl, 500 mM imidazole, 10 mM 2-mercaptoethanol, 10% glycerol).  Eluates 
were collected in four fractions and analyzed by SDS-PAGE. Eluates containing PDE4B 
protein were pooled and stored at -80˚C in 50% glycerol until further use.  
PDE4B enzymatic assay 
The inhibition of PDE4B enzyme was measured using PDElight HTS cAMP 
phosphodiesterase assay kit (Lonza) according to manufacturer’s recommendations. Briefly, 
10 ng of PDE4B enzyme was pre-incubated either with DMSO (vehicle control) or 
compound for 15 min before incubation with the substrate cAMP (5 µM) for 1 h. The 
reaction was halted with stop solution followed by incubation with detection reagent for 10 
minutes in dark. Luminescence values (RLUs) were measured by a Multilabel plate reader 
(Perklin Elmer 1420 Multilabel counter). The percentage of inhibition was calculated using 
the following formula: 
%	ℎ =

		ℎ	 − 		ℎ
		ℎ	
	100 
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3.6.5 Docking study 
Method: We docked all the molecules by using schrodinger 2011 software. The results are 
compared with the cocrystal ligand and In vitro activity. The PDB ID 3O0J was used for the 
docking study. The protein was prepared by giving preliminary treatment like adding 
hydrogen, adding missing residues, refining the loop with prime and finally minimized by 
using OPLS 2005 force field. The search grid was generated by picking the cocrystal ligand 
upto 20 Å search area. The hydroxyl groups of search area were allowed to move.  
All the molecules were minimized by using macromodule application. We used 1000 
iteration for minimization using OPLS 2005 force field and charges were also added from 
force field only. The PRCG (Polak-Ribier conjugate gradient) method was used for 
minimization. All the molecules were docked by using glide XP (extra precision) dock 
application. We performed flexible docking by allowing sample ring conformations and 
sample nitrogens to move to possible extent in docking. 10 poses were generated for each 
ligand. The docking results are documented and analyzed. 
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4. Synthesis & pharmacological evolution of substituted phenyl 
oxazoles as a novel class    of LSD1 inhibitors with anti-
proliferative properties  
 
4.1 Introduction 
 Cancer is traditionally viewed as a primarily genetic disorder. However, it is now 
increasingly apparent that epigenetic abnormalities play a fundamental role in cancer 
development.1 Cancer may affect people at all ages, even fetuses, but risk for the more 
common varieties tends to increase with age. Cancer causes about 13% of all deaths.2  
4.2 Epigenetics   
Epigenetics is defined as heritable changes in gene activity and expression that occur without 
alteration in DNA sequence. Examples of such changes are DNA methylation and histone 
modification, both of which serve to regulate gene expression without altering the basic DNA 
sequence. Epigenetic changes are preserved when cells divide.3 Thus, epigenetic is 
considered a bridge between genotype and phenotype.4, 5 Different epigenetic phenomena are 
linked by the fact that DNA exist as an intimate complex with histones and other chromatin 
remodeling proteins. Mainly, epigenetic information is stored as chemical modifications to 
cytosine bases and to the histones protein.6, 7 and 8 
4.2.1 Epigenetic alterations in the genesis of cancer 
DNA methylation and cancer 
The first epigenetic alteration to be observed in cancer cells is DNA methylation.9 
Hypermethylation of CpG islands at tumour suppressor genes switches off these genes, where 
as global hypomethylation leads to genome instability and inappropriate activation of 
oncogenes. The genomic DNA methylation levels are maintained by DNMT enzymes 
(Figure1), are delicately balanced within cells; Over-expression of DNMTs is linked to 
cancer in humans, and their deletion from animals capable of causing death. Since, DNA 
exists as an intimate complex with histones in chromatin, most of the factors that affect DNA 
methylation levels will also affect histone modifications. For example, methylation of DNA, 
H3K9 is linked and interruption of DNA methylation is linked to loss of H4K20 
methylation.10 
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Figure1: Epigenetic mechanism1- DNA methylation 
Histone modifications and cancer 
Histones are proteins which bind to DNA and facilitate efficient ‘packing’ of DNA in 
eukaryotic cells (Figure 2). Histones are highly basic in nature due to the presence of 
positively charged amino acids, and this allows them to associate well with DNA and cause 
the DNA to fold around them into compact structures (nucleosomes).The unwound DNA in 
chromosomes would be very long (1.8 meters), but wound on the histones it has about 90 
micrometers (0.09 mm) of chromatin.  
 
 
Figure 2: Components of epigenetic code (Taken from Nature 2006, 441, 143-5 with licence)  
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Five major families of histones exist: H1/H5 (linker histones), H2A, H2B, H3, and H4 (core 
histones).11, 12, 13, 14 The ability of histones to regulate gene expression is regulated by post-
translational modifications on the N-terminal (and likely C-terminal) “tails” of the core 
histones which project out of the nucleosome (Figure 2). Modifications including 
phosphorylation, acetylation, methylation, ubiquitination, sumoylation and biotinylation have 
been identified on the histone tails. 
• Acetylation: Histone acetylation tends to open up chromatin structure.  Accordingly, 
histone acetyltransferase (HATs) tend to be transcriptional activators whereas histone 
deacetylases (HDACs) tend to be repressors.  Many HAT genes are altered in some 
way in a variety of cancers.  For instance, the p300 HAT gene is mutated in a number 
of gastrointestinal tumors.  On the other hand, alteration of HDAC genes in cancer 
seems to be far less common.  However, despite this low incidence of genetic mutation 
in cancer, HDAC inhibitors are performing well in the clinic as anti-cancer drugs. 
• Methylation:  All lysine methyltransferases that target histone N-terminal tails contain 
a so-called SET domain.  This domain possesses lysine methyltransferase activity and 
numerous SET domain-containing proteins are involved in cancer. One example is the 
Suv39 family of enzymes that catalyse methylation of H3K9.  Although there are clear 
links to disease15-18, the role of histone methylation is much less well understood and 
appears to be context dependent.  
• Phosphorylation:  H3S10 and H3S28 are phosphorylated at mitosis - a crucial part of 
the cell cycle; misregulation here is often associated with cancers.  Indeed, the Aurora 
kinases that perform this H3 phosphorylation are implicated in cancer.   
The large-scale development of small molecule inhibitors of DNA and histone-modifying 
enzymes is now in full swing.  In the clinic, the success of HDAC inhibitors and DNA 
demethylating agents like aza cytidine as anti-cancer drugs demonstrates 'proof of principle' 
of this approach and provides great hope for the development of a more comprehensive 
portfolio of 'epigenetic drugs' in the future. 
 
4.2.2 Lysine-specific histone demethylase 1 (LSD1) 
LSD1 (Lysine Specific Demethylase 1) was the first histone demethylase identified.19 LSD1 
is highly conserved in organisms ranging from Schizosaccharomyces pombe to human and 
consists of three major domains: an N-terminal SWIRM (Swi3p/Rsc8p/Moira) domain, a C-
terminal AOL (amine oxidase-like) domain, and a central protruding Tower domain. The C-
terminal catalytic domain reveals high sequence homology to amine oxidases that belong to 
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the flavin adenine dinucleotide (FAD)-dependent enzyme family including mono- and 
polyaminoxidase. The N-terminal SWIRM domain seems to be important for chromatin 
binding.20 The Tower domain, inserted into the AOL domain, forms a long helix-turn-helix 
structure and serves as a platform for binding of LSD1 partner proteins such as corepresser 
element silencing factor, CoREST (Figure 3).  
 
Figure 3: Structure of human LSD1 (A) Domain structure. (B) Structure of LSD1 in complex 
with CoREST and a peptide substrate.  
 
Its discovery significantly advanced the understanding of epigenetic regulation of gene 
expression; changing the paradigm that methylation is a non-reversible feature of histones.21 
Histone methylation/demethylation has since been found to be an important epigenetic 
modification linked to activation as well as repression of transcription.  
 
Two types of histone demethylases have been discovered. The flavin-dependent demethylase 
LSD1 acts on lysine 4 and lysine 9 of histone H3 (H3K4 and H3K9). LSD1 acts on mono- 
and dimethylated H3K4 through a flavin-dependent mechanism. The reaction results in a 
hybrid transfer with reduction of FAD to FADH2 which is reoxidized by molecular oxygen, 
producing hydrogen peroxide. The resulting imine intermediate is hydrolyzed to generate the 
demethylated H3 tail and formaldehyde (Figure 4). 
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Figure 4: Demethylation of K4H3Me2 by LSD1 
LSD1 cannot demethylate trimethylated lysine residues, since a lone pair of electrons in the 
unprotonated state of N of methylated lysine is required in FAD-mediated reaction. LSD1 
requires the first 20 N-terminal amino acids of the histone tail for productive binding in the in 
vitro enzymatic assay.22  
The other major class are Jumonji domain-containing histone demethylases which are Fe(II) 
and 2-oxoglutarate dependent oxygenases that, act on mono-, di- and trimethylated Lys and 
methylated Arg residues depending on the particular enzymes.23 Histone demethylase activity 
is associated with several pathological states. Increased LSD1 expression in prostate tumors 
correlates significantly with relapse during therapy.24, 25 Suppressed LSD1 expression is 
associated with vascular smooth muscle cell inflammatory damage in a mouse model of 
diabetes26. Demethylation of p53 (tumor suppressor) by LSD1 prevents p53 interaction with 
its co-activator 53BP1.14 Activation of the telomerase reverse transcriptase (hTERT) gene is 
known to be dependent on LSD1 levels and recruitment to the hTERT promoter.13 
 
4.3 Design of novel LSD1 inhibitors:  
Studies on LSD1 have identified a few classes of molecules that exhibit inhibitory 
activity. Several Monoamine oxidase inhibitors (MAOIs), more commonly used as 
antidepressants, inhibit LSD1, indicating one possible direction for small molecule design.27 
Biguanide and bisguanidine polyamine analogs are another class of molecules that was 
identified for this process (Figure 5). These molecules have been used in cultured colon 
cancer cells to demonstrate LSD1 inhibition and resultant activation of silenced genes.19  
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Peptides containing methionine as the key structural element also showed LSD1 
inhibition. However, none of these molecules are likely to be selective for LSD1 or are 
druggable. Small molecules which can selectively modulate the activity of LSD1 should 
therefore hold great promise in two main areas – (1) in laboratory experiments to understand 
the cellular and physiological effects of LSD1 inhibition and the interaction of histone H3K4 
methylation with other epigenetic modifications such as histone acetylation, histone 
phosphorylation and DNA methylation, (2) in animal studies aimed at defining the potential 
of clinical therapy as LSD1 inhibitors for the treatment of chronic conditions such as cancer, 
diabetes and obesity. Herein, we report the synthesis and biological study of a novel class of 
molecules as probes of LSD1 function, as possible epigenetic modulators or as potential anti-
cancer agents. 
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Figure 5: Design of novel LSD1 inhibitors based on pharmacophore similarity with reported 
inhibitors. 
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Using the available X-ray diffraction crystal structure of LSD1 as a starting point,28 we 
designed a series of small molecules as potential inhibitors taking the key pharmacophore 
features identified for the MAO-, the polyamine/guanidine and methionine based peptide 
inhibitors into account (Figure 1) being linked through an oxazole moiety. 19, 27 and 28-34 The 
Schrodinger molecular modelling suite was used to visualize the three-dimensional structure 
of LSD1 and predict the docking sites, inhibitory interactions and the theoretical 
effectiveness of small molecules.  
 
4.4 Results and discussion:  
4.4.1 Chemistry:  
The synthesis of target compounds and their derivatives was efficiently performed using the 
reaction sequence as shown in Scheme 1. 
3-nitrobenzamide derivatives 235,36 were readily obtained by reacting appropriate 3-
nitrobenzoic acids (1a-c) with methionine methyl ester hydrochloride in the presence of 
HBTU, followed by treatment with LiOH•H2O, to give rise to the corresponding carboxylic 
acids 3.37 Those were subsequently converted to keto-amides 4 in the presence of acetic 
anhydride and pyridine via a Dakin-West type reaction.38 After refluxing with POCl3, the 
keto-amides 4 cyclized spontaneously to produce the 3-nitro phenyl oxazole derivatives     
5a-c38 which on reduction with SnCl2•2H2O afforded 3-amino phenyl oxazole derivatives 6.39  
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Scheme 1: Synthesis of substituted 3-guanidine phenyl oxazoles 
 
Scheme 2: Synthesis of analogues 10-14 of 6b 
 
The installation of a bis-BOC protected 3-guanidine group was achieved by treating 6 with 
N1,N2-bis-(tert-butoxycarbonyl)-S-methylisothiourea (7),40 to give the corresponding 3-
guanidine phenyl oxazole derivatives 8. Finally, on deprotection with trifluoroacetic acid 3-
guanidine phenyl oxazole derivatives 9 were obtained. A number of N-substituted derivatives 
(10-14) were also prepared via N-acylation, N-sulfonation or N-alkylation of 6b (Scheme 2). 
All synthesized compounds were fully characterized by spectroscopic methods (NMR, IR, 
MS and HRMS).  
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4.4.2 Pharmacology: 
 
4.4.2.1 Cell viability 
Having synthesized the desired target molecules 
pharmacological evaluation in vitro
compounds were subjected to 
MB-231 with concentrations 
.Among the compounds tested 
at 1 nM (Table 1). The data was plotted with log (compound concentration) on the x
% viability of cells on the y-axis
 
 
Figure 6: Log Concentration Vs % Viable Cells for Compound 6a against HeLa and MDA
 
Figure 7: Log Concentration Vs % Viable Cells for Compound 
Results & discussion 
6 and 9 along with 10-14 
 determining cell viability by a MTT assay
cervical cancer cell line HeLa and breast cancer cell line MDA
ranging from 0.5 nM to 3.7 nM (log concentrations) for 36h
6a, 6b, 9a and 9c showed significant inhibitory effects on cell 
 (Figure 6-10).  
-MB231 Cells by MTT assay
6b against HeLa and MDA-MB231 Cells by MTT assay
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Figure 8: Log Concentration Vs % Viable Cells for Compound 
 
Figure 9: Log Concentration Vs % Viable Cells for Compound 
Figure 10: Log Concentration Vs % Viable Cells for 10% DMSO Control against HeLa and MDA
From these data it was evident that a 
advantages over an amino group (e.g. 
activities. IC50 values were calculated for all test compounds and
values for 6a were 1.29nm for HeLa and 1.328 nm for MDA
Results & discussion 
9a  against HeLa and MDA-MB231 Cells by MTT assay
9c against HeLa and MDA-MB231 Cells by MTT assay
-MB231 
guanidine moiety did not offer any significant 
9a and 9c vs 6a and 6b) with respect to 
 are shown in table1. IC
-MB-231 cells, 
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Cells by MTT assay 
in vitro 
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6b were 1.22nm 
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for HeLa and 1.202nm for MDA-MB-231 cells, 9a were 1.48nm for HeLa and 1.328nm for 
MDA-MB-231 cells, 9c were 2.14nm for HeLa and 1.035nm for MDA-MB-231 cells.  
 
4.4.2.2 In vitro LSD1 activity 
The in vitro LSD1 activity assays showed that compounds 6a, 6b and 9a showed detectable 
inhibition of in vitro LSD1 activity at a concentration of 1 µM whereas all the other 
compounds showed no detectable inhibition. A concentration response study of the above 
compounds was performed using concentrations of 10 µM, 1 µM, 0.1 µM, 0.01 µM and 
0.001 µM. IC50 values were then calculated with compound 6a showing 16.1µΜ, 6b showing 
10.2µΜ and 9a showing 9.5µM IC50 values. The data is summarized in table 1. 
4.4.2.3 Zebrafish embryo toxicity and apoptosis 
Developing embryos of the zebrafish Danio rerio are excellent animal models for studying 
specific developmental effects of small molecules, thus allowing effective in vivo evaluations 
of potential drugs before embarking on highly expensive studies on mice and humans.41The 
histone demethylase LSD1 is known to be encoded by the zebrafish genome42, and the 
protein sequence has 85% sequence identity with that of human LSD1 protein. This makes 
the zebrafish embryo an attractive in vivo model to evaluate the effects of small molecules as 
LSD1 inhibitors as well as in vivo toxicity-related effects. 
IC50 values calculated using non-linear regression analysis in the software GraphPad Prism. 
The data was plotted with log (compound concentration) on the x-axis and % initial activity 
on the y-axis (Figure11). 
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                 6b Estimated IC50: 10.2 µM  
Figure 11: Log Concentration Vs % Initial aactivity  for compounds 6a, 6b and 9a against LSD1 
Compounds 5c, 5b and 9b showed general toxicity-related effects in zebrafish embryos, with 
death resulting after 24h of treatment at 10µM. Compounds 6b, 9a and 9c showed increased 
apoptosis at 10 µM with no general toxicity-related effects even after 72h of treatment. The 
data is summarized in table 1 and the microscopy images of treated embryos are shown in 
figure 2. The data clearly show increased apoptosis as indicated by acridine orange 
fluorescence, especially in the area of the brain. This observation is consistent with reported 
brain-related effects of LSD1 inhibition.43  
Table 1: Summary of the pharmacological evaluation of compounds. 
 
 
Pharmacological 
Activity 
      
NH2
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 6a        6b           9a 9c 
HeLa cell viability 
(IC50) 
1.29 nm 1.22 nm 1.48 nm 2.14 nm  
MDA-MB-231  cell 
viability (IC50) 
1.328 nm 1.202 nm 1.328 nm 1.035 nm 
In vitro LSD1 
inhibition (IC50) 
16.1 µM 10.1 µM 9.5 µM >50µM 
Zebrafish embryo 
apoptosis 
Insignificant Yes (10 µM) Yes (10 µM) Yes (10 µM) 
Zebrafish embryo 
toxicity 
None None Not done None 
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Our results indicate that compounds 
mechanisms involved in cell viability. The data from
with compounds 6a, 6b and 
values are higher by an order of 10
cells tested is mediated by addition
include those on epigenetic modifications other than histone methylation, such as histone 
acetylation and DNA methylation leading to a significant suppression of cell viability. Such 
non-specific epigenetic effects are plausible
structural features of the LSD1 protein and that of other known inhibitors of LSD1. 
The data from studies with zebrafish embryos show
significant increase in apoptosis
treatment was done at a concentration of 10 
inhibition IC50 values. The significant difference in activity shown by the compounds in cells 
and in zebrafish embryos suggests that the cancer cells used may possess features (such as 
specific mutations or epigenetic targets) which make them more sensitive to the effects of 
LSD1 inhibition, compared to the developing zebrafish embryos which represent a non
diseased, living organism. This is plausible since cancer cells are known to have several 
accumulated defects compared to normal cells. Our data thus support the possibility that the 
compounds are selective for cancer cells over normal cells. Overall, the results of our detailed 
pharmacological analysis suggest that compounds 
consistent across in vitro, cell culture and 
 
Results & discussion 
6a, 6b, 9a and 9c possess biological activity related to 
 in vitro LSD1 inhibition is consistent 
9a possessing LSD1 inhibition properties, although the IC
4
. This suggests that the activity of the compounds on the 
al effects apart from LSD1 inhibition. Possible effects 
 because the compounds were designed based on 
s that compounds 6b, 9a
 (Figure 12), with no general toxicity-related effects. The 
µM, which is in the range of 
6b and 9a possess biological activit
in vivo systems. 
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Figure 12: Zebrafish embryos treated with compounds and stained with acridine orange. 
Brightly stained spots, highlighted with a circle represent apoptotic cells with fragmented 
nuclei.  
 
4.4.3 Molecular modeling  
To understand the binding mode and stability 
molecular modeling studies (Docking analysis and Molecular dynamics simulations) 
Results & discussion 
of ligand receptor complex
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6a, 6b and 9a against LSD1
interaction with the LSD1 enzyme. The amino group of molecule 
with Thr-335, Tyr-571 and His
participated in a π stacking with Tyr
bonding with Met-332 and Val
showed a good π stacking with Tyr
LSD1 inhibition data has a nice correlation wi
 
Table 2: Contribution of glide XP terms in docking score
Comp. GScore 
6a -5.43 
6b -6.50 
9a -6.74 
 
LipophilicEvdW: Chemscore lipophilic pair term and fraction of the total protein
HBond: Rewards for hydrogen bonding interaction between ligand and protein
Electro: Electrostatic reward 
PhobEn: Hydrophobic enclosure reward
LowMW:Reward for ligands with low m
Results & discussion 
 (Figure 13-15). Docking studies predicted good binding 
9a wa
-812 by hydrogen bonding whereas 
-761. The sulfur atom of molecule 6b 
-333. In case of molecule 6a, the oxazole and 
-761 and Trp-751, respectively. The docking score and 
th each other. 
 
LipophilicEvdW HBond Electro PhobEn
-3.9 -0.7 -0.2 -0.5 
-4.8 -0.8 -0.4 -0.3 
-5.0 -0.7 -0.5 -0.5 
-ligand vdw energy
 
 
olecular weight 
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 LowMW 
-0.5 
-0.5 
-0.5 
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Figure 13: Binding orientation and interactions of 6a at the LSD1inhibitors binding site.  
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Figure 14: Binding orientation and interactions of 
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6b at the LSD1inhibitors binding site.
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Figure 15: Binding orientation and interac
 
Furthermore, the molecular dynamics (MD) simulations of 
were also performed using the Desmond package incorporated in Maestro. To evaluate 
stability of the MD trajectories 
total energy of ligand-protein complex and RMSD values for the protein backbone atoms 
relative to the initial minimized structure through the phase of the simulation were calculated. 
There was no significant change in 
simulation period. The RMSD values remain
equilibrium, which demonstrate
Throughout MD simulations the studied compound maintained binding pose in the expected 
orientation. 
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tions of 9a at the LSD1inhibitors binding site.
9a at the binding site of 
and the differences in the stability of the MD simulations, the 
the total energy of system observed during entire 
ed within 6.0 Å for the system after reaching at 
d the conformational stabilities of the protein structures. 
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4.5  Summary: 
In summary, we have designed, synthesized and performed detailed pharmacological analysis 
of 3-amino / guanidine substituted phenyl oxazoles as a novel class of LSD1 inhibitors and 
likely epigenetic modulators. These molecules were conveniently prepared via a multistep 
sequence involving an amide bond formation, construction of oxazole ring and introduction 
of quanidine moiety as key steps. Among all the compounds tested 6a, 6b and 9a showed 
promising activities against LSD1 and cancer cells in vitro. Additionally, the compounds 6b 
and 9a were found to increase apoptosis in zebrafish embryos in the brain area when 
evaluated in a phenotype-based zebrafish assay. All these compounds showed good binding 
interactions with the LSD1 enzyme in silico as indicated by docking studies. Overall, our 
study provides the basis for future research which can be directed at elucidating the details of 
the mechanisms of action of the compounds presented, and the contribution of specific 
structural features to their activity.  
 
       4.6  Experimental section 
4.6.1 Chemistry - General methods  
All reactions were carried out under an inert atmosphere with dry solvents, unless otherwise 
stated. Reactions were monitored by thin layer chromatography (TLC) on silica gel plates (60 
F254), using UV light detection.  Visualization of the spots on TLC plates was achieved 
either by UV light or by staining the plates in 2, 4 Dinitro phenyl hydrazine and Ninhydrin 
stains charring on hot plate. Flash chromatography was performed on silica gel (230-400 
mesh) using distilled hexane, ethyl acetate, dichloromethane.  
NMR-Spectroscopy  
1H NMR and 13C NMR spectra were recorded in CDCl3 or acetone-d6 solution by using 
VARIAN 400 MHz spectrometers. Deuterium exchange studies were done in CD3OD, 
DMSO-d6 and D2O. Chemical shifts are reported as δ values relative to internal CDCl3 δ 7.26 
or TMS δ 0.0 DMSO-d6 δ 2.50 and CD3OD δ 3.34 for 1H NMR and CDCl3 δ 77.0 and 
CD3OD δ 49.05 for 13C NMR.  1H NMR data was recorded as follows: chemical shift 
[multiplicity, coupling constant(s) J (Hz), relative integral] where multiplicity is defined as: s 
(singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublet), m (multiplet), bs (broad 
singlet).  
IR spectroscopy, mass spectrometry and melting points  
FTIR spectra were recorded on Bruker (Alpha) spectrometer. Mass spectra were recorded on 
Micro Mass VG-7070H mass spectrometer for ESI and are given in mass units (m/z). High 
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resolution mass spectra (HRMS) [ESI+] were obtained using either a TOF or a double 
focusing spectrometer. Melting points were determined by using a Buchi melting point B-540 
apparatus. Values thus obtained were not corrected. 
4.6.2 Synthesis: 
1a, 1b, 1c were commercially available, whereas methionine ester (1d) was synthesized from 
natural amino acid methionine and 7 from thiourea using literature protocols in quantitative 
yield. 
 
General procedure for synthesis of 2a-c: 
O
OH
NO2
ClHH2N
O
S
O
HBTU,TEA
DCM, N2
0 oC - RT, 24 h
O
N
H
NO2
O
S
OR
R
 
HBTU (1.5 mmol) was added to a mixture of benzoic acid (1a, 1b, 1c) (1 mmol), methionine 
methyl ester hydrochloride (1.2 mmol) in dry DCM (10 mL) at 0 °C. The reaction mixture 
was stirred for 1 hr followed by drop wise addition of dry triethylamine (10.0 mmol) at 0 °C 
and stirring was continued at room temperature for 12 h.  A clear solution of the reaction 
mixture was cooled in an ice bath and acidified with 2N HCl. The residue was dissolved in 
ethyl acetate (750 mL), washed with water (2 x 250 mL), brine (1 x 100 mL), dried over 
Na2SO4, filtered and the solvent evaporated. The residue was purified by flash 
chromatography (n-hexane/ ethylacetate 4:1) to afford the desired products (2a, 2b, 2c). 
 
(S)-Methyl 4-(methylthio)-2-(3-nitrobenzamido) butanoate (2a): 
White semi solid; yield (87 % ); Rf = 0.60 (30% EtOAc-n-Hexane); 
IR (cm-1): 3325, 3056, 2956, 2876, 1735 (C=O of ester), 1690 
(C=O of amide), 1540, 1340; 1H NMR (300 MHz, CDCl3) δ 2.13 
(s, 3H), 2.16 -2.22 (m, 1H), 2.27 -2.34 (m, 1H),  2.62 (t, J = 7.2 Hz, 
1H), 3.81 (s, 3H), 4.92- 4.97  (m, 1H), 7.33 (d, J = 7.6 Hz, 1H), 7.66 (d, J = 8.0 Hz, 1H), 8.17- 
8.22 (dd, J1= 7.4 Hz, J2= 1.6 Hz, 1H),  8.36- 8.39 (dd, J1= 7.4 Hz, J2= 1.6 Hz, 1H), 8.67 (s, 
1H); 13C NMR (75 MHz, CDCl3) δ 15.5, 30.2, 31.1, 52.4, 52.8, 122.1, 126.3, 126.3, 129.8, 
133.2, 135.2, 148.2, 164.7 ; MS (EI, 70ev):  m/z (%) [M]-.  311.1 (100%). 
O
N
H
S
O
OCH3
NO2
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(S)-Methyl 2-(2-chloro-5-nitrobenzamido)-4-(methylthio) butanoate (2b): 
The title compound was prepared in 80% yield according to the 
general procedure as described above; Brown solid; Rf = 0.55 (30% 
EtOAc-n-Hexane); mp 265-267 °C; IR (cm-1): 3295, 3042, 2955, 
2865, 1728 (C=O of ester), 1678 (C=O of amide), 1520, 1334; 1H 
NMR (300 MHz, CDCl3) δ 2.13-2.2 (m, 4H), 2.31-2.38 (m, 1H), 2.56-2.67 (m, 2H), 3.82 (s, 
3H), 4.93- 4.98 (m, 1H), 7.02 (d, J = 7.2 Hz, 1H), 7.62 (d, J = 8.8 Hz, 1H), 8.22-8.25 (dd, J1= 
8.8 Hz, J2= 2.6 Hz, 1H), 8.53 (d, J = 3.2 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 15.5, 29.9, 
31.3, 52.3, 52.8, 125.2, 125.8, 131.4, 135.7, 137.6, 146.4, 163.8, 171.6; MS (EI, 70ev):  m/z 
(%) [M]+.  347.1 (100%). 
 
(S)-Methyl 2-(3, 5-dinitrobenzamido)-4-(methylthio)butanoate (2c): 
The title compound was prepared in 82% yield according to 
the general procedure as described above and isolated as 
yellow solid;  Rf = 0.7 (30% EtOAc-n-Hexane); mp 285-288 
°C; IR (cm-1): 3310, 3010, 2975, 2855, 1732 (C=O of ester), 
1660 (C=O of amide), 1515, 1324;  1H NMR (300 MHz, 
CDCl3) δ  2.16 (s, 3H), 2.17- 2.37 (m, 2H), 2.6-2.68 (m, 2H), 3.84 (s, 3H), 4.99 (td, J1= 7.2 
Hz, J2 = 4.8 Hz, 1H), 7.56 (d, J = 7.2 Hz, 1H), 9.00(d, J = 2.0 Hz, 1H), 9.18 (d, J = 2.0 Hz, 
1H). 13C NMR (75MHz, CDCl3) δ 15.5, 30.2, 30.7, 38.6, 52.8, 52.9, 121.3, 127.3, 137.0, 
148.6, 162.4, 172.2; MS (EI, 70ev):  m/z (%) [M]+.  358.2 (100%). 
 
General procedure for synthesis of 3a-c: 
O
N
H
NO2
O
S
O
O
N
H
NO2
O
H
S
O
LiOH.H2O
THF: H2O (1:1)
0 oC to RT, 1 hR
R
 
LiOH·H2O (1.5 mmol) was added to the solution of (S)-Methyl 4-(methylthio)-2-(3-
nitrobenzamido) butanoate 2a (1.0 mmol) in THF (6 mL), H2O (5 mL) at 0 °C. The reaction 
was stirred at 23 °C for 1 h. After completion of the reaction, the reaction mixture was 
concentrated to remove THF. The solution was cooled in an ice bath and acidified with 2N 
HCl, extracted with EtOAc, followed by brine wash then dried over anhydrous Na2SO4, 
O
N
H
S
O
OCH3
NO2
Cl
O
N
H
S
O
OCH3
NO2
O2N
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filtered and the solvent evaporated. The residue was purified by flash chromatography (n-
hexane/ ethylacetate 3:2) to afford the desired product 3a. 
 
(S)-4-(Methylthio)-2-(3-nitrobenzamido) butanoic acid (3a): 
White solid; yield (88 % ); Rf = 0.4 (30% EtOAc-n-Hexane); mp 
276-278 °C; IR (cm-1): 3302, 2989, 2866, 1712 (C=O of acid), 
1650 (C=O of amide), 1525, 1314;  1H NMR (300 MHz, CDCl3) δ 
2.12 (s, 3H), 2.15 -2.34 (m, 2H), 2.65 (t, J = 7.2 Hz, 1H), 4.92- 
4.97  (m, 1H), 7.28 (bs, 1H), 7.61-7.69 (m, 2H), 8.15 (d, J = 7.8 
Hz, 1H),  8.33 (d, J= 7.8 Hz, 1H), 8.65 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 15.4, 30.2, 30.6, 
52.5, 122.2, 126.5, 129.9, 133.4, 134.9, 148.1, 165.6, 175.3; MS (EI, 70ev):  m/z (%) [M]-.  
297.0 (100%) 
 
(S)-2-(2-chloro-5-nitrobenzamido)-4-(methylthio) butanoic acid (3b): 
The title compound was synthesized in 94% yield according to the 
general procedure as described above for 3a and isolated as brown 
solid; Rf = 0.42 (30% EtOAc-n-Hexane); mp 231-235 °C; IR (cm-1): 
3299, 3050, 2979, 2856, 1722 (C=O of acid), 1650 (C=O of amide), 
1515, 1324; 1H NMR (300 MHz, CDCl3) δ 2.14 (s, 3H), 2.16-2.4 
(m, 2H), 2.65-2.69 (m, 4H), 4.13-5.11 (m, 3H), 7.10 (d, J = 7.6 Hz, 1H), 7.62 (d, J = 8.4 Hz, 
1H), 8.22-8.25 (dd, J1= 8.4 Hz, J2= 2.8 Hz, 1H), 8.53 (d, J = 2.4 Hz, 1H); 13C NMR (75 MHz, 
CDCl3) δ 15.5, 29.7, 30.1, 30.9, 52.4, 125.3, 126.0, 131.5, 135.4, 137.7, 146.5, 164.4, 175.2 
MS (EI, 70ev):  m/z (%) [M]+.  333.1 (100%). 
 
(S)-2-(3, 5-dinitrobenzamido)-4-(methyl thio) butanoic acid (3c): 
The title compound was synthesized in 90% yield according to 
the general procedure as described for 3a as light brown solid; 
Rf = 0.42 (30% EtOAc-n-Hexane); mp 268-270 °C; IR (cm-1): 
3301, 3060, 2985, 2862, 1718 (C=O of acid), 1660 (C=O of 
amide), 1525, 1334; 1H NMR (300 MHz, DMSO-d6) δ 2.12 (s, 
3H), 2.13- 2.33 (m, 2H), 2.57-2.70 (m, 2H), 4.80-4.86 (m, 2H), 9.11(d, J = 2.0 Hz, 1H), 9.21 
(d, J  = 7.6 Hz, 1H), 9.31(d, J = 2.0 Hz, 2H). 13C NMR (75MHz, DMSO-d6) δ 15.3, 30.4, 30.9, 
52.6, 120.8, 127.8, 137.4, 148.3, 162.6, 173.3; MS (EI, 70ev):  m/z (%) [M]+.  344.1 (100%).  
O
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General procedure for synthesis of 4a-c: 
O
N
H
NO2
O
H
S
OR
Ac2O, Py,
110 oC, 2 h
O
N
H
NO2
S
OR
 
To a solution of (S)-4-(Methylthio)-2-(3-nitrobenzamido) butanoic acid 3a (4.9 mmol) in acetic 
anhydride (30.4 mmol, 3 mL), pyridine (58.8 mmol, 5 mL) was added and heated at 90 °C for 
2 h. The reaction mixture was concentrated to remove excess acidic anhydride and pyridine, 
extracted with EtOAc (150 mL). EtOAc layer was washed successively with 1.0 N HCl (50 
mL), water (50 mL) and brine then dried over anhydrous Na2SO4, filtered and the solvent 
evaporated. The residue was purified by column chromatography (EtOAc/hexanes) to 
provide of the desired product 4a. 
 
N-(1-(Methyl thio)-4-oxopentan-3-yl)-3-nitrobenzamide (4a): 
Light brown semi solid; Rf = 0.6 (30% EtOAc-n-Hexane); IR (cm-
1): 3100, 3060, 2985, 2862, 1720 (C=O of ketone), 1665 (C=O of 
amide), 1515, 1314;   1H NMR (300 MHz, CDCl3) δ 2.13 (s, 3H), 
2.14 -2.17 (m, 2H), 2.34 (s, 3H), 2.41 -2.64 (m, 2H),  4.96 - 4.99  
(m, 1H), 7.35 (d, J = 6.4 Hz, 1H), 7.67 (t, J = 7.8 Hz, 1H), 8.17 (d, J 
= 7.8 Hz, 1H),  8.37- 8.39 (dd, J1= 8.0 Hz, J2= 1.6 Hz, 1H), 8.67 (s, 1H) ; 13C NMR (75 MHz, 
CDCl3) δ 15.7, 27.3, 30.1, 30.5, 58.9, 122.1, 126.4, 129.8, 133.1, 135.4, 148.3, 164.8, 205.7; 
MS (EI, 70ev):  m/z (%) [M]-.  295.0 (100%). 
 
2-chloro-N-(1-(methylthio)-4-oxopentan-3-yl)-5-nitrobenzamide (4b): 
The title compound was synthesized as yellow semi solid in 78% 
yield according to the general procedure as described above for 4a; 
Rf = 0.65 (30% EtOAc-n-Hexane); IR (cm-1): 3200, 3050, 2976, 
2862, 1710 (C=O of ketone), 1655 (C=O of amide), 1518, 1323;  1H 
NMR (300 MHz, CDCl3) : 2.00- 2.07 (m, 1H), 2.13 (s, 3H), 2.34 (s, 
3H),  2.39- 2.46 (m, 1H), 2.53-2.61 (m, 2H), 4.96-5.00 (m, 1H), 7.16 (d, J = 4.8 Hz, 1H), 7.62 
(d, J = 7.2 Hz, 1H), 8.22-8.25 (dd, J1= 7.2 Hz, J2= 2.4 Hz, 1H), 8.51 (d, J = 2.8 Hz, 1H); 13C 
O
N
H
S
O
NO2
O
N
H
S
O
NO2
Cl
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NMR (75 MHz, CDCl3):15.5, 25.0, 30.9, 33.3, 126.7, 128.2, 131.7, 133.2, 140.2, 146.9, 
156.4, 208.2 ;  MS (EI, 70ev):  m/z (%) [M]+.  333.1 (100%). 
 
N-(1-(methylthio)-4-oxopentan-3-yl)-3,5-dinitrobenzamide (4c): 
The title compound was synthesized as colorless semi solid in 
74% yield according to the general procedure as described 
above for 4a; Rf = 0.7 (30% EtOAc-n-Hexane); IR (cm-1): 
3233, 3040, 2978, 2872, 1718 (C=O of ketone), 1656 (C=O of 
amide), 1520, 1321; 1H NMR (300 MHz, CDCl3) δ 2.03- 2.19 
(m, 5H), 2.25-2.36 (m, 2H), 2.55-2.64 (m, 2H), 4.90-5.00 (m, 1H), 7.85 (bs, 1H), 9.03 (d, J = 
1.6 Hz, 2H), 9.17 (d, J = 1.6 Hz, 1H). 13C NMR (75MHz, CDCl3) δ 15.7, 27.3, 29.6, 59.1, 
121.2, 127.5, 137.1, 148.5, 162.6, 205.6; MS (EI, 70ev):  m/z (%) [M]+.  288.4 (100%).  
 
General procedure for synthesis of 5a-c: 
O
N
H
NO2
S
OR
NO2
N
O
S
R
POCl3, DMF,
90 oC, 30 min
 
Phosphorus oxychloride (1 mL, 10 mmol) was added dropwise to a solution of N-(1-
(Methylthio)-4-oxopentan-3-yl)-3-nitrobenzamide 4a (3.3 mmol) in DMF (10 mL) at 0 OC.  
The mixture was heated to 90°C for 45 min and then cooled to 0 OC before being quenching 
with water and extracted with EtOAc. The combined organic phases were washed with water 
and brine (15 mL), dried over anhydrous Na2SO4, filtered and the solvent evaporated. The 
residue was purified by column chromatography (EtOAc/hexanes) to provide of the desired 
products. 
 
5-Methyl-4-(2-(methylthio) ethyl)-2-(3-nitrophenyl) oxazole (5a): 
Brownish semi solid; Rf = 0.7 (30% EtOAc-n-Hexane); Yield 84 % ; 
IR (cm-1): 3060, 2955, 2862, 1520, 1321; 1H NMR (300 MHz, CDCl3) 
δ 2.15 (s, 3H), 2.39 (s, 3H), 2.78 -2.87 (m, 4H),  7.59 - 7.63 (t, J = 8.0 
Hz, 1H), 8.23 (d, J = 8.0 Hz, 1H), 8.25 (d, J = 1.6 Hz, 1H), 8.8 (s, 1H) 
; 13C NMR (75 MHz, CDCl3) δ 10.3, 15.7, 26.1, 33.5, 1207, 124.0, 
O
N
H
S
O
NO2
O2N
NO2
N
O
S
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129.3, 129.8, 131.4, 135.4, 145.5, 148.6, 157.1; MS (EI, 70ev):  m/z (%) [M]+.  279.0 (100%). 
2-(2-chloro-5-nitrophenyl)-5-methyl-4-(2-(methylthio) ethyl) oxazole (5b): 
The title compound was synthesized as brown color semi solid in 80% 
yield according to the general procedure as described above for 5a; Rf 
= 0.7 (30% EtOAc-n-Hexane); IR (cm-1): 3070, 2978, 2856, 1510, 
1318; 1H NMR (300 MHz, CDCl3) δ 2.15 (s, 3H), 2.41(s, 3H), 2.80-
2.89 (m, 4H), 7.65 (d, J = 8.4 Hz, 1H), 8.14-8.16 (dd, J1= 8.4 Hz, J2= 
2.8 Hz, 1H), 8.85 (d, J = 2.8 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 
10.3, 15.7, 26.0, 33.5, 124.3, 125.8, 127.7,  132.3, 135.5, 138.4, 145.9, 146.4, 155.1MS (EI, 
70ev):  m/z (%) [M]+.  313.1 (100%). 
 
2-(3,5-Dinitrophenyl)-5-methyl-4-(2-(methylthio) ethyl) oxazole (5c): 
The title compound was synthesized as brown color semi solid 
in 88% yield according to the general procedure as described 
above for 5a; Rf = 0.72 (30% EtOAc-n-Hexane); IR (cm-1): 
3048, 2978, 2856, 1530, 1325; 1H NMR (300 MHz, CDCl3) δ 
2.15 (s, 3H), 2.43 (s, 3H), 2.80-2.89 (m, 4H), 9.02 (d, J = 2.0 
Hz, 1H), 9.10 (d, J = 2.0 Hz, 2H). 13C NMR (75MHz, CDCl3) δ 10.4, 15.7, 25.9, 33.5, 118.6, 
125.3, 130.9, 136.4, 146.9, 148.9, 155.2; MS (EI, 70ev):  m/z (%) [M]+.  324.2 (96%), 
294.2(100%). 
 
General procedure for synthesis of 6a-c: 
NH2
N
O
S
R
NO2
N
O
S
R
SnCl2 2H2O
12N HCl
65 oC - 85 oC
5-9 min
 
To a solution of 5-Methyl-4-(2-(methylthio) ethyl)-2-(3-nitrophenyl) oxazole (5a) (2.5 mmol) in 
36% HCl (6 mL), stannouschloride monohydrate (12.5 mmol) was added. The mixture was 
heated to 100 °C for 15min, cooled to 0 OC the aqueous solution was basified with 2N NaOH 
and extracted three times with dichloromethane. The organic layers were combined, washed 
with brine solution and dried over anhydrous Na2SO4 and concentrated to give desired product 
6a. 
NO2
N
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S
Cl
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O
S
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3-(5-Methyl-4-(2-(methylthio) ethyl) oxazol-2-yl) aniline (6a): 
Brown solid; Rf = 0.4 (30% EtOAc-n-Hexane); mp 292-294 °C; 
Yield (65 %);  IR (cm-1): 3390, 3350 (NH2), 3020, 2910, 2858, 1650, 
1110; 1H NMR (300 MHz, CDCl3) δ  2.12 (s, 3H), 2.33 (s, 3H), 2.74 
-2.85 (m, 4H), 6.70 - 6.73 (dd, J1= 7.8 Hz, J2= 2.2 Hz, 1H), 7.18 – 
7.22 (m, 2H), 7.31  (t, J = 1.6 Hz, 1H), 7.32 - 7.37 (dt, J1= 8.6 Hz, 
J2= 1.2 Hz, 1H), 8.8 (s, 1H) ; 13C NMR (75 MHz, CDCl3) δ 10.2, 
15.7, 26.1, 33.7, 112.1, 116.6, 116.9, 128.3, 129.7, 134.2, 144.4, 146.2, 159.6; MS (EI, 70ev):  
m/z (%) [M]+.  249.3 (100%). HRMS [M] + Calcd. for C13H17N2O5S 249.1062; Found: 
249.1056. 
 
4-chloro-3-(5-methyl-4-(2-(methylthio) ethyl) oxazol-2-yl) aniline (6b): 
The title compound was synthesized as yellow color semi solid in 76% 
yield according to the general procedure as described above for 6a; Rf 
= 0.42 (30% EtOAc-n-Hexane); IR (cm-1): 3400, 3375 (NH2), 3010, 
2962, 2892, 1620, 1220; 1H NMR (300 MHz, CDCl3) δ 2.14 (s, 3H), 
2.36 (s, 3H), 2.77-2.86 (m, 4H), 3.5 (bs, 2H), 6.63-6.66 (dd, J1= 8. Hz, 
J2= 2.8 Hz, 1H), 7.22-7.26 (dd, J1= 8.0 Hz, J2= 2.8 Hz, 2H). 13C NMR (75MHz, CDCl3) δ 
10.23, 15.6, 26.1, 33.6, 116.5, 117.6, 121.2, 126.8, 131.6, 134.3, 144.7, 157.6; MS (EI, 70ev): 
m/z (%) [M]+. 283.1 (100%). HRMS [M]+ Calcd. for C13H16N2OSCl  283.0672; Found: 
283.0675. 
 
5-(5-Methyl-4-(2-(methylthio) ethyl) oxazol-2-yl) benzene-1,3-diamine (6c): 
The title compound was synthesized as dark brown color semi 
solid in 76% yield according to the general procedure as 
described above for 6a; Rf = 0.2 (30% EtOAc-n-Hexane); IR (cm-
1): 3425, 3396 (NH2), 3030, 2954, 2892, 1600, 1550, 1190; 1H 
NMR (300 MHz, CDCl3) δ  2.12 (s, 3H), 2.32 (s, 3H), 2.73-2.83 
(m, 4H), 3.69-3.78 (bs, 4H), 6.07 (t, J = 2.0 Hz, 1H), 6.74 (d, J = 2.0 Hz, 2H). 13C NMR 
(75MHz, CDCl3) δ 15.7, 26.2, 29.7, 33.7, 40.9, 58.8, 71.63, 87.1, 103.1, 103.6, 125.9, 128.4, 
128.5, 129.4, 134.3, 143.8, 147.7, 159.7; MS (EI, 70ev):  m/z (%) [M]+.  264.1 (100%), 216.2 
(78%) HRMS [M] + Calcd. for C13H18N3OS  264.1171; Found: 264.1174. 
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General procedure for synthesis of 8a-c: 
To a solution of 3-(5-Methyl-4-(2-(methylthio) ethyl) oxazol-2-yl) aniline 6a (0.4 mmol) in 
dryDMF (6 mL),    N1, N2-bis (tert-butoxycarbonyl)-S-methylisothiourea (0.45 mmol), 
triethylamine (0.1 mL, 0.4 mmol) and HgCl2 (or AgNO3) (0.48 mmol) was added. The 
suspension was stirred at room temperature for 12 h then concentrated in vacuo. The crude 
reaction mixture was taken up in DCM (20 mL), filtered through a pad of celite on a sintered 
glass funnel, washed with saturated aqueous NH4Cl (5 mL) and organic layer was washed 
with brine (50 mL), and dried over Na2SO4, filtered and concentrated to give desired product 
(8a). 
NH
N
O
S
N
NH
N
NH
S
HgCl2, TEA, DMF
12 h
7
RBoc
Boc
Boc
Boc
NH2
N
O
S
R
 
 
 
(E)-tert-butyl (tert-butoxycarbonylamino) (3-(5-methyl-4-(2-(methylthio) ethyl) oxazol-2-
yl) phenylamino) methylenecarbamate (8a): 
Colorless semi solid;  Rf = 0.8 (30% EtOAc-n-Hexane); Yield 
(78%); IR (cm-1): 3261(NH), 3154, 2978, 2926, 1721(amide), 
1644 (C=N); 1H NMR (300 MHz, CDCl3) δ 1.52(s, 9H), 
1.53(s, 9H), 2.14 (s, 3H), 2.35 (s, 3H), 2.75 -2.85 (m, 4H), 7.40 
(t, J = 8.0 Hz, 1H), 7.71(d, J = 8.0 Hz, 1H ), 7.92  (t, J = 2.2 Hz, 
1H), 8.06 (s, 1H), 10.45(bs, 1H), 11.63(bs, 1H) ; 13C NMR (75 
MHz, CDCl3) δ 10.2, 15.7, 26.2, 33.7, 112.3, 116.3, 116.6, 128.5, 129.6, 134.4, 143.9, 146.5, 
159.6; MS (EI, 70ev):  m/z (%) [M]+.  491.23 (100%). HRMS [M] + Calcd. for C24H35N4O5S 
491.2328; Found: 491.2316. 
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(E)-tert-butyl (tert-butoxycarbonylamino) (4-chloro-3-(5-methyl-4-(2 (methylthio) ethyl) 
oxazol-2-yl) phenylamino) methylenecarbamate (8b): 
The title compound was synthesized as colorless solid in 
72% yield according to the general procedure as described 
above for 8a;  Rf = 0.8 (30% EtOAc-n-Hexane); mp 310-
312 °C. IR (cm-1): 3321(NH), 3124, 2978, 2862, 1700 
(amide), 1665 (C=N); 1H NMR (300 MHz, CDCl3) δ 1.51 
(s, 9H), 1.53 (s, 9H), 2.14 (s, 3H), 2.37 (s, 3H), 2.80-2.86 
(m, 4H), 7.43 (d, J = 8.8 Hz, 1H), 7.87-7.90 (dd, J 1= 8.8 
Hz, J2 = 2.4 Hz, 1H), 8.04 (d, J = 2.4 Hz, 1H). 13C NMR (75MHz, CDCl3) δ 10.3, 15.7, 26.2, 
28.0, 28.1, 29.7, 33.6, 79.9, 84.0, 123.2, 124.2, 126.7, 127.4, 131.6, 134.7, 135.8, 144.9, 
153.2, 153.4, 156.9, 163.2; MS (EI, 70ev):  m/z (%) [M]+.  542.3 (10%), 525.3 (100%) HRMS 
[M] + Calcd. for C24H34N4O6SCl  541.1874; Found: 541.1865. 
 
Tert-butyl(5-(5-methyl-4-(2-(methylthio)ethyl)oxazol-2-yl)-1,3-phenylene)bis(azanediyl) 
bis ((tert-butoxycarbonylamino) methan-1-yl-1-ylidene) dicarbamate (8c): 
 
The title compound was synthesized as colorless solid in 
80% yield according to the general procedure as described 
above for 8a; Rf = 0.85 (30% EtOAc-n-Hexane); mp 369-
372 °C . IR (cm-1): 3361(NH), 3133, 2958, 2862, 
1710(amide), 1660 (C=N); 1H NMR (300 MHz, CDCl3):  
1.52 (s, 3H), 2.13 (s, 3H), 2.34 (s, 3H), 2.74-2.85 (m, 4H), 
8.12 (d, J = 1.6 Hz, 2H), 8.16 (s, 1H), 10.48 (s, 2H), 11.54 
(bs, 2H). 13C NMR (75MHz, CDCl3): 10.1, 15.7, 26.2, 28.1, 33.6, 79.6, 83.8, 115.4, 116.5, 
128.7, 134.7, 137.9, 144.3, 153.3, 158.8, 163.2; MS (EI, 70ev):  m/z (%) [M]+.  748.36 (68%), 
348.15 (100%). 
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General procedure for synthesis of 9a-c: 
 
A solution containing (E)-Tert-butyl (tert-butoxycarbonylamino) (3-(5-methyl-4-(2-(methylthio) 
ethyl) oxazol-2-yl) phenylamino) methylenecarbamate 8a (0.023 mmol) in DCM (1 ml), 1mL of TFA 
was added at 0 oC, and then stirred at RT for 1 h. The solvent was removed under high 
vacuum to generate the trifluoroacetate salt. This salt was redissolved in 20 mL of an aqueous 
solution of NaHCO3 and washed with DCM (3 × 15 mL). The organic layer was washed with 
water (2 × 10 mL), followed by brine wash, dried over anhydrous Na2SO4 and concentrated to 
give the corresponding free guanidine (9a). 
 
1-(3-(5-Methyl-4-(2-(methylthio) ethyl) oxazol-2-yl) phenyl) guanidine (9a): 
Color less semi solid; Rf = 0.3 (5% MeOH-CH2Cl2); Yield 
(85%); IR (cm-1): 3340(NH), 3178, 2963, 2854, 1680 (C=N);  1H 
NMR (300 MHz, CDCl3) δ 2.15 (s, 3H), 2.33 (s, 3H), 2.74 -2.84 
(m, 4H), 2.86- 3.40(bs, 4H), 6.98 (d, J = 8.0 Hz, 1H ), 7.33  (t, J 
= 8.0 Hz, 1H), 7.56 (s, 1H),7.61 (d, J = 8.0 Hz, 1H);  13C NMR 
(75 MHz, CDCl3) δ 8.6, 14.3, 29.3, 33.1, 122.2, 124.4, 126.6, 
128.7, 130.4, 134.5, 135.7, 145.7, 156.6, 158.6; MS (EI, 70ev):  m/z (%) [M]+.  291.3 (100%). 
HRMS [M] + Calcd. for C14H18N4OS 291.3228; Found: 291.3216. 
 
1-(4-chloro-3-(5-methyl-4-(2-(methylthio)ethyl)oxazol-2-yl)phenyl)guanidine (9b): 
The title compound was synthesized as colorless semi solid in 
80% yield according to the general procedure as described 
above for 9a; Rf = 0.3 (5% MeOH-CH2Cl2); Yield (74%); IR 
(cm-1): 3420(NH), 3178, 2978, 2921, 2834, 1690 (C=N); 1H 
NMR (300 MHz, CDCl3) δ 2.18 (s, 3H), 2.38 (s, 3H), 2.71 -2.89 
(m, 4H), 7.10-7.30 (m, 2H ), 7.52  (d, J = 8.0 Hz, 1H), 7.78 (s, 
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1H), 10.00 (s, 1H), 10.29 (bs, 2H) ; 13C NMR (75 MHz, CDCl3) δ 10.2, 15.5, 29.7, 33.4, 
126.7, 127.2, 128.2, 131.7, 132.9, 133.2, 146.9, 156.4; MS (EI, 70ev):  m/z (%) [M]+.  291.3 
(100%).  MS (EI, 70ev):  m/z (%) [M]+.  324.3 (100%). HRMS [M] + Calcd. for 
C14H17ClN4OS 324.3134; Found: 324.3146. 
 
1,1’-(5-(5-methyl-4-(2-(methylthio)ethyl) oxazol-2-yl)-1,3-phenylene)diguanidine (9c): 
The title compound was synthesized as white color solid in 
80% yield according to the general procedure as described 
above for 9a; mp 308-311 °C; Rf = 0.3 (15% MeOH-CH2Cl2); 
Yield (80%); IR (cm-1): 3390 (NH), 3156, 2985, 2911, 2865, 
1676 (C=N);  1H NMR (300 MHz, CD3OD) δ  2.06 (s, 3H), 
2.33 (s, 3H), 2.74-2.77 (m, 4H), 7.24 (s, 1H), 7.79 (s, 2H); 13C 
NMR (75MHz, CD3OD) δ 10.1, 15.5, 26.6, 34.4, 121.7, 124.0, 131.8, 136.5, 138.7, 147.6, 
158.1, 158.9; MS (EI, 70ev):  m/z (%) [M]+.  348.1 (100%) %) HRMS [M] + Calcd. for 
C15H22N7OS  348.1607; Found: 348.1612. 
 
N-(4-chloro-3-(5-methyl-4-(2-(methylthio)ethyl)oxazol-2-yl)phenyl)acetamide (10): 
HN
N
O
S
NH2
N
O
S
CH3COCl,
DCM, TEA
0 oC to RT 2 hr
Cl
Cl
O  
Acetyl chloride (1.2 mmol) was added to a mixture of 4-chloro-3-(5-methyl-4-(2-(methylthio) 
ethyl)oxazol-2-yl) aniline (6b) (1 mmol), triethylamine (2.4 mmol) in dry dichloromethane 
(10 mL) at 0 °C. The reaction mixture was stirred for 2 hr followed by drop wise addition of 
2N HCl. The residue was dissolved in dichloromethane (50 mL), washed with water (2 x 250 
mL), brine (1 x 100 mL), dried over Na2SO4, filtered and the solvent evaporated. The residue 
was purified by flash chromatography (n-hexane/ ethylacetate 4:1) to afford the desired 
product (10) as yellow colour semi solid in 90% yield; Rf = 0.42 (30% EtOAc-n-Hexane); IR 
(cm-1): 3345, 3066, 2966, 2866, 1685 (C=O of amide), 1340; 1H NMR (300 MHz, CDCl3) δ 
1.88 (s, 3H), 2.15 (s, 3H), 2.50 (s, 3H),  2.87-2.98 (m, 4H), 7.12 (d, J= 8.1 Hz, 1H), 7.64 (dd, 
J1= 8.1 Hz, J2= 2.8 Hz, 2H), 7.82 (s, 1H), 9.86 (bs, 1H) . 13C NMR (75MHz, CDCl3) δ 10.3, 
NH
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15.6, 23.6, 29.6, 33.6, 119.8, 127.6, 131.8, 131.9, 134.9, 138.0, 145.3, 156.1, 169.6; MS (EI, 
70ev): m/z (%) [M]-  323.15 (100%).  
 
N-(4-chloro-3-(5-methyl-4-(2-(methyl thio)ethyl)oxazol-2-yl)phenyl)benzamide (11): 
 
 The title compound was synthesized as colourless semi solid in 
86% yield according to the procedure as described above for 10 ( 
instead of acetyl chloride benzoyl chloride was taken); Rf = 0.42 
(10% EtOAc-n-Hexane); IR (cm-1): 3195, 3052, 2965, 2875, 1679 
(C=O of amide), 1314;   1H NMR (300 MHz, CDCl3) δ 2.16 (s, 3H), 
2.48 (s, 3H), 2.96-3.08 (m, 4H), 7.36 (d, J= 8.2 Hz,  1H), 7.47-7.52 (m, 2H), 7.63-7.74 (m, 
2H), 8.06 (d, J= 7.2 Hz, 1H), 8.85 (bs, 1H). 13C NMR (75MHz, CDCl3) δ 11.2, 15.1, 29.8, 
33.8, 121.1, 125.1, 126.9, 127.9, 128.6, 130.7, 132.0, 136.9, 138.8, 158.6, 166.6; MS (EI, 
70ev): m/z (%) [M]-. 385.27 (100%).  
 
N-(4-chloro-3-(5-methyl-4-(2-(methylthio)ethyl)oxazol-2-yl)phenyl)methane sulfonamide 
(12): 
HN
N
O
S
NH2
N
O
S
CH3SO2Cl,
DCM, DMAP,
TEA, 0 oC to RT
3 hr
Cl
Cl
S
O
O
 
Methane sulfonyl chloride (1.2 mmol) was added to a mixture of 4-chloro-3-(5-methyl-4-(2-
(methylthio) ethyl) oxazol-2-yl) aniline (6b) (1 mmol), triethylamine (2.4 mmol) and DMAP 
(0.1 mmol) in dry dichloromethane (10 mL) at 0 °C. The reaction mixture was stirred for 3 hr 
followed by drop wise addition of 2N HCl. The residue was dissolved in dichloromethane (50 
mL), washed with water (2 x 150 mL), brine (1 x 50 mL), dried over Na2SO4, filtered and the 
solvent evaporated. The residue was purified by flash chromatography (n-hexane/ ethylacetate 
3.5:1.5) to afford the desired product (12) as brown colour semi solid in 90% yield; Rf = 0.30 
(30% EtOAc-n-Hexane); IR (cm-1): 3290, 3050, 2985, 2865, 1680 (C=O of amide), 1326;  1H 
NMR (300 MHz, CDCl3) δ 2.25 (s, 3H), 2.35 (s, 3H), 2.75 (s, 3H), 2.87-3.02 (m, 4H), 5.96 
(bs, 1H), 6.85 (d, J= 8.4 Hz,1H), 7.13 (d, J= 8.6 Hz,1H), 7.40-7.46 (m, 1H). 13C NMR 
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(75MHz, CDCl3) δ 11.5, 15.6, 28.6, 36.6, 39.3, 115.5, 121.1, 125.0, 130.4, 136.7, 138.6, 
144.5, 158.6; MS (EI, 70ev): m/z (%) [M]+. 360.97 (100%).  
 
N-(4-chloro-3-(5-methyl-4-(2-(methylthio)ethyl)oxazol-2-yl)phenyl)-4-methylbenzene 
sulphonamide (13): 
The title compound was synthesized as yellow colour 
semi solid in 86% yield according to the procedure as 
described above for 12 ( instead of methane sulfonyl 
chloride 4-toluene sulfonyl chloride was taken); Rf = 0.6 
(10% EtOAc-n-Hexane); IR (cm-1): 3210, 3010, 2965, 
2875, 1690 (C=O of amide), 1314; 1H NMR (300 MHz, 
CDCl3) δ 2.20 (s, 3H), 2.32 (s, 3H), 2.41(s, 3H), 2.85-2.96 
(m, 4H), 6.15 (bs, 1H), 6.91 (d, J= 8.4 Hz, 1H), 6.98 (d, J= 7.2 Hz, 1H), 7.21-7.26 (m, 1H), 
7.41 (d, J= 8.2 Hz, 2H), 7.62 (d, J= 8.2 Hz, 1H). 13C NMR (75MHz, CDCl3) δ 10.3, 15.6, 
20.9, 25.9, 35.9,110.5, 121.7, 124.5, 128.7, 130.2, 130.9, 136.2, 136.9, 139.9, 157.7; MS (EI, 
70ev): m/z (%) [M]+. 437.23 (100%).  
 
4-chloro-N,N-dimethyl-3-(5-methyl-4-(2-(methylthio)ethyl)oxazol-2-yl)aniline (14): 
 
N
N
O
S
NH2
N
O
S
K2CO3, dry DMF,
CH3I, 0 oC to RT
12 hr
Cl
Cl
 
Methyl iodide (6.0 mmol) was added to a mixture of 4-chloro-3-(5-methyl-4-(2-(methylthio) 
ethyl) oxazol-2-yl) aniline (6b) (1 mmol), anhydrous K2CO3 (6.0 mmol) in dry dimethyl form 
amide (10 mL) at 0 °C. The reaction mixture was stirred for 12 hr followed by drop wise 
addition of 1N HCl at 0 °C. The residue was dissolved in dichloromethane (2 x  50 mL), 
washed with water (2 x 150 mL), brine (1 x 50 mL), dried over Na2SO4, filtered and the 
solvent evaporated. The residue was purified by flash chromatography (n-hexane/ ethylacetate 
3:2) to afford the desired product (14) as brown colour semi solid in 65% yield; Rf = 0.20 
(40% EtOAc-n-Hexane); IR (cm-1): 3050, 2972, 2872, 1630, 1290; 1H NMR (300 MHz, 
CDCl3) δ 2.14 (s, 3H), 2.45 (s, 3H), 3.05-3.16 (m, 4H), 3.55 (s, 6H), 6.82 (d, J= 8.4 Hz, 1H), 
Cl
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6.96 (d, J= 7.8 Hz, 1H), 7.15 (m,1H). 13C NMR (75MHz, CDCl3) δ 10.3, 15.6, 26.0, 31.8, 
45.9, 111.7, 117.5, 124.5, 125.2, 128.7, 136.9, 145.3, 148.2, 155.6; MS (EI, 70ev): m/z (%) 
[M]+. 311.17 (100%).  
 
4.6.3 Pharmacology 
4.6.3.1 Evaluation of cell viability 
The MTT assay was used for evaluating the effect of the compounds on cell viability. RPMI 
medium supplemented with 10% FBS and antibiotics was used to culture HeLa and MDA-
MB-231 cells. MTT dye prepared in 1X PBS was used for cell viability assays. HeLa and 
MDA-MB-231 cells in monolayer were trypsinised and the cell count was adjusted to 3x106 
cells/ml using medium containing 10% fetal calf serum. Cells were pre-incubated at a 
concentration of 1×106 cells/ml in culture medium for 3h at 37°C and 6.5% CO2. Cells were 
then seeded at a concentration of 5×104 cells/well in 100 µl culture medium and the plates 
incubated at 37 ºC in 5% CO2 incubator for 24 h. After 24h, 100 µl of previously diluted 
compounds of different concentrations of test compounds in media were added and incubated 
at 37 ºC in 5% CO2 for 72h and cells were periodically checked for granularity, shrinkage and 
swelling. After 72h, 10ml of MTT dye was added to each well. The plates were gently shaken 
and incubated for 4h at 37 oC in 5% CO2. The supernatant was removed and 100 µl of 1:1 
DMSO: Ethanol was added and the plates were gently shaken to solubilize the formed 
formazan. The absorbance was measured using a microplate reader at a wavelength of 550 
nm.  
4.6.3.2 Evaluation of in vitro LSD1 activity 
The effect of the compounds was evaluated in an in vitro LSD1 enzyme assay. The 
compounds were dissolved in 100% DMSO to a stock concentration of 10mM and used in the 
assay as per the manufacturer’s instructions (Cayman Chemical Company, LSD1 screening 
kit Catalog # 700120). Briefly, the assay is based on the generation of the product Resorufin 
by the enzyme Horse radish peroxidase in the presence of hydrogen peroxide, which is 
produced by the demethylation of a methylated histone H3K4 peptide by LSD1. The amount 
of Resorufin generated is measured spectrophotometrically at 595/60 nm and is an indicator 
of LSD1 activity.  
The assay was performed in a 96-well plate format with triplicates of all samples. Absorbance 
values were normalized to background (lacking the substrate peptide) and % initial activity 
was calculated using the formula 100-[(I-S)/S)*100], where I was the absorbance of the Initial 
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activity samples (without inhibition) and S was the absorbance of the test samples (with 
various compounds).  
 
4.6.3.3 Evaluation of in vivo apoptosis and toxicity using zebrafish embryos44 
All procedures using zebrafish were in accordance with ethical guidelines for animal use and 
followed those published by the NIH. An indigenous wild type adult zebrafish strain from 
India was used for this study (obtained from Vikrant Aquaculture, Mumbai, India). They were 
maintained in a recirculation system using purified ELIX System (Millipore, Billerica, US) 
grade water containing 200mg/l sea salt at 28 oC under a 14:10 h light and dark cycle. Fish 
were fed three times daily with a combination of freshly hatched live brine shrimp and dry 
food. Males and females were kept in separate tanks for four days before they were allowed to 
spawn. On day five, 300-400 embryos were obtained by natural mating of both adult sexes 
(3:2 female and male ratios) in a breeding tank setup. Embryos were collected and raised in 
60 mm Petri dishes containing E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, and 
0.33 mM MgSO4) for 24h. Compound stocks were diluted in E3 medium to obtain final 
concentrations of 10µM in 0.1% DMSO. Zebrafish embryos at 24h post fertilization were 
dechorionated with 500µg/ml Pronase K for 10 minutes. Six embryos per well were placed in 
24-well plates containing E3 medium and compounds added to a final concentration of 10µM 
(in 0.1% DMSO). The embryos were grown in the presence of the compounds for 24h, 48h 
and 72h. Control embryos were incubated in 0.1% DMSO. Apoptosis was assessed at the 
respective time points using acridine orange staining. Briefly, embryos were washed twice 
with 1X PBS (phosphate buffer saline) for 5min each, followed by incubation in acridine 
orange solution (5µg/ml in E3 medium) for 1h at room temperature. Embryos were then 
washed with 1X PBS three times for 5min each and visualized under an upright fluorescence 
microscope (Zeiss Axioscope) at an excitation wavelength of 502nm and an emission 
wavelength of 525nm. Acridine orange is a fluorescent dye that binds to DNA and exhibits 
increased fluorescence in fragmented nuclei, a hallmark of apoptosis [1-2]. Embryos were also 
observed using visible light microscopy at regular intervals after compound treatment to 
document general toxicity-related effects such as developmental delays, deformations, edema 
and death. 
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4.6.4 Molecular Modeling Studies
 
4.6.4.1 Docking method 
We carried out Molecular modeling (Docking analysis and Molecular dynamics simu
studies to reveals the binding mode and ligand receptor complex stability. The docking 
studies of most potent molecules were performed using the Schrodinger software suite 
(Maestro, version 9.2, Schrodinger, LLC: New York, NY 2012). The compounds 
sketched in 3D format using build panel and were prepared for docking using ligprep 
application. The Protein (PDB ID: 2Z3Y)
bank (PDB). The protein was prepared by giving preliminary treatment like 
adding missing residues, refining the loop with prime and finally minimized by using OPLS 
2005 force field. Grids for molecular docking were generated with bound co
ligand. Compounds were docked using Glide (Glide version 5.7,
York, NY 2012) in extra-precision mode, with up to three poses saved per molecule.
 
4.6.4.2 Molecular Dynamics Simulations Protocols:
Molecular dynamics (MD) simulations of 
using the Desmond package incorporated in the Maestro 
OPLS-AA force field in an explicit solvent with the single point charges (SPC) water model 
(OPLS-AA/SPC). The initial coordinates for the MD calculations were taken from the 
docking experiments. The SPC water molecules were then added and system was neutralized 
by adding Na+ counter-ion to balance the net charges of the system. After the construction of 
the solvent environment, the complex system was composed of approximately 126117 atoms. 
Before equilibration and long production MD simulations, the systems were minimized and 
pre-equilibrated using the default relaxation routine implemented in Desmond.
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Figure 16: Time dependence of the total energy (
to the initial minimised complex of 
 
The MD simulations were run for 5 ns and during the MD simulations, the equations of 
motion were integrated with a 2 fs time step in the NVT ensemble. The SHAKE algorithm 
was applied to all hydrogen atoms; the van der Waals (VDW) cutoff was set to 9 A
temperature was maintained at 300 K, employing the Nosé
relaxation time of 1ps. The trajectory recording interval was kept for every 10 ps during entire 
MD runs. 
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5. Design, synthesis & pharmacological evolution of isovanillin 
derived Isoxazolidines as potential vanilloid receptors 
5.1 Introduction:  
5.1.1 Importance for Noval Scaffolds to Treat Pain: 
 International Association for the Study of Pain (IASP) define pain as unpleasant 
sensory and emotional experience associated with actual or potential tissue damage. It has 
been observ as a major symptom in many disease conditions, which can lead to significant 
changes in a patient’s lifestyle, functional ability and overall quality of life. Based on the 
nature of impact on body, pain has been classified into two types acute pain that stops 
without a major treatment pain that is no longer considered a symptom but an illness by itself 
termed as chronic pain (Figure 1), latter is a major health problem for both individuals and 
society. Nociception (sensation of pain) can be regulated by a number of chemical (e.g. low 
pH) or physical stimuli (e.g. mechanical, thermal) that have the potential to damage tissue. 
The receptors (sensory neurons) which can detect and response to these harmful stimuli 
above a set of threshold are known as “nociceptors” (also called pain receptors) which are 
found in many areas of the body like skin, cornea, mucosa, muscle, joint, bladder, gut and 
along the digestive track that can sense pain either externally or internally. As soon as 
nociceptor stimulated it will transmits a signal along the spinal cord, to the brain thereby 
triggering a variety of autonomic responses followed by pain.  
Pain
Acute pain
- < 1 month
- Usually tissue damage
- Increased nervous system activity
- Pain resolves upon heating
- Serves a protective function
Chronic pain
- > 3-6 months
- Pain beyond expected period of
healing
- No protective function
- Degrades health and function
Nociceptive pain
- Caused by mechanical, thermal or
chemical stimuli resulting in injury
to body tissues
- Warns against injury
- Subsides over time
Acute pain
- Caused by damaging the sensory
nerves of the peripheral and central
nervous system
- May be treated with NSAIDs but with
limited successs
 
Figure 1: Classification of pain 
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There is often no satisfactory treatment for chronic pain whereas neuropathic pain, in 
particular, poorly standard therapies such as NSAIDs, opioids, and tricyclic antidepressants, 
which reduce approximately 30-50% pain in about 50% of patients, along with producing 
undesired side effects such as dizziness and somnolence in some patients. Thus, there 
remains a great medical need for new medicines to treat pain. 
 Neuropathic pain affecting 26 million patients worldwide resulting healthcare cost 
over $ 3 billion per year. While little is known about the proteins that detect noxious stimuli 
(especially those of a physical nature), vanilloid receptor, an excitatory ion channel expressed 
by nociceptors, has been identified as molecular target for the development of recent 
therapies to treat pain.  
5.1.2 The Transient Receptor Potential (TRP) Super family: 
The vanilloid receptor subtype 1 (VR1) or transient receptor potential vanilloid 1 (TRPV1, 
also as cation channel on C-fiber sensory neurons that stimulate many organs, including the 
skin, bladder and gut), can found in the peripheral and central nervous system. TRPV1 not 
only involved in the transmission and modulation of pain, but also act as the integration of 
diverse painful stimuli.  
TRPC TRPM TRPML TRPV TRPP TRPA
TRPV1 TRPV2 TRPV3 TRPV4 TRPV5 TRPV6
Heigh activated receptors & non selective for
cations Ca+2, Na+2 also
Heigh Ca+2, Na+2 selectivity & low
temparature sensitivity
TRP Super family
  
Figure 2: Classification of transient receptor potential (TRP) super family 
 
The TRPV1 is a member of the transient receptor potential (TRP) super family, a group of 
ion channels currently containing >30 members which are widely expressed in mammalian 
tissues and playing a vital role in sensory processes.1a Based on sequences homology and 
functional behaviour the TRP family believed to constitute six different subfamilies: C 
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(canonical or classical), M (melastatin-related), P (PKD type), ML (mu-colipin), A (ankyrin) 
and V (vanilloid).1b It is important to notice that this classification is not based on activating 
stimuli because both V and M subfamilies have members that respond to temperature. 
TRPV1 was the first and best characterized member of the transient receptor potential 
vanilloid receptor, while the physiological functions of most of these channels were 
unrevealed. This receptor is a nonspecific cation channel which can be activated by a variety 
of exogenous and endogenous physical and chemical stimuli. Exogenous stimuli are protons 
(pH 5, chemical stimuli), heat (> 42 ºC, physical stimuli), where as endogeneous substances, 
such as endocannabinoid anadamide, lipoxygenase & arachidonic acid metabolites etc. can 
stimulate it.  
 
 
 
Figure 3: TRPV1 is an integer of inflammatory pain path ways.  The figure shows a schematic of TRPV1 and its 
activators. It is directly activated by a multiplicity of stimuli including vanilloids, such as capsaicin, low pH, elevated 
temperature and arachidonic acid metabolites such as anandamide. It can also indirectly activate by prostaglandin and 
bradykinin receptors via protein kinase activity. Filled circles represents amino acids required for  TRPV1 activation, red 
circles corresponds to residues important for capsaicin activation, green circles for low pH and blue circles for protein kinase 
phosphorylation sites. 
Activation of TRPV1 can also be achieved by some natural ligands such as capsaicin (the 
pungent principle of chili peppers) and other vanilloids (a group of compounds, structurally 
related to capsaicin) and resiniferatoxin (RTX, an extreme irritant and natural diterpene 
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isolated from the sap of Euphorbia resinifera) and hence, it has been classified as a ligand-
gated ion channel.2,3  
5.1.2.1 Physiological functions of TRPV1: 
As soon as the TRPV1 stimulated, it results in influx of calcium in to cells and also releases 
calcium from the endoplasmic reticulum to a lesser extent. Due to high permeability of 
calcium, the extracellular calcium (and also sodium) enters through the channel pore, 
resulting in depolarization of cell membrane. This increases excitation of primary sensory 
neurons, leading to action of potential firing and transmission of a noxious nerve impulse to 
the spinal cord, thereby increase the perception of pain.4, 5 Besides this the process can lead to 
release of a short chain poly peptide P that functions as a neurotransmitter and as a neuro 
modulator and CGRP, resulting to enhanced peripheral sensitization of tissue. It also 
observed that TRPV1 can following inflammation and nerve damage which directly confirms 
TRPV1 as a key regulator of pain response.6,7 Hence, a clinically effective therapeutic 
method to treat pain can be via blockade of the TRPV1 thereby inhibiting the transmission of 
painful signals from periphery to the CNS. 
5.1.2.2 TRPV1 Agonists:  
A chemical substrate or scaffold which can binds to some receptor of a cell and triggers a 
response by that cell known as Agonists. In general agonists mimic the action of a naturally 
occurring substance. The vanilloid receptors were named after the presence of vanillyl (i.e. 4-
hydroxy-3-methoxybenzyl) moiety in capsaicin (1) & resiniferatoxin (2), which is 
responsible for the interactions with the receptor (see Figure 4).  
MeO
HO
NH O
OMe
OH
O
O
O
O OH
H
O
Vanillyl
(i.e. 4-hydroxy-3-methoxy benzyl)
1 (Capsaicin)
2
(resinfer
atoxin)
Vanilloids
A
B
C
 
Figure 4: TRPV1 agonists with vanillyl moiety 
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H
N
O
H
N
O
NH2
OMe
4 5
HO
NH
O
3 (anandamide)  
 
Figure 5: TRPV1 agonists with lack of vanillyl moiety 
 
However, there several reports of vanilloid receptor agonists which lacked any recognizable 
vanillyl moiety e.g. (3-5). Nevertheless, compound 2 showed binding potency (Ki = 0.13 nM 
in CHO/VR1) approximately 4 orders of magnitude greater than that of 1 (Ki = 1,700 nM in 
CHO/VR1). Vanilloid agonist such as 1 has an analgesic effect, due to the rapid calcium 
influx leads to stimulation of the sensory neurons and release of neurotransmitter such as 
substance P. Upon continued stimulation, the neurotransmitters undergo depletion leads to 
selective damage of the nerves and, thereby, desensitizing them toward further stimulations. 
There by TRPV1 receptors become less sensitive to subsequent application of painful stimuli 
including noxious stimuli such as heat and acid or to additional agonist challenges. Therefore 
repeated exposure to large amounts of capsaicin results in insensitivity to further activation 
by this agent. Both 1 and 2 have been used to treat the pain associated with diabetic 
neuropathy and arthritis.8 While a number of agonists e.g. 4 and 5 (see Figure 5) along with 2 
progressed into clinical trials, these agonists were limited due to side effects of a burning 
sensation, irritation and neurotoxicity.5 To avoid this persisting side effect found in TRPV1 
agonists, the focus of drug discovery research was shifted towards the development of 
competitive antagonists which can be obtained through blockade of the pain-signalling 
pathway.  
 
5.1.2.3 TRPV1 Antagonists:  
Antagonist is defined as an inverse agonist causes an action opposite to that of the agonist. 
Capsazepine (6) was the first antagonist of TRPV1 and was discovered during the 
investigation of structure activity relationship of capsaicin (1), in order to predict the effect of 
conformational constraint on lipophilic C-region (see Figure 4). It has blocked the capsaicin-
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induced uptake of Ca2+in neonatal rat dorsal root ganglion (DRG) with a reported IC50= 
0.420 (±0.046) µM. And also has shown anti-hyperalgesic effects not only against capsaicin 
challenge but also against other inflammatory stimuli indicating that analgesic effects  were 
common to both TRPV1 agonists and antagonists.9,10 Other classes of TRPV1 antagonists 
structurally unrelated to the exogenous agonist capsaicin have been discovered during the 
past few years, some of them are listed in figure 6.11 
N
S
H
N
Cl
HO
HO
6 (capsazepine)
N
N
N
O
S
N
NHAc
Ar4-CF3
F3C
H3CO
NH
O
NH
N
7 8  
Figure 6: Few examples of TRPV1 antagonists 
 
5.2 Research objective:  
 In view of the therapeutic value of such vanilloids, as a part of our drug discovery 
program we were interested in generation of novel molecular scaffolds from vanilloid 
precursors. In this context, Isoxazolidines (A, Fig. 7) are important heterocycles12 commonly 
found in a diverse array of bioactive natural products (e.g. cycloserin, acivicine). They are 
also valuable intermediates in organic synthesis.13 Compounds such as capsaicin, the main 
capsaicinoid in chili peppers containing a vanillyl moiety (B, Fig. 7) on the other hand have 
attracted considerable interest as they target TRPV1 (transient receptor potential vanilloid 1), 
a molecular integrator for a broad variety of seemingly unrelated noxious stimuli.14 This and 
our longstanding interest on bioactive fused heterocycles prompted us to design novel 
molecular scaffolds by combining the isovanillyl moiety and isoxazolidine ring in a single 
framework C (Fig. 1). We anticipated that isovanilloid based tricyclic drug-like molecules 
derived from C might show pharmacological properties similar to capsaicin as well as 
vanilloid receptors. 
 
Figure 7: Design of C by combining A and B 
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 While several methods have been reported for the synthesis of isoxazolidines, the dipolar 
cycloaddition of nitrile oxides/hydroxylamines to allyl dipolarophiles appears to be 
attractive.15 The intramolecular version of 1,-3-dipolar cycloadditions of hydroxylamines to 
simple allylic or N/O-allylic dipolarophiles has also been reported.16 For example benzo 
analogues of tricyclic isoxazolidines have been prepared by using this strategy17-19(Scheme 
1). While all these methods were not precisely suitable for our purpose these findings 
however provided a valuable lead to develop a strategically related but unique approach to C 
(Scheme 1). 
 
Scheme 1.  Synthesis of benzo analogues of tricyclic isoxazolidine 
 
Herein we report the intramolecular 1-3-dipolar cycloaddition of isovanillin derived N-
substituted hydroxylamines possessing allylic dipolarophiles at the o-position. In extension of 
this approach the corresponding N-unsubstituted hydroxyl amines give rise to 
tetrahydroisoquinolines. Further synthetic applications and pharmacological properties of 
some of these compounds synthesized are presented. 
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5.3 Results and Discussion: 
  5.3.1 Chemistry  
As a starting point the O-allyl isovanillin 9a was prepared by sequential O-allylation of 
isovanillin followed by Claisen rearrangement.20 In an experiment designed to synthesize 
isoxazolidines by 1,3 dipolar cycloaddition of the nitrones obtained from unsubstituted 
hydroxylamine hydrochloride on allylic dipolarophile in the adjacent position, we observed 
the formation of tetrahydroisoquinoline 13 as the only product in 88% yield. We visualized 
this possibility through the formation of nitrone 11 by an apparently favourable 
intramolecular aza-Michael addition over the expected [3+2] cycloaddition. The formation of 
11 was further supported by the generation of two regioisomers 12a and 12b obtained as 
major products via intermolecular [3+2] cycloaddition with ethyl acrylate. There was no 
noticeable change in conversions in the presence of additives like sodium acetate or 
triethylamine or higher temperatures (Scheme 2).   
 
 
Scheme 2. Formation of tetrahydroisoquinolines via intramolecular aza-michael addition on 
allyl carboxylate  
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However when the same reaction conditions were applied to phenyl hydroxylamine, we 
observed intramolecular cyclization to form isoxazolidines with both simple and activated 
allyl dipolarophiles (Scheme 3; entry 1, Table 1, see footnote). We were pleased to find that 
stirring an equimolar mixture of phenyl hydroxylamine and aldehyde 9 in the presence of 
magnesium sulphate in ethanol under reflux conditions afforded a 1:2 mixture of the two 
regioisomers 16 and 17 each one in racemic form via an apparent formation of nitrone. The 
structure of one of the isomers 16a was unequivocally characterized by single crystal X-ray 
diffraction studies (See supporting information). 
 
Scheme 3. Intramolecular 1,3-dipolar cyclo additions on simple and activated allyl 
dipolaraphiles 
 
We then focused our attention to the influence of electronic factors of the phenyl ring. For 
this, a range of substituted phenyl hydroxyl amines with electron-donating and electron-
withdrawing groups were synthesized21 and were applied under similar reaction conditions. 
The observations demonstrated that there is a negligible influence of electronic factors on the 
favorability of cycloaddition (Table 1).  
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Table 1. Influence of electronic factors of the aryl substituent on reaction mechanism 
Entry 14; Ar =  9; Z Products Yieldb (%) 
 
1 
 
14a; Ph 
 
9a; H 
 
16a:17a (1:2) c 
 
96 
2 14b; 4-MeC6H4 9a; H 16b:17b (1:2)c 100 
3 14c; 4-NCC6H4 9a; H 16c:17c (1:2)c 94 
4 14d; 3-(MeSO2NH)C6H4 9a; H 16d:17d (1:2)c 95 
5 14e; 2-NCC6H4 9a; H 15e  88 
6 14a 9b; CO2Et 16f 78 
7 14e 9b; CO2Et 18 58 
 
a) At 80 °C, the ratios of 16a: 17a, 16b: 17b, 16c: 17c and 16d:17d were 1: 2 where as at 130 °C, the ratios of 16a: 17a, 
16b: 17b, 16c: 17c and 16d:17d were 2:1 b). Regioisomers (16, 17) cannot be separable without TBS protection on 
column chromatography.   
 
The reaction well accommodated both electron withdrawing and electron releasing 
substituent on N-phenyl moiety. The presence of methyl and cyano groups in para position of 
N-phenyl substituent led to the formation of isoxazolidines 16b and 16c respectively with 
simple allyl dipolarophiles (entries 2 and 3, Table 1).  An electron withdrawing group -
NHSO2CH3 in meta-position had no significant effect on the yields (entry 4).  The presence 
of cyano substituent in ortho-position did not afford isoxazolidine with simple allyl 
dipolarophile and nitrone 15e was recovered. While the reason for this observation was not 
clear an intramolecular interaction between the –N+-O- moiety and –CN group could prevent 
the reaction to proceed further. However, the presence of ethyl carboxylate was sufficient to 
make the reaction facile and afforded 16f as a major product. The oxime not only cyclised but 
also underwent further cleavage to afford the corresponding amino alcohol 18 in 58% yield, 
in a single pot (entry 4). In all the cases, the intramolecular 1, 3-dipolar cycloaddition of 
nitrones and allylic dipolarophiles was observed to be facile and in many cases preceded with 
remarkable acceleration. The favorability and origin of the acceleration could be attributed to 
proximity of the functionalities within the cyclization precursor.  
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Figure 7. Endo approach of the C=C moiety to the Z-nitrone leading to 16f with trans-
relationship of HA with HB and HC from NOESY spectrum.  
The regiochemistry of all the four pairs of regioisomers was deduced from NMR spectra. X-
ray diffraction analysis confirmed the cis-fusion (HB and HC) of rings A and B in 16a (see 
Figure 8). The proton HA coupled with the vicinal proton HC but no long range coupling with 
the HB was observed in the NOESY spectrum thus confirming the relative trans-relationship 
of HA with HB and HC in 16f.  An endo approach of the C=C moiety to the Z-nitrone aided by 
the secondary orbital interactions between the nitrone nitrogen p orbitals and the –C=O 
group21e possibly favored the formation of this particular diastereomer (Figure 7). 
The presence of electron withdrawing group in the form of ethyl carboxylate ester on the allyl 
moiety of aldehyde 9 led to complete stereo selectivity to afford 16f in quantitative yields. 
The polycyclic lactam 20 was also accessible from isoxazolidine 16f on treatment with 
Zn/acetic acid. Interestingly, 16f afforded an amino alcohol 19 on treatment with Pd/C 
(Scheme 3).  
ON
OTBS
H3CO
16f
NH
OTBS
H3CO COOEt
19
N
OTBS
H3CO
20
OH
O 5% Pd/C
H2, MeOH,
6h,
80%
Zn/AcOH:THF:H2O
70 °C, 6h,
60%
COOEt
H
H
H
H
OH H
  
Scheme 3. Exposing the Latent functionalities of isoxazolidines  
Finally we were inclined to create further molecular complexity from the synthesized 
isoxazole derived amino alcohols. Simple  transformations  were  carried  out  on  each  
regioisomer  to  construct viable highly  functionalized  tricyclic  scaffold containing 
oxazepine core. The amino and hydroxyl appendages in γ-amino alcohol 21 obtained on 
reductive cleavage of 16a respectively was readily elaborated. The γ-amino alcohol 21 on 
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stirring with ethylbromoacetate in DMF in presence of potassium carbonate afforded 
oxazepine 22 (Scheme 4).  
NH
OTBS
H3CO OH
N
OTBS
H3CO
O
O
16f 21
ON
H3CO
OTBS
5% Pd/C, H2,
MeOH, rt,
6h, 80 %
BrCH2COOEt
K2CO3/ DMF,
100 OC, 36h
22
60%
 
Scheme 4. Synthesis of Oxazepine containing tricyclic scaffold  
Finally –OTBS in all the compounds was deprotected using tetra-butyl ammonium iodide 
(TBAF) in presence of THF at 0 oC afforded the required compounds 23-36. 
 
ORTEP diagrams: 
While all the compounds synthesized were characterized by spectral (NMR, IR, MS and 
HRMS) data the molecular structure of one of the representative compounds for example, 
16a was confirmed unambiguously by single crystal X-ray diffraction (Figure 8). 
 
OCH3
OTBS
NO H
H
 
Figure 8: ORTEP representation of the 16a (C23H31NO3Si). (Thermal ellipsoids are drawn at 
50% probability level). 
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5.3.2 Pharmacology 
EVALUATION OF TEST COMPOUNDS FOR CAPSAICIN LIKE ACTIVITY IN ZEBRAFISH MODEL OF 
ANXIETY  
The compounds synthesised were inspired from Capsaicin and hence were assessed to 
evaluate their Capsaicin like activity (after removal of TBS protecting group, see 
Experimental section). Capsaicin is known to show anxiogenic activity in various animal 
models 23 and therefore, was expected to show the same in zebrafish model of anxiety. We 
used the adult zebrafish model of light/dark box anxiety test to assess the activity 22. This 
method was used as it is simple and does not require invasive procedures or euthanasia 22. We 
first tested the hypothesis that Capsaicin administration results in anxiogenic behaviour in 
adult zebrafish. Thereafter, test compounds were tested in this model to identify the most 
potent anxiogenic compounds. 
   
Figure 9: The figure shows the evaluation of anxiety like behaviours in the adult zebrafish using light/dark box 
paradigm. Normal fish move across freely in both light and dark environments, however, when anxious their 
movements and higher in the dark environment as compared to light.  
Results: 
Capsaicin when tested in the adult zebrafish model of anxiety using the dark light box 
paradigm showed clear anxiogenic behaviour, which was evident from the fact that the 
percentage time spent in light box was significantly lower in the Capsaicin treated fish as 
compared to control at 10 µg/kg dose and the effect was dose dependent (Figure 10 A). The 
erratic movement (number and duration) were also observed and they increased in a dose 
dependent manner in Capsaicin treated fish (Figure 10 B & 10 C).  This concludes that 
Capsaicin shows anxiogenic effect in adult zebrafish that is similar to the effect seen in other 
mammalian species. Screening of test compound in a single dose screening was performed 
and screening suggested that compound -23 was the most potent anxiogenic compound 
(Figure 11). Multi-dose evaluation of Compound-23 confirmed the anxiogenic activity as the 
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fish administered with this compound showed significant reduction in the percentage time 
spent in the light as compared to control fish (Figure 10 A).  
 
Figure 10: Multi-dose 
evaluation of capsaicin 
and 23 in the adult 
zebrafish model of 
anxiety for  
A. Percentage time spent 
in light. 
B. Duration of erratic 
movements.  
C. Number of erratic 
movements using the 
light/dark box paradigm.  
D. Structure of 23 
 
 
 
The erratic movement (number and duration) were also observed and there is dose-dependent 
increase in Compound-23 group (Figure 10 B & 10 C). This verifies that Compound -23 has 
anxiogenic activity which is an activity similar to Capsaicin.  
 
5.3.2.1 Video for anxiogenic activity of compound 23  
This study was done by Swapna Yellanki, Raghavender Medishetti, and Pushkar Kulkarni at 
Zephase Therapeutics, Dr Reddy’s Institute of Life Sciences, University of Hyderabad 
Campus, and Hyderabad. Video was recorded for the anxiogenic activity of compound 23 
(Video attached to this thesis as separate file). 
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Figure 11: Screening of compounds for anxiolytic activity. Effect of compounds was 
assessed at 10 mg/kg) in the light/dark box paradigm to evaluate the parameter of percentage 
time spent in light. Compound-23 was found have maximum effect in this study.  
 
 
5.3.3 Molecular docking studies   
Molecular docking studies were done by K. Lalith Kumar at Institute of Life Sciences, India. 
To understand the nature of interactions of these molecules with the TRPV1(Transient 
receptor potential vanilloid 1) in silico docking studies were performed with compounds 23, 
24 and 35 along with the known inhibitor of  TRPV1 using Surflex-Dock (SFXC) programme 
of Sybyl software.  
Till date, the complete crystal structure of the transient receptor potential vanilloid subtype1 
(TRPV1) is not reported. Therefore a TRPV1 homology model was developed and used for 
this purpose. The docking results for capsaicin were in close relevance with the earlier 
reported docking studies. As reported earlier the vanillyl moiety of capsaicin occupied the 
deep pocket surrounded by Tyr511, Tyr565, and Lys571.24 The hydrophobic tail region 
occupied the upper hydrophobic pocket formed at the interface of two monomers Figure 12. 
Using the above docking parameters we performed a docking study of synthesized 
compounds 23, 24 and 35.  The dock scores and their contributing factors are represented in 
Table 2. 
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Table 2: Surflex dock score of the compounds 
Compound Total_Scorea Crashb Polarc Straind Totale 
Capsaicin      5.9  -1.4   0   2.2  3.74 
  23      5.8  -0.7  1.1  0.28  5.6 
  24      5.0  -1.7 0.98  1.57  3.5 
  35      4.6  -1.8  1.1  1.6  3.0 
           
a
 The total Surflex-Dock score 
b
 The degree of inappropriate penetration by the ligand in to protein. 
c
 Contributions of polar interactions to the total score 
d
 Normal ligand strain relative to the local minimum 
e
 Ligands score corrected for strain energy 
 
 
 (a)                                                                                (b) 
 
Figure 12: a) Binding mode of capsaicin in rTRPV1 b) MOLCAD surface of rTRPV1 with solid and mesh type 
representation of two monomers forming active site occupied by capsaicin. 
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Figure 13: a) Binding mode of 23 in rTRPV1 b) MOLCAD surface of rTRPV1 with solid and mesh type 
representation of two monomers forming active site occupied by 23. 
 
Figure 14: a) Binding mode of 24  in rTRPV1 b) MOLCAD surface of rTRPV1 with solid and mesh type 
representation of two monomers forming active site occupied by 24. 
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Figure 15: a) Binding mode of 35 in rTRPV1 b) MOLCAD surface of rTRPV1 with solid and mesh type 
representation of two monomers forming active site occupied by 35. 
As shown in Figure 12, the vanillyl moiety of 23 has also occupied close to the binding site 
where capsaicin vanillyl moiety interacts. The 4-cyano phenyl substituent of 23 replaces the 
lipophilic tail of capsaicin and occupies the upper hydrophobic pocket. Also, the nitrogen of 
the cyano group makes hydrogen bond interaction with the side chain hydroxyl group of Thr 
670 from the adjacent ‘C’ chain. Removal of this cyano group in 24 resulted slight decrease 
in the dock score (Figure 14). Whereas, introducing of hydrophobicity through ring extension 
(from oxazole to oxazepine) in the compound 35 has increased the dock score (Figure 15).  
 
5.4 Summary:  
In conclusion, we have demonstrated an intramolecular 1,3-dipolar cycloaddition of 
isovanillin derived nitrones to activated and inactivated allylic dipolarophiles.  The reaction 
was highly regioselective, afforded highly functionalized tricyclic isoxazolidines and 
tolerated electronically different N-substituents well.  The utility of the reported methodology 
was also demonstrated by exploiting the latent functionality of resulting isoxazolidines to 
unique tricyclic system with an oxazepine core. The single crystal X-ray diffraction study 
was used to confirm the molecular structure of one of the representative compounds 
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unambiguously. To the best of our knowledge synthesis of the class of designed compounds 
was not known in the literature. Few of these compounds were found to be interesting when 
tested for anxiogenicity. Based on in vivo (anxiogenic assay) studies indicated that 23 found 
to be similar activity with capsaicin. Moreover, our efforts to elucidate the biological 
activities of all these vanilloid scaffolds containing isoxazolidine, amino alcohol and 
oxazepine core against the vanilloid receptors are underway.  
 
5.5 Experimental Sections: 
5.5.1 Chemistry - General methods 
All reactions were carried out under an inert atmosphere with dry solvents, unless otherwise 
stated. Reactions were monitored by thin layer chromatography (TLC) on silica gel plates (60 
F254), using UV light detection.  Visualization of the spots on TLC plates was achieved 
either by UV light or by staining the plates in 2, 4 Di-Nitro Phenyl hydrazine stain, Ninhydrin 
stain and charring on hot plate. Flash chromatography was performed on silica gel (230-400 
mesh) using distilled hexane, ethyl acetate, dichloromethane. 1H NMR, 13C NMR, 1D- NOE, 
and 2D-NOE spectra were recorded in CDCl3 solution by using VARIAN 400 MHz 
spectrometers. Chemical shifts are reported as δ values relative to internal CDCl3 δ 7.26 or 
TMS δ 0.0 for 1H NMR and CDCl3 δ 77.0 for 13C NMR.  1H NMR data is furnished as 
follows: chemical shift [multiplicity, coupling constant(s) J (Hz), relative integral] where 
multiplicity is defined as: s (singlet), d (doublet), t (triplet), q (quartet), dd (doublet of 
doublet), m (multiplet), bs (broad singlet). FTIR spectra were recorded on Bruker (Alpha) 
spectrometer. Mass spectra were recorded on Micro Mass VG-7070H mass spectrometer for 
ESI and are given in mass units (m/z). High resolution mass spectra (HRMS) [ESI+] were 
obtained using either a TOF or a double focusing spectrometer. 
 
5.5.2 Synthesis 
General procedure for 1,3 dipolar Cyclo addition 
To a solution of aldehyde (1 mmol) in ethanol (5 mL) substituted phenyl hydroxyl amine (2 
mmol), MgSO4 (5 mmol) were added. The reaction mixture was refluxed for 3-5 h (for 
inversion in the yields of regio isomers reaction heated at 130 oC for 12 h); ethanol was 
removed under high vacuum followed by column chromatography on silica gel yields the 
products. The yields are observed at 80 oC. 
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2-Allyl-3-(tert-butyldimethylsilyloxy)-4-methoxybenzaldehyde (9a): 
To a solution of 2-allyl-3-hydroxy-4-methoxybenzaldehyde (1.92 g, 
10 mmo) and imidazole (1.36 g, 20 mmol) in N,N-
dimethylformamide (6 mL) tert-butyldimethylsilyl chloride (3 g, 20 
mmol) was added under N2, and the solution was stirred for 
overnight. The resulting mixture was diluted with saturated NH4Cl solution and extracted 
with CH2Cl2. The organic layer was collected, washed with saturated aqueous sodium 
bicarbonate solution and water, dried over Na2SO4, filtered and concentrated under low 
vacuum to give the desired product (2.99 g, 98%). Rf = 0.7 (1:9 EtOAc : Hex); 1H NMR (400 
MHz, CDCl3) δ  10.10 (s, 1H), 7.52 (d, J = 14.6 Hz, 1H), 6.87 (d, J = 14.6 Hz, 1H), 6.10-
5.92 (m, 1H), 4.99 (d, J = 10.2 Hz, 1H), 4.86 (d, J = 17.2 Hz, 1H), 3.95 (s, 3H), 1.07 (s, 9H), 
0.18 (s, 6H); 13CNMR (100 MHz, CDCl3) δ 191.3, 154.5, 143.1, 136.8, 133.1, 128.2, 126.1, 
115.3, 108.9, 54.8, 28.6, 26.1 (3C), 18.9,  -3.7 (2C);  Mass (ES): m/z 307.05 (M+H, 100%). 
 
(E)-Ethyl4-(2-(tert-butyldimethylsilyloxy)-6-formyl-3-methoxyphenyl)but-2-enoate (9b): 
An oven dried round bottomed flask fitted with a rubber 
septum containing a stir bar was charged with 2-allyl-3-
(tert-butyldimethylsilyloxy)-4-methoxybenzaldehyde 
(0.95 g, 3.10 mmol), ethyl acrylate (0.99 mL, 9.10 
mmol), freshly distilled CH2Cl2 (25 mL), Grubbs-2 catalyst (0.079 g, 9.10 µmol), and CuI 
(0.011 g, 9.10 µmol) under an N2 atmosphere. The rubber septum was then replaced with a 
reflux condenser under an N2 atmosphere. The solution was then heated at 50 οC (oil bath 
temperature) for 3h. After cooling to room temperature, the reaction mixture was 
concentrated under vacuum and the residue was purified by using column chromatography on 
silica gel (eluting with 30% EtOAc/Hexanes) to afford the desired product as a colorless oil 
(1.0 g, 86%); Rf = 0.3 (1:9 EtOAc: Hex); IR   (cm-1): 3010, 2957, 2858, 2720 (CH aldehyde), 
1720 (CO aldehyde), 1700 (CO ester), 1600, 1247; 1H NMR (400 MHz, CDCl3) δ 9.93 (s, 
1H), 7.45 (d, J = 8.5 Hz, 1H), 7.15-7.05 (td, J = 15.7, 5.8 Hz, 1H), 6.90 (d, J = 8.5 Hz, 1H), 
5.59 (d, J = 15.6 Hz, 1H), 4.12 (q, J = 7.2 Hz, 3H), 4.09-4.01 (m, 2H), 3.90 (s, 3H), 1.26 (t, J 
= 7.2 Hz, 4H), 1.03 (s, 9H), 0.20 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 191.3, 166.5, 154.5, 
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147.0, 143.6, 130.4, 128.6, 128.1, 121.6, 109.2, 60.0, 54.9, 27.6, 26.0 (3C), 18.9, 14.2, -3.7 
(2C); Mass (ES): m/z 379.15 (M+H, 100%). 
(E)-2-allyl-3-(tert-butyldimethylsilyloxy)-4-methoxybenzaldehyde oxime (10): 
To a solution of 2-allyl-3-(tert-butyldimethylsilyloxy)-4-
methoxybenzaldehyde (0.612 g, 2 mmol) in MeOH (5 mL) was 
added NH2OH·HCl (0.207 g, 3 mmol) and NaOAc (0.246 g, 3 
mmol) and the mixture was refluxed for 1.0 h. After completion of 
the reaction, MeOH was removed using high vacuum and the residue was treated with water. 
The mixture was extracted with ethyl acetate. The organic layer was collected, dried over 
anhydrous Na2SO4, filtered, and concentrated to afford the desired product as a light yellow 
oil (0.60 g, 88%); Rf = 0.75 (1:9 EtOAc: Hex); IR (cm-1): 3430, 3029, 2975, 2852, 1728 (CO, 
ester), 1612, 1583, 1456, 1255; 1H NMR (400 MHz, CDCl3) δ  8.30 (s, 1H), 7.62 (d, J = 14.8 
Hz, 1H), 6.90 (d, J = 14.8 Hz, 1H), 6.14-5.94 (m, 1H), 5.01 (d, J = 10.4 Hz, 1H), 4.92 (d, J = 
17.2 Hz, 1H), 3.96 (s, 3H), 1.08 (s, 9H), 0.19 (s, 6H); 13CNMR (100 MHz, CDCl3) δ 154.7, 
148.1, 143.1,  136.9, 133.1, 128.3, 126.0, 115.3, 108.8, 56.7, 28.7, 26.1 (3C), 18.9, -3.5 (2C);  
Mass (ES): m/z 322.08 (M+H, 100%). 
 
5-(tert-butyldimethylsilyloxy)-3-(2-ethoxy-2-oxoethyl)-6-methoxy-3,4 dihydro 
isoquinoline 2-oxide (11): 
To a solution of (E)-ethyl-4-(2-(tert-
butyldimethylsilyloxy)-6-formyl-3-methoxyphenyl)but-2-
enoate (0.758 g, 2 mmol) in MeOH (5 mL) was added 
NH2OH·HCl (0.207 g, 3 mmol) and NaOAc (0.246 g, 3 
mmol) and the mixture was refluxed for 1.0 h. After completion of the reaction MeOH was 
removed using high vacuum and the residue was treated with water. The mixture was 
extracted with ethyl acetate. The organic layer was collected, dried over anhydrous Na2SO4, 
filtered and concentrated. The residue was purified by column chromatography on silica gel 
(eluting with 100% EtOAc) to afford the desired product as a colorless oil (0.69 g, 88%); Rf = 
0.7 (8:2 EtOAc: Hex); IR (cm-1): 3030, 2965, 2862, 1728 (CO, ester), 1610, 1587, 1468, 
1247; 1H NMR (400 MHz, CDCl3) δ 7.67 (s, 1H), 6.75 (s, 2H), 4.50-4.60 (m, 1H), 4.24-4.11 
(m, 2H), 3.82 (s, 3H), 3.35-3.05 (m, 4H), 2.55-2.65 (dd, J = 16.3, 9.3 Hz, 1H), 1.33 (t, J = 
7.4 Hz, 3H), 1.03 (s, 9H), 0.17 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 170.2, 151.8, 142.5, 
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134.0, 121.5, 119.9, 119. 1, 110.1, 63.5, 60.9, 54.9, 35.6, 29.6, 27.1, 25.9 (3C), 18.7, 14.1, -
3.9, -4.0; Mass (ES): m/z 394.20 (M+H, 10%), 192.17 (100%); HRMS (ESI): calcd for 
C20H32NO5Si (M+H) +  394.2049 found 394.2035. 
 
Procedure for 1,3 dipolar addition on 11: 
To a solution of 5-(tert-butyldimethylsilyloxy)-3-(2-ethoxy-2-oxoethyl)-6-methoxy-3,4 
dihydroisoquinoline 2-oxide (0.393 g, 1 mmol) in ethanol (5 mL) was added ethylacrylate 
(0.5 g, 5 mmol) and the mixture was refluxed for 3.5 h. After completion of the reaction, 
solvent was removed under high vacuum and the residue was purified by column 
chromatography on silica gel (eluting with 10% EtOAc/Hexanes) to afford the desired 
product(s).  
 
Ethyl7-(tert-butyldimethylsilyloxy)-5-(2-ethoxy-2-oxoethyl)-8-methoxy-2,5,6,10b-
tetrahydro-1H-isoxazolo [3,2-a] isoquinoline-1-carboxylate (12a): 
Colorless viscous oil; Yield: 50%; Rf = 0.6 (2:8 EtOAc: 
Hex); IR (cm-1): 3050, 2966, 2862, 1735 (CO ester), 1725 
(CO ester), 1620;  1H NMR (400 MHz, CDCl3) δ 6.76 (s, 
2H), 4.76 (d, J = 8.9 Hz, 1H), 4.40-4.35 (dd, J = 9.7, 8.4 
Hz, 1H), 4.32-4.23 (m, 2H), 4.22-4.11 (m, 2H), 4.10-4.06 
(dd, J = 8.1, 6.4 Hz, 1H), 3.77 (s, 3H), 3.44-3.33 (m, 2H), 3.17-3.12 (dd, J = 16.7, 3.7 Hz, 
1H), 2.95-2.89 (dd, J = 15.4, 6.5 Hz, 1H), 2.54-2.41 (ddd, J = 21.1, 16.0, 8.5 Hz, 2H), 1.30 
(m, 6H), 0.99 (s, 9H), 0.20 (s, 3H), 0.14 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 172.7, 172.1, 
148.6, 141.6, 126.6, 124.4, 119.3, 110.2, 69.3, 67.4, 61.3, 60.5, 55.0, 54.9, 53.0, 39.5, 30.6, 
26.0 (3C), 18.8, 14.2, 14.2, -3.8, -4.0; Mass (ES): m/z 494.25 (M+H, 100%); HRMS (ESI): 
calcd for C25H40NO7Si (M+H) +  494.2574 found 494.2595. 
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Ethyl7-(tert-butyldimethylsilyloxy)-5-(2-ethoxy-2-oxoethyl)-8-methoxy-2,5,6,10b-
tetrahydro-1H-isoxazolo [3,2-a] isoquinoline-2-carboxylate (12b): 
Colorless viscous oil; Yield: 20%;  Rf = 0.6 (2:8 EtOAc: 
Hex); IR (cm-1): 3050, 2966, 2862, 1735 (CO ester), 1725 
(CO ester), 1620;  1H NMR (400 MHz, CDCl3) δ 6.75 (t, J 
= 7.4 Hz, 1H), 6.69 (d, J = 8.4 Hz, 1H), 4.75 (dd, J = 
10.0, 3.4 Hz, 1H), 4.63 (dd, J = 10.6, 7.5 Hz, 1H), 4.29-
4.12 (m, 4H), 3.78 (s, 3H), 3.45-3.37 (m, 1H), 3.11 (dd, J = 16.7, 3.5 Hz, 1H), 2.98 (dd, J = 
15.5, 6.75 Hz, 1H), 2.83-2.75 (m, 1H), 2.62-2.41 (m, 3H), 1.34-1.27 (m, 7H), 0.99 (s, 9H), 
0.21 (s, 3H), 0.15 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 172.3, 171.3, 148.3, 141.7, 127.3, 
124.5, 119.3, 110.3, 75.7, 63.1, 61.4, 60.5, 54.9, 53.8, 40.8, 39.5, 30.8, 26.0 (3C), 18.8, 14.2, 
14.1, -3.8, -4.0; Mass (ES): m/z 494.25 (M+H, 100%); HRMS (ESI): calcd for C25H40NO7Si 
(M+H)+  494.2574 found 494.2595. 
Ethyl 2-(5-(tert-butyldimethylsilyloxy)-6-methoxy-1,2,3,4 tetrahydroisoquinolin-3-yl) 
acetate (13): 
To a solution of 5-(tert-butyldimethylsilyloxy)-3-(2-
ethoxy-2-oxoethyl)-6-methoxy-3,4 dihydroisoquinoline  2-
oxide (0.393 g, 1 mmol) in acetic acid (5 mL) was added 
activated zinc (0.64 g, 10 mmol) and the mixture was stirred at room temperature for 0.5 h. 
After completion of the reaction NaOAc·H2O was added followed by water. The mixture was 
extracted with ethyl acetate. The organic layer was dried over anhydrous Na2SO4, filtered, 
and concentrated. The residue was purified by column chromatography on silica gel (eluting 
with 100% EtOAc) to afford the desired product as a colorless oil (0.228 g, 60%); Rf = 0.5 
(8:2 EtOAc: Hex); IR (cm-1): 3300, 3040, 2956, 2872, 1740 (CO ester), 1620;  1H NMR (400 
MHz, CDCl3) δ 6.68 (d, J = 8.3 Hz, 1H), 6.59 (d, J = 8.3 Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 
3.99 (q, J = 15.4 Hz, 2H), 3.75 (s, 3H), 3.32-3.18 (m, 1H), 2.92-2.86 (dd, J = 16.7, 4.1 Hz, 
1H), 2.64-2.51 (m, 2H), 2.37-2.30 (dd, J = 16.6, 10.5 Hz, 1H), 2.00 (s, 1H), 1.27 (t, J = 7.2 
Hz, 3H), 0.99 (s, 9H), 0.16 (d, J = 20.0 Hz, 6H); 13C NMR (100 MHz, CDCl3) 172.2, 147.8, 
142.3, 128.0, 125.9, 118.2, 109.3, 60.5, 54.9, 50.4, 47.2, 40.9, 30.5, 26.1 (3C), 18.9, 14.2,      
-3.8, -3.9; Mass (ES): m/z 380.22 (M+H, 100%); HRMS (ESI): calcd for C20H34NO4Si 
(M+H) +  380.2257 found 380.2249. 
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OTBS
H3CO
General procedure for 1,3 dipolar Cyclo addition 
To a solution of aldehyde (1 mmol) in ethanol (5 mL) was added aryl hydroxyl amine (2 
mmol) and MgSO4 (5 mmol) under  N2 atmosphere. The reaction  mixture was refluxed for 3-
5 h (for inversion in the yields of regio isomers the reaction mixture was heated at 130 oC for 
12 h). After completion of the reaction, ethanol was removed under high vacuum and the 
residue was purified by column chromatography on silica gel to give the desired product.  
 
(E)-N-(2-allyl-3-(tert-butyldimethylsilyloxy)-4-methoxybenzylidene)-2-cyanoaniline 
oxide (15e): 
The title compound was synthesized by using the general procedure; 
colorless solid; m.p : 176-178 oC; Yield (88%), Rf = 0.5 (2:8 EtOAc: 
Hex); IR (cm-1): 3277, 2935, 2857, 2120 (CN), 1725, 1662, 1600, 
1247; 1H NMR (400 MHz, CDCl3) δ  7.96 (d, J = 8.6 Hz, 1H), 7.36 
(d, J = 8.6 Hz, 1H), 7.34-7.28 (m, 1H), 6.88 (t, J = 7.5 Hz, 1H), 
6.84 (t, J = 6.6 Hz, 1H), 6.62 (d, J = 8.0 Hz, 1H), 6.06-5.93 (m, 2H), 5.06-5.03 (dd, J = 10.2, 
1.5 Hz, 1H), 4.84-4.78 (dd, J = 17.2, 1.6 Hz, 1H), 3.82 (s, 3H), 3.69-3.51 (m, 2H), 1.04 (s, 
9H), 0.19 (s, 6H); 13CNMR (100 MHz, CDCl3) δ 165.0, 150.2, 147.5, 142.9, 137.4, 133.7 
(2C), 129.5, 128.9, 128.5, 120.2, 119.1, 115.5, 115.2, 114.4, 109.6, 54.5, 29.7, 26.1 (3C), 
18.8, -3.8, -3.82; Mass (ES): m/z 423.2 (M+H, 100%). 
 
 5-(tert-butyldimethylsilyloxy)-6-methoxy-1-phenyl-3,3a,4,8b-tetrahydro-1H-indeno[1, 
2-c] isoxazole (16a): 
The title compound was synthesized by using the general procedure; 
colorless solid; m.p : 210-212 oC; Yield (36%), Rf = 0.7(1:9 EtOAc: 
Hex);  IR (cm-1):  3050, 2967, 2847, 1620, 1575, 1465, 1280; 1H 
NMR (400 MHz, CDCl3) δ 7.34 (t, J = 7.6 Hz, 2H), 7.20 (d, J = 7.9 
Hz, 2H), 7.06 (d, J = 8.1 Hz, 1H), 7.02 (dd, J = 17.3, 10.1 Hz, 1H), 
6.85 (d, J = 8.2 Hz, 1H), 5.36 (d, J = 7.5 Hz, 1H), 4.18 (t, J = 7.9 
Hz, 1H), 3.89-3.77 (m, 4H), 3.49-3.38 (m, 1H), 3.25-3.18 (dd, J = 16.8, 8.6 Hz, 1H), 3.08-
2.98 (m, 1H), 1.03 (s, 9H), 0.20 (t, J= 5.6 Hz, 6H);  13C NMR (100MHz, CDCl3) δ 150.9, 
150.1, 140.6, 135.1, 134.4, 128.9 (2C), 121.6, 117.6 (2C), 
114.6, 111.8, 76.3, 74.1, 55.4, 46.4, 35.6, 25.9 (2C), 18.6, −4.1, −4.15; Mass (ES): m/z 
N
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398.21 (M+H, 100%), 292.13 (30%); HRMS (ESI): calcd for C23H32NO3Si (M+H)+  
398.2151 found 398.2165. 
5-(tert-butyldimethylsilyloxy)-6-methoxy-1-p-tolyl-3,3a,4,8b-tetrahydro-1H-indeno[1,2-
c] isoxazole (16b): 
The title compound was synthesized by using the general procedure; 
yellow color solid; mp: 180-183 oC; Yield (32%), Rf = 0.9 (1:9 
EtOAc: Hex); IR (cm-1):  3030, 2953, 2868, 1609, 1576, 1456, 1278; 
1H NMR (400 MHz, CDCl3) δ 7.13 (m, 4H), 7.09-7.01 (m, 1H), 6.85 
(d, J = 8.2 Hz, 1H), 5.32 (d, J = 7.5 Hz, 1H), 4.19 (t, J = 8.0 Hz, 
1H), 3.87-3.78 (m, 4H), 3.48-3.36 (m, 1H), 3.25-3.15 (dd, J = 16.8, 
8.5 Hz, 1H), 3.05-2.95 (dd, J = 16.8, 2.7 Hz, 1H), 2.34 (s, 3H), 1.09 (s, 9H), 0.19 (d, J = 5.1 
Hz, 6H); 13CNMR (100 MHz, CDCl3) δ 150.2, 148.7, 140.7, 135.2, 134.4, 131.1, 129.5, 
117.7, 114.9 (2C), 111.9, 76.5, 74.2, 55.5, 46.4, 35.7, 25.9 (3C), 20.6, 18.7, -4.1, -4.0. Mass 
(ES): m/z 412.22 (M+H 100%); HRMS (ESI): calcd for C24H34NO3Si (M+H) + 412.2307 
found 412.2297. 
 
4-(5-(tert-butyldimethylsilyloxy)-6-methoxy-3,3a,4,8b-tetrahydro-1H-indeno[1,2-c] 
isoxazol-1-yl)benzonitrile (16c): 
The title compound was synthesized by using the general procedure; 
white color solid; mp: 210-214 oC; Yield (32%), Rf = 0.9(1:9 
EtOAc: Hex); IR (cm-1):  3050, 2967, 2847, 2220, 1615, 1565, 
1477, 1269; 1H NMR (400 MHz, CDCl3) δ  7.57 (d, J = 8.9 Hz, 
2H), 7.18 (d, J = 8.9 Hz, 2H),  6.98 (d, J = 8.2 Hz, 1H), 6.83 (d, J = 
8.2 Hz, 1H), 5.33 (d, J = 7.6 Hz, 1H), 4.12-4.01 (m, 1H), 3.89- 3.86 
(dd, J = 8.3, 2.6 Hz, 1H), 3.80 (s, 3H), 3.61-3.49 (m, 1H), 3.33-3.15 
(dd, J = 16.9, 8.7 Hz, 1H), 3.11-2.99 (dd, J = 16.9, 3.1 Hz, 1H), 1.07 (s, 9H), 0.18 (d, J = 6.4 
Hz, 6H); 13CNMR (100 MHz, CDCl3) δ  154.1, 150.4, 140.8, 134.5, 133.9 (2C), 133.4, 119.5, 
117.5, 114.0 (2C), 111.9, 103.7, 75.2, 74.5, 55.4, 46.6, 35.4, 25.9 (2C), 18.6, -4.0, -4.1; Mass 
(ES):m/z 423.20 (M+H 80%), 307.16 (100%); HRMS (ESI): calcd for C24H31N2O3Si (M+H) 
+
 423.2103 found 423.2093. 
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N-(3-(5-(tert-butyldimethylsilyloxy)-6-methoxy-3,3a,4,8b-tetrahydro-1H-indeno[1,2-c] 
isoxazol-1-yl) phenyl)methanesulfonamide (16d): 
The title compound was synthesized by using the general 
procedure; yellow color solid; mp: 190-193 oC; Yield (30%), 
Rf = 0.2 (1:9 EtOAc: Hex); IR (cm-1): 3247, 3078, 2928, 2856, 
1713, 1598, 1489, 1320, 1277; 1H NMR (400 MHz, 
CDCl3) δ 7.28-7.24 (dd, J = 9.21, 6.90 Hz, 1H), 7.09-6.93 (m, 
3H), 6.87-6.78 (m, 2H), 6.64 (s, 1H), 5.30 (d, J = 7.53 Hz, 
1H), 4.13 (t, J = 7.96 Hz, 1H), 3.91-3.74 (m, 5H), 3.48-3.38 
(m, 1H), 3.22-3.16 (dd, J = 16.8, 8.6 Hz, 1H), 3.01 (s, 3H), 1.03 (s, 10H), 0.19 (d, J = 8.8 Hz, 
6H); 13CNMR (100 MHz, CDCl3) δ 152.4, 150.2, 140.7, 137.6, 134.5, 130.2 (2C), 117.6, 
113.3, 111.8 (2C), 111.4, 106.5, 76.11, 74.2, 55.4, 46.5, 39.3, 35.4, 25.9 (2C), 18.6, -4.1; 
Mass (ES): m/z 513.18 (M+Na, 100%), 491.20 (M+H 90%); HRMS (ESI): calcd for 
C24H35N2O5SiS (M+H)+ 491.2035 found 491.2021. 
 
Ethyl5-(tert-butyldimethylsilyloxy)-6-methoxy-1-phenyl-3,3a,4,8b-tetrahydro-1H-
indeno[1,2-c]isoxazole-3-carboxylate (16f): 
The title compound was synthesized by using the general 
procedure; Colorless oil: yield (78%), Rf = 0.6 (1: 9 
EtOAc: Hex); IR (cm-1): 3011, 2925, 2854, 1737, 1610, 
1578, 1449,  1247;  1H NMR (400 MHz, CDCl3) δ  7.36-
7.22 (m, 4H), 7.07-6.96 (m, 1H), 6.89 (d, J = 8.2 Hz, 1H), 
6.78 (t, J = 6.6 Hz, 1H),  5.37 (d, J = 7.2 Hz, 1H), 4.31 (d, 
J = 5.9 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 3.79 (s, 3H), 3.74-3.63 (m, 1H), 3.15 (d, J = 3.8 
Hz, 2H), 1.27 (q, J = 7.2, 3H), 1.05 (s, 9H), 0.19 (d, J = 9.5 Hz, 6H); 13C NMR (100 MHz, 
CDCl3)δ 170.7, 150.6, 150.5, 141.3, 134.3, 133.2, 128.6, 122.2, 117.8, 115.8 (2C), 111.7, 83.
4, 75.4, 61.4, 55.4, 50.1, 33.2, 29.7, 25.9 (3C), 18.6, 14.0, −4.0, −4.1;   Mass (ES): m/z 
470.23 (M+H, 100%), 366.18 (40%); LC Mass: 470.2 (13.13% at 9.067 rt, 72.3% at 9.213 
RT respectively. We failed to isolate minor isomer, where as major isomer 16f was well 
characterised as mentioned above); HRMS (ESI): calcd for C26H36NO5Si (M+H)+ 470.2362 
found 470.2348. 
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Compound (17a): 
The title compound was synthesized by using the general procedure; 
Color less oil; yield (60%), Rf = 0.5 (1:9 EtOAc: Hex); IR (cm-1):  
3060, 2977, 2857, 1610, 1567, 1455, 1291; 1H NMR (400 MHz, 
CDCl3) δ 7.26 ( m, 3H), 7.13 (d, J = 7.6 Hz, 2H), 6.97 (d, J = 7.3 
Hz, 1H), 6.84 (d, J = 8.2 Hz, 1H), 6.70 (d, J = 8.2 Hz, 1H),  5.12-
5.03 (m, 1H), 4.59 (d, J = 4.2 Hz, 1H),  3.77 (s, 3H), 3.09 (d, J = 2.4 
Hz, 1H), 2.83- 2.78  (dd, J = 17.8, 1.8 Hz, 1H), 2.31 (m, 1H), 1.99 (d, J = 11.1 Hz, 2H), 1.00 
(s, 9H), 0.18 (d, J = 9.6 Hz,  6H); 13CNMR (100 MHz, CDCl3) δ  151.6, 149.2, 143.2, 130.4, 
128.1 124.9, 121.9, 119.4, 116.2 (2C), 108.8, 73.7, 66.1, 54.5, 34.3, 32.6, 25.8 (3C), 25.3, 
18.5, -3.9, -4.2,; Mass (ES):m/z 398.21 (M+H, 100%), 292.13 (30%); HRMS (ESI): calcd for 
C23H32NO3Si (M+H) +  398.2151 found 398.2152. 
Compound (17b): 
The title compound was synthesized by using the general procedure; 
Light yellow oil; yield (68%), Rf = 0.6 (1:9 EtOAc: Hex); IR (cm-1):  
3025, 2978, 2856, 1580, 1495, 1268; 1H NMR (400 MHz, 
CDCl3) δ 7.15-7.01 (m, 4H), 6.86 (d, J = 8.2 Hz, 1H), 6.72 (d, J = 
8.2 Hz, 1H), 5.14-5.02 (m, 1H), 4.55 (d, J = 4.2 Hz, 1H), 3.87 (s, 
3H), 3.22-3.06 (m, 1H), 2.81 (d, J = 17.7 Hz, 1H), 2.38-2.23 (m, 
4H), 1.98 (d, J = 11.1 Hz, 1H), 1.05 (s, 9H), 0.20 (d, J = 10.9 Hz, 6H); 13CNMR (100 MHz, 
CDCl3) δ 149.6, 149.4, 143.5, 131.5, 130.8, 128.9 (2C), 125.2, 119.6, 116.6 (2C), 109.1, 
73.9, 66.6, 54.7, 34.6, 32.6, 26.0 (3C), 20.5, 18.8, -3.7 -3.9; Mass (ES): m/z 412.23 (M+H 
100%); HRMS (ESI): calcd for C24H34NO3Si (M+H)+ 412.2307 found 412.2309. 
Compound (17c): 
The title compound was synthesized by using the general procedure; 
Colorless oil; yield (62%), Rf = 0.55 (1:9 EtOAc: Hex); IR (cm-1):  
3060, 2987, 2869, 2198, 1605, 1545, 1487, 1277;1H NMR (400 
MHz, CDCl3) δ 7.49 (d, J = 8.8 Hz, 2H), 7.09 (d, J = 8.8 Hz, 2H), 
6.76 (d, J = 8.2 Hz, 1H), 6.65 (d, J = 8.3 Hz, 1H), 5.12-5.01 (m, 
1H), 4.76 (d, J = 4.4 Hz, 1H), 3.75 (s, 3H), 3.15-3.05 (dd, J = 18.1, 
1.9 Hz, 1H), 2.90-2.80 (dd, J = 18.0, 2.2 Hz, 1H), 2.37 (td, J = 10.7, 5.4 Hz, 1H), 2.15 (d, J 
= 8.8 Hz, 1H), 0.99 (s, 9H), 0.17 (d, J = 4.9 Hz, 6H); 13CNMR (100 MHz, CDCl3) δ  154.2, 
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149.7, 143.6, 132.8 (2C), 129.3, 124.7, 119.8, 119.6, 115.8 (2C), 108.9, 103.81, 74.3, 64.5, 
54.8, 34.6, 34.6, 26.1 (3C), 18.9, -3.7, -3.8; Mass (ES): m/z 445.18 (M+Na 100%), 423.20 
(M+H 80%), 307.16 (100%); HRMS (ESI): calcd for C24H31N2O3Si (M+H) + 423.2103 found 
423.2085. 
Compound (17d): 
The title compound was synthesized by using the general 
procedure; Brown color oil; yield (65%), Rf = 0.2 (1:9 
EtOAc: Hex); IR (cm-1): 3233, 3063, 2954, 2854, 1713, 
1595, 1479, 1310, 1257; 1H NMR (400 MHz, 
CDCl3) δ 7.17 (t, J = 8.0 Hz, 1H), 6.88-6.98 (dd, J = 8.0, 
6.0 Hz, 1H), 6.91-6.83 (m, 2H), 6.82-6.74 (m, 2H), 6.64 
(d, J = 8.2 Hz, 1H), 5.03 (dd, J = 5.9, 2.5 Hz, 1H), 4.63 (d, J = 4.2 Hz, 1H), 3.75 (d, J = 15.5 
Hz, 3H), 3.14-3.00 (m, 1H), 3.00-2.88 (m, 3H), 2.78-2.81 (dd, J = 17.9, 1.9 Hz, 1H), 2.30-
2.35 (td, J = 10.7, 5.3 Hz, 1H), 0.97 (s, 9H), 0.23 (s, 6H); 13CNMR (100 MHz, CDCl3) 152.8, 
149.6, 143.5, 137.2, 130.1, 129.7 (2C), 125.0, 120.0, 114.00, 113.4, 108.9, 106.6, 74.1, 65.8, 
54.8, 39.0, 34.7, 26.1 (3C), 18.9, -3.70, -3.77; Mass (ES): m/z 513.18 (M+Na, 100%), 491.20 
(M+H 90%); HRMS (ESI): calcd for C24H35N2O5SiS (M+H) + 491.2035 found 491.2015. 
 
Ethyl 5-(tert-butyldimethylsilyloxy)-1-(2-cyanophenylamino)-3-hydroxy-6-methoxy-1,2, 
3 4-tetrahydronaphthalene-2-carboxylate (18): 
The title compound was synthesized by using the general 
procedure; white color solid; mp: 180-183 oC, Yield 
(58%), Rf = 0.4 (2:8 EtOAc: Hex); IR (cm-1): 3311, 2934, 
2856, 2140 (CN), 1729, 1620, 1600, 1489,  1247;  1H 
NMR (400 MHz, CDCl3) δ 7.99 (d, J = 7.9 Hz, 1H), 7.32 
(d, J = 7.5 Hz, 1H), 6.94 (t, J = 8.1 Hz, 2H), 6.86 (d, J = 
8.3 Hz, 1H), 6.76 (d, J = 7.9 Hz, 1H), 5.83 (s, 1H), 5.46 (d, J = 5.9 Hz, 1H), 4.27 (s, 1H), 
4.16-4.02 (m, 2H), 3.83 (s, 3H), 3.20 (d, J = 16.3 Hz, 1H), 2.94 (d, J = 5.4 Hz, 1H), 2.45 (d, 
J = 6.8 Hz, 1H), 2.35 (d, J = 7.9 Hz, 1H), 1.22 (t, J = 8.4 Hz, 3H), 1.00 (s, 9H), 0.22 (s, 3H), 
0.14 (s, 3H);  13CNMR (100 MHz, CDCl3) δ 170.8, 163.8, 149.9, 146.8, 142.9, 133.1, 129.0, 
124.9, 124.8, 119.9, 118.5, 117.8, 115.2, 110.1, 64.6, 60.6, 54.8, 44.2, 36.4, 27.3, 25.8 (3C), 
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18.7, 13.9, -3.9, -4.2; Mass (ES): m/z 519.22 (M+Na, 100%), 497.24 (M+H, 80%); HRMS 
(ESI): calcd for C27H37N2O5Si (M+H) + 497.2471 found 497.2459. 
 
(R)-Ethyl2-((1R,2R)-4-(tert-butyldimethylsilyloxy)-5-methoxy-1-(phenylamino)-2,3-
dihydro-1H-inden-2-yl)-2-hydroxyacetate (19): 
To a solution of (3R,3aR,8bR)-ethyl 5-(tert-
butyldimethylsilyloxy)-6-methoxy-1-phenyl-3, 3a,4,8b-
tetrahydro-1H-indeno [1,2-c] isoxazole-3-carboxylate (8f) 
(0.470 g, 1.0 mmol) in MeOH (5 mL) was added 5% Pd/C 
(47 mg) under balloon pressure of H2. TLC shows completion 
of reaction after 6h. The Pd was filtered through celite, and 
the filtrate was concentrated under high vacuum. The residue was purified by column 
chromatography with EtOAc/Hexane (2:8) as eluent to yield the desired product; yield 
(80%). Rf = 0.4 (2:8 EtOAc: Hex); IR (cm-1): 3340, 3079, 2930, 2847, 1681, 1650, 1585; 1H 
NMR (400 MHz, CDCl3) δ 7.18 (t, J = 7.93 Hz, 2H), 6.82-6.65 (m, 5H), 7H), 5.15 (d, J = 
7.3 Hz, 1H), 4.34 (d, J = 4.7 Hz, 1H), 3.96 (dd, J = 10.7, 7.2 Hz, 1H), 3.77 (s, 3H), 3.63 (dd, 
J = 10.7, 7.1 Hz, 1H), 3.28-2.96 (tdd, J = 37.6, 16.4, 6.3 Hz, 4H), 1.11 (t, J = 7.1 Hz, 3H), 
1.01 (s, 9H), 0.17 (d, J =  6.3 Hz); 13C NMR (100 MHz, CDCl3) δ 172.7, 150.8, 141.2, 136.6, 
135.9, 132.7, 128.8 (2C), 126.7, 125.3 (2C), 118.7, 109.9 (2C), 71.1, 65.6, 55.1, 42.7, 28.2, 
25.9 (3C), 18.6, 14.4, -4.1 (2C); Mass (ES): m/z 494.23 (M+Na, 100%), 379.19 (100%); 
HRMS (ESI): calcd for C26H37NO5SiNa (M+Na)+  494.2338 found  494.2341. 
 
(3S,3aR,8bR)-5-(tert-butyldimethylsilyloxy)-3-hydroxy-6-methoxy-1-phenyl-1,3a,4,8b-
tetrahydroindeno[1,2-b]pyrrol-2(3H)-one (20): 
To a solution of (3R,3aR,8bR)-ethyl 5-(tert-
butyldimethylsilyloxy)-6-methoxy-1-phenyl-3, 3a,4,8b-
tetrahydro-1H-indeno [1,2-c] isoxazole-3-carboxylate (0.470 g, 
1.0 mmol) in AcOH: THF:H2O (2:1:1, 40 mL) was added Zn 
dust (0.4 g, 6.1 mmol) at 60 oC. The reaction mixture was stirred 
for 5h. After completion of the reaction the mixture was cooled 
to room temperature and Zn was filtered off. The filtrate was concentrated to remove THF, 
and neutralized with saturated NaHCO3 solution. The reaction mixture was extracted with 
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CH2Cl2. The organic layer was washed with brine, dried over Na2SO4, filtered and 
concentrated. The residue was purified by column chromatography using EtOAc/Hexane 
(3:7) as eluent to yield a colorless solid (0.255 g, 60%); mp: 160-163 oC  Rf = 0.4 (3:7 
EtOAc: Hex); IR (cm-1): 3450, 3088, 2965, 2874, 1700, 1630, 1565; 1H NMR (400 MHz, 
CDCl3) δ 7.40-7.33 (m, 2H), 7.26-7.20 (m, 3H), 6.46 (q, J = 8.2 Hz, 2H), 5.30 (d, J = 6.30 
Hz, 1H), 4.73 (d, J = 8.3 Hz, 1H), 3.70 (s, 3H), 3.59-3.50 (m, 1H),  3.30 (s, 1H), 3.24-3.03 
(m, 2H), 1.00 (s, 9H), 0.15 (d, J = 1.5 Hz, 6H); 13CNMR (100 MHz, CDCl3) δ 173.3, 150.7, 
141.2, 136.6, 132.8, 128.8 (2C), 126.7, 125.4 (2C), 118.7, 109.9, 71.0, 65.6, 55.1, 42.6, 28.3, 
26.0 (3C), 18.6, -4.04, -4.07; Mass (ES): m/z  448.19 (M+Na, 20%), 371.23 (40%), 313.19 
(100%); HRMS (ESI): calcd for C24H31NO4SiNa (M+Na) +  448.1920 found 448.1909. 
 
(4-(tert-butyldimethylsilyloxy)-5-methoxy-1-(phenylamino)-2,3-dihydro-1H-inden-2-
yl)methanol (21): 
The title compound was synthesized by using a procedure similar 
to synthesis of 11; brown viscous oil, yield (88%), Rf = 0.4 (1:9 
EtOAc: Hex); IR (cm-1): 3373, 3079, 2930, 2854, 1600, 1494, 
1443; 1H NMR (400 MHz, CDCl3) δ 7.27-7.22 (m, 1H), 6.89-
6.80 (m, 3H), 6.73 (q, J = 8.1 Hz, 2H),  5.06 (d, J = 6.6 Hz, 1H), 
3.84-3.77 (m, 4H), 3.72 (dd, J = 11.2, 4.6 Hz, 1H), 3.40-3.27 (bs, 
1H), 3.05-2.86 (m, 3H), 1.02 (s, 9H), 0.19 (d, J = 12.2 Hz, 6H); 13CNMR (100 MHz, CDCl3) 
δ 150.1, 148.0, 141.1, 137.3, 133.1, 129.4 (2C), 118.1, 116.1, 113.6 (2C), 110.8, 63.4, 61.0, 
55.3, 44.5, 31.1, 25.9 (3C), 18.6, -4.0, -4.2; Mass (ES): m/z 422.21 (M+H, 40%), 400.23 
(35%), 307.17 (100%); HRMS (ESI): calcd for C23H34NO3Si (M+H)+ 400.2307 found 
400.2313. 
7-(tert-butyldimethylsilyloxy)-8-methoxy-1-phenyl-5,5a,6,10b-tetrahydro-1H-
indeno[1,2-e][1,4]oxazepin-2(3H)-one (22): 
To a solution of (4-(tert-butyldimethylsilyloxy)-5-methoxy-1-
(phenylamino)-2,3-dihydro-1H-inden-2-yl)methanol (0.422 g, 1.0 
mmol) in dry DMF (10 mL), was added ethylbromo acetate (0.2 g, 
1.2 mmol) and oven dried K2CO3 (0.548 g, 4.0 mmol). The 
mixture was refluxed for 36 h. After completion of the reaction, 
the mixture was diluted with saturated NH4Cl solution and extracted with CH2Cl2. The 
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organic layer was collected, washed with 2N HCl and water, then dried over anhydrous 
Na2SO4, filtered and concentrated. The residue was purified by column chromatography on 
silica gel using EtOAc/Hexane (3:7) as eluent to afford the desired product as a brown solid 
(0.228 g, 60%); mp: 280-282 o C; Yield (60%), Rf = 0.4 (3:7 EtOAc: Hex); IR (cm-1):  3021, 
2973, 2877, 1720, 1615, 1585; 1H NMR (400 MHz, CDCl3) δ  7.41 (t, J = 7.7 Hz, 2H), 7.34 
(d, J = 7.3 Hz, 2H), 7.31-7.23 (m, 1H), 6.92 (d, J = 8.0 Hz, 1H), 6.75 (d, J = 8.0 Hz, 1H), 
5.30 (d, J = 7.1 Hz, 1H), 4.34 (d, J = 15.5 Hz, 1H), 4.11 (dd, J = 12.6, 3.9 Hz, 1H), 3.91 (d, J 
= 15.5 Hz, 1H), 3.79 (s, 3H), 3.72 (dd, J = 12.7, 4.8 Hz, 1H), 2.94 (dd, J = 20.0, 13.3 Hz, 
3H), 1.00 (s, 9H), 0.20 (s, 3H), 0.13 (s, 3H);  13CNMR (100 MHz, CDCl3)  172.6, 150.2, 
144.5, 141.3, 134.8, 131.8, 129.2 (2C), 126.9, 126.5 (2C), 114.7, 110.5, 72.5, 71.7, 68.8, 
55.2, 43.5, 32.0, 25.8 (3C), 18.5, -4.2, -4.4; Mass (ES): m/z 462.20 (M+Na, 100%), 440.22 
(M+H, 10%), 289.16 (80%); HRMS (ESI): calcd for C25H33NO4 NaSi (M+Na)+  462.2076 
found 462.2060. 
 
A typical procedure for the deprotection of tert-butyldimethylsilyloxy group of 
compound 16c: 
To a solution of  4-(5-(tert-butyldimethylsilyloxy)-6-methoxy-3,3a,4,8b-tetrahydro-1H-
indeno[1,2-c] isoxazol-1-yl) benzonitrile (16c) (1 mmol) in dry THF (5 mL), was added 
tetra-butyl ammonium iodide (1.5 mmol) at 0 oC. The reaction mixture was stirred at the 
same temperature for 0.5 h, THF was removed under high vacuum followed by extraction 
with DCM. The DCM layer was collected, dried over anhydrous Na2SO4, filtered and 
concentrated. The residue was purified by using column chromatography over silica gel to 
give the product 4-(5-hydroxy-6-methoxy-3,3a,4,8b-tetrahydro-1H-indeno[1,2-c]isoxazol-1-
yl)benzonitrile (23). 
White  color solid; m.p: 180 oC; Yield (88%), Rf = 0.2 (1:9 EtOAc: 
Hex); IR (cm-1): 3430, 3256, 3060, 2973, 2868, 2205, 1620, 1555, 
1486, 1276; 1H NMR (400 MHz, CDCl3) δ 7.58 (d, J = 8.9 Hz, 
2H), 7.19 (d, J = 8.9 Hz, 2H), 6.93 (d, J = 8.1 Hz, 1H), 6.84 (d, J = 
8.2 Hz, 1H), 5.67 (s, 1H), 5.35 (d, J = 7.6 Hz, 1H), 4.10-4.05 (m, 
1H), 3.98-3.85 (m, 4H), 3.56-3.48 (m, 1H), 3.30-3.22 (m, 1H), 3.03 
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ON
OH
H3CO
(dd, J = 16.9, 3.1 Hz, 1H); 13CNMR (100 MHz, CDCl3) δ 154.0, 146.6, 141.4, 134.5 (2C), 
133.4, 128.6, 119.5, 116.1, 114.0 (2C), 110.7, 103.8, 75.0, 74.6, 56.4, 46.7, 34.2, 29.7; Mass 
(ES): m/z 309.13 (M+H 100%). 
 
6-methoxy-1-phenyl-3,3a,4,8b-tetrahydro-1H-indeno[1,2-c]isoxazol-5-ol (24): 
The title compound was synthesized by following the typical 
procedure for synthesis of compound 15; colorless solid; m.p: 180 
oC; Yield (90%), Rf = 0.2 (1:9 EtOAc: Hex);   IR (cm-1): 3360,  3040, 
2957, 2832, 1620, 1565, 1445, 1290; 1H NMR (400 MHz, 
CDCl3) δ 7.34 (t, J = 7.6 Hz, 2H), 7.20 (d, J = 7.9 Hz, 2H), 7.03 (d, 
J = 8.1 Hz, 2H), 6.83 (d, J = 8.1 Hz, 1H), 5.65 (s, 1H), 5.35 (d, J = 
7.5 Hz, 1H), 4.17 (t, J = 7.9 Hz, 1H), 3.83 (s, 3H), 3.84-3.82 (m, 1H), 3.48-3.42 (m, 1H), 
3.25-3.18 (dd, J = 16.8, 8.6 Hz, 1H), 3.08-2.98 (m, 1H); 13C NMR (100 MHz, 
CDCl3) δ  148.1, 145.0, 141.6, 135.1, 134.4, 128.9 (2C), 121.6, 117.6 (2C), 
114.6, 111.8,  76.3, 74.1, 55.4, 46.4, 25.9; Mass (ES): m/z 284.21 (M+H, 100%). 
6-Methoxy-1-p-tolyl-3,3a,4,8b-tetrahydro-1H-indeno [1, 2-c] isoxazol-5-ol (25): 
The title compound was synthesized by following the typical 
procedure for synthesis of compound 15; light yellow solid; m.p: 
170 oC; Yield (86%), Rf = 0.2 (1:9 EtOAc: Hex); IR (cm-1): 3296, 
3050, 2963, 2878, 1619, 1567, 1476, 1286; 1H NMR (400 MHz, 
CDCl3) δ 7.19-7.09 (m, J = 8.7 Hz, 4H), 6.97 (d, J = 8.2 Hz, 1H), 
6.81 (d, J = 8.2 Hz, 1H), 5.30 (d, J = 7.5 Hz, 1H), 4.16 (t, J = 8.0 
Hz, 1H), 3.85 (s, 3H), 3.79-3.68 (dd, J = 8.4, 2.7 Hz, 1H), 3.47-3.37 (m, 1H), 3.19 (dd, J = 
16.8, 8.6 Hz, 1H), 2.99 (dd, J = 16.8, 2.6 Hz, 1H), 2.30 (s, 3H); 13CNMR (100 MHz, CDCl3) 
δ 148.6, 146.4, 141.4, 135.9, 131.21, 129.5, 116.2, 114.9 (2C), 110.7, 76.3, 74.2, 56.4, 46.6, 
34.4, 20.5. Mass (ES): m/z 298.13 (M+H 100%). 
 
 
 
 
 
ON
OH
H3CO
Experimental section - Chapter 5 
 
B. Dulla, PhD thesis (2013) Page 145 
 
N-(3-(5-(tert-butyldimethylsilyloxy)-6-methoxy-3,3a,4,8b-tetrahydro-1H-indeno[1,2-c] 
isoxazol-1-yl) phenyl) methanesulfonamide (26): 
The title compound was synthesized by following the typical 
procedure for synthesis of compound 15; yellow solid; mp: 
190-193 oC; Yield (70%), Rf = 0.2 (3:7 EtOAc: Hex); IR (cm-
1): 3437, 3068, 2948, 2856, 1711, 1588, 1482, 1310, 1287; 1H 
NMR (400 MHz, CDCl3) δ 7.25-7.21 (dd, J = 9.21, 6.90 Hz, 
1H), 7.11-6.95 (m, 3H), 6.89-6.79 (m, 2H), 6.54 (s, 1H), 5.32 
(d, J = 7.5 Hz, 1H), 4.15 (t, J = 7.9 Hz, 1H), 3.93-3.77 (m, 
5H), 3.51-3.41 (m, 1H), 3.24-3.19 (dd, J = 16.8, 8.6 Hz, 1H), 3.09 (s, 3H); 13CNMR (100 
MHz, CDCl3) δ 153.4, 151.2, 141.2, 138.2, 135.1, 130.9 (2C), 118.5, 113.6, 112.2, 111.9 
(2C), 105.7, 77.41, 75.2, 56.4, 47.5, 39.8, 36.4, 26.9; Mass (ES): m/z 377.10 (M+H 100%). 
Compound 27: 
The title compound was synthesized by following the 
typical procedure for synthesis of compound 15; colorless 
viscous oil; Yield (72%), Rf = 0.15 (1:9 EtOAc: Hex); IR 
(cm-1): 3423, 3070, 2992, 2876, 2198, 1615, 1565, 1497, 
1287; 1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 8.8 Hz, 
2H), 7.09 (d, J = 8.8 Hz, 2H), 6.72 (d, J = 8.1 Hz, 1H), 
6.66 (d, J = 8.1 Hz, 1H), 5.72 (s, 1H), 5.11-5.02 (m, 1H), 4.78 (d, J = 4.40 Hz, 1H), 3.84 (s, 
3H), 3.11 (dd, J = 18.0, 1.8 Hz, 1H), 2.88 (dd, J = 18.0, 2.2 Hz, 1H), 2.47-2.31 (m, 1H), 2.17 
(d, J = 11.1 Hz, 1H); 13CNMR (100 MHz, CDCl3) δ  154.3, 149.7, 143.6, 140.3, 132.8 (2C), 
124.7 (2C), 119.7, 119.6, 115.8, 108.9, 103.6, 74.2, 64.5, 54.8, 41.0, 24.3; Mass (ES): m/z 
309.16 (M+H 100%). 
Compound (28): 
The title compound was synthesized by following the typical 
procedure for synthesis of compound 15; brown semi solid, Yield 
(80%), Rf = 0.2 (1:9 EtOAc: Hex); IR (cm-1): 3345, 3050, 2967, 
2875, 1620, 1566, 1465, 1298; 1H NMR (400 MHz, CDCl3) δ 7.24 
(t, J = 7.9 Hz, 2H), 7.12 (d, J = 7.7 Hz, 2H), 6.93 (t, J = 7.3 Hz, 
1H), 6.76 (d, J = 8.1 Hz, 1H), 6.67 (d, J = 8.1 Hz, 1H), 5.79 (s, 1H), 
5.12-5.00 (m, 1H), 4.59 (d, J = 4.3 Hz, 1H), 3.84-3.74 (m, 3H), 3.10 (dd, J = 17.7, 2.0 Hz, 
ON
OH
H3CO
NH
S
O
O
ON
OH
H3CO
CN
ON
OH
H3CO
Experimental section - Chapter 5 
 
B. Dulla, PhD thesis (2013) Page 146 
 
1H), 2.80 (dd, J = 17.8, 1.7 Hz, 1H), 2.32 (td, J = 10.9, 5.3 Hz, 1H), 2.04-1.96 (m, 1H); 
13CNMR (100 MHz, CDCl3) δ 153.6, 146.7, 141.8, 132.8, 129.3, 124.7, 119.8, 119.6, 115.9, 
108.9, 103.8, 74.2, 64.5, 54.8, 48.9, 34.6, 26.1; Mass (ES): m/z  284.21 (M+H, 100%). 
Compound 29: 
The title compound was synthesized by following the typical 
procedure for synthesis of compound 15; colorless semi solid; Yield 
(90%), Rf = 0.8 (1:9 EtOAc: Hex); IR (cm-1): 3346, 3053, 2987, 
2867, 1590, 1505, 1286; 1H NMR (400 MHz, CDCl3) δ 7.07-7.01 
(m, 4H), 6.77 (d, J = 8.1Hz, 1H), 6.69 (d, J = 8.1 Hz, 1H), 5.12-4.98 
(m, 1H), 5.98-5.45 (m, 1H),  4.53 (d, J = 4.3 Hz, 1H), 3.82 (s, 3H), 
3.10 (dd, J = 17.7, 1.8 Hz, 1H), 2.80 (dd, J = 17.7, 1.6 Hz, 1H), 2.38-2.29 (m, 1H), 2.29 (d, J 
= 11.0 Hz, 3H), 1.99 (d, J = 11.1 Hz, 1H); 13CNMR (100 MHz, CDCl3) δ  149.6, 146.1, 
144.1, 131.7, 131.2 (2C), 129.1, 119.8, 118.4, 116.7 (2C), 108.3, 73.9, 66.6, 56.1, 33.2, 33.0, 
20.6; Mass (ES): m/z 298.13 (M+H 100%). 
Compound (30): 
The title compound was synthesized by following the 
typical procedure for synthesis of compound 15; colorless 
semi solid; yield (85%), Rf = 0.2 (3:7 EtOAc: Hex); IR 
(cm-1): 3420, 3253, 3083, 2965, 2874, 1713, 1585, 1489, 
1320, 1267; 1H NMR (400 MHz, CDCl3) δ 7.20 (t, J = 8.0 
Hz, 1H), 6.97 (s, 1H), 6.90 (d, J = 8.1 Hz, 1H), 6.80-6.73 
(m, 2H), 6.67 (d, J = 8.2 Hz, 1H), 5.12-5.03 (m, 1H), 4.66 (d, J = 4.3 Hz, 1H), 5.93-5.46 (m, 
1H), 3.85 (s, 3H), 3.11 (dd, J = 17.9, 1.7 Hz, 1H), 2.95 (s, 3H), 2.85 (dd, J = 17.8, 1.8 Hz, 
1H), 2.45-2.35 (m, 1H), 2.10 (d, J = 11.2 Hz, 1H); 13CNMR (100 MHz, CDCl3) 152.8, 146.1, 
144.0, 137.1, 130.4, 129.7 (2C), 119.5, 118.6 (2C), 113.9, 113.4, 108.6, 108.1, 74.0, 65.6, 
56.0, 39.1, 33.9; Mass (ES): m/z 513.18 (M+Na, 100%), 377.20 (M+H 90%). 
Ethyl-5-hydroxy-6-methoxy-1-phenyl-3,3a,4,8b-tetrahydro-1H-indeno[1,2-c]isoxazole-3-
carboxylate (31): 
The title compound was synthesized by following the 
typical procedure for synthesis of compound 15; Light 
yellow color oil; yield (88%), Rf = 0.2 (1:9 EtOAc: Hex); 
IR (cm-1): 3367, 3067, 2954, 2874, 1742, 1620, 1565, 
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1435,  1255;  1H NMR (400 MHz, CDCl3) δ  7.33-7.23 (m, 4H),  7.00 (ddd, J = 8.3, 6.9, 3.6 
Hz, 1H), 6.84-6.73 (m, 2H), 5.70 (s, 1H), 5.37 (d, J = 7.3 Hz, 1H), 4.33 (d, J = 5.8 Hz, 1H), 
4.17 (q, J = 7.1 Hz, 2H), 3.85 (d, J = 11.8 Hz, 4H), 3.73 (ddd, J = 13.4, 6.4, 3.4 Hz, 1H), 
3.23-3.08 (m, 2H), 1.25 (t, J =7.14Hz, 4H); 13C 
NMR(100MHz,CDCl3)δ 170.7, 150.4, 146.2, 141.9, 134.8,  128.6 (2C), 127.4, 122.2, 116.3, 
115.9 (2C), 110.5, 83.4, 75.1, 61.4, 56.3, 50.2, 32.2, 14.0;  Mass (ES): m/z 355.24 (M+H, 
100%).  
 
2-(Hydroxyl methyl)-5-methoxy-1-(phenylamino)-2,3-dihydro-1H-inden-4-ol (32): 
The title compound was synthesized by following the typical 
procedure for synthesis of compound 15; yellow color viscous 
oil, Yield (88%), Rf = 0.3 (3:7 EtOAc: Hex); IR (cm-1): 3383, 
3089, 2950, 2864, 1610, 1534, 1484, 1453; 1H NMR (400 MHz, 
CDCl3) δ 7.27-7.12 (m, 2H), 6.80-6.69 (m, 5H), 5.05 (d, J = 6.8 
Hz, 1H), 3.83 (s, 3H), 3.79-3.72 (m, 1H), 3.65 (dd, J = 11.2, 4.8 
Hz, 1H), 3.04-2.92 (m, 2H), 2.87 (d, J = 12.2 Hz, 1H);  13CNMR (100 MHz, CDCl3) δ 148.0, 
146.4, 141.8, 137.9, 129.4 (2C), 127.4, 118.2, 114.5, 113.7 (2C), 109.8, 63.4, 61.0, 56.3, 
44.6, 29.9; Mass (ES): m/z 285.21 (M+H, 100%). 
2-Methoxy-5-(phenylamino)-5,6,7,8-tetrahydronaphthalene-1,7-diol (33): 
The title compound was synthesized by following the typical 
procedure for synthesis of compound 15; yellow color viscous 
oil, Yield (88%), Rf = 0.3 (3:7 EtOAc: Hex); IR (cm-1): 3383, 
3089, 2950, 2864, 1610, 1534, 1484, 1453; 1H NMR (400 
MHz, CDCl3) δ 7.25-7.15 (m, 2H), 6.95 (d, J = 8.5 Hz, 1H), 
6.77-6.68 (m, 4H),  6.16-6.15 (m, 1H), 6.13-5.50 (m, 1H), 4.66 (t, J = 5.9 Hz, 1H), 4.33-4.19 
(m, 1H), 3.85 (s, 3H), 3.03 (dd, J = 17.1, 4.9 Hz, 1H), 2.83 (dd, J = 17.1, 6.4 Hz, 1H), 2.28-
2.20 (m, 1H), 2.06-1.95 (m, 1H); 13CNMR (100 MHz, CDCl3) δ 147.0, 145.4, 143.1, 131.0, 
129.4 (2C), 121.0, 118.9, 117.9, 113.6 (2C), 108.9, 65.9, 56.1, 36.4, 32.4; Mass (ES): m/z 
285.21 (M+H, 100%). 
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3-(2-Ethoxy-2-oxoethyl)-5-hydroxy-6-methoxy-3,4-dihydroisoquinoline-2-oxide (34): 
The title compound was synthesized by following the 
typical procedure for synthesis of compound 15; colorless 
oil (88%); Rf = 0.4 (8:2 EtOAc: Hex); IR (cm-1): 3326, 
3060, 2985, 2872, 1720 (CO, ester), 1621, 1575, 1474, 
1257; 1H NMR (400 MHz, CDCl3) δ 7.66 (s, 1H), 6.75 (s, 1H), 6.70 (s, 1H), 6.12-5.99 (m, 
1H), 4.53-4.48 (m, 1H), 4.22-4.15 (m, 2H), 3.92 (s, 5H), 3.20-3.13 (m, 3H), 3.12-3.06 (m, 
1H), 2.65-2.56 (m, 1H), 1.28 (d, J = 7.1 Hz, 4H); 13CNMR (100 MHz, CDCl3) δ 173.8, 
152.0, 142.5, 135.1, 121.3, 119.9, 109. 8, 63.5, 60.9, 55.0, 35.8, 27.1, 14.1; Mass (ES): m/z  
280.20 (M+H, 100%). 
7-Hydroxy-8-methoxy-1-phenyl-5,5a,6,10b-tetrahydro-1H-indeno[1,2-e][1,4]oxazepin-
2(3H)-one ( 35): 
The title compound was synthesized by following the typical 
procedure for synthesis of compound 15; Brown solid (90%); mp: 
250 oC; Yield (90%), Rf = 0.2 (3:7 EtOAc: Hex); IR (cm-1):  3345, 
3051, 2983, 2867, 1710, 1625, 1575; 1H NMR (400 MHz, 
CDCl3) δ 7.42 (t, J = 7.7 Hz, 2H), 7.35 (d, J = 7.6 Hz, 2H), 7.27 
(dd, J = 12.8, 4.8 Hz, 1H), 6.88 (d, J = 8.0 Hz, 1H), 6.75 (d, J = 8.0 Hz, 1H), 5.82 (s, 1H), 
5.29 (d, J = 6.9 Hz, 1H), 4.33 (d, J = 15.7 Hz, 1H), 4.11 (dd, J = 12.6, 3.2 Hz, 1H), 3.93 (d, J 
= 15.7 Hz, 1H), 3.89 (d, J = 18.5 Hz, 3H), 3.79 (dd, J = 12.6, 3.3 Hz, 1H), 3.08-2.89 (m, 
3H);  13CNMR (100 MHz, CDCl3) 172.3, 146.4, 144.9, 141.9, 136.0, 129.3 (2C), 127.0 (2C), 
126.6 (2C), 112.9, 109.4, 72.7, 72.1, 68.8, 56.2, 43.8, 31.2; Mass (ES): m/z 326.20.  
3,5-Dihydroxy-6-methoxy-1-phenyl-1,3a,4,8b-tetrahydroindeno[1,2-b]pyrrol-2(3H)-one 
(36): 
The title compound was synthesized by following the typical 
procedure for synthesis of compound 15; Colorless solid (80%); 
mp: 168 oC  Rf = 0.25 (3:7 EtOAc: Hex); IR (cm-1): 3434, 3085, 
2975, 2864, 1718, 1628, 1576; 1H NMR (400 MHz, 
CDCl3) δ 7.40-7.33 (m, 2H), 7.26-7.20 (m, 3H), 6.46 (q, J = 8.2 
Hz, 2H), 5.30 (d, J = 6.3 Hz, 1H), 4.73 (d, J = 8.3 Hz, 1H), 3.70 
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(s, 3H), 3.59-3.50 (m, 1H),  3.30 (s, 1H), 3.24-3.03 (m, 2H); 13CNMR (100 MHz, CDCl3) 
δ 173.3, 146.5, 144.7, 141.2, 136.6, 136.0, 132.8, 128.8 (2C), 126.7, 125.4 (2C), 118.7, 
109.9, 71.0, 65.6, 55.1, 42.6, 28.3, 26.0; Mass (ES): m/z 312.18 (M+H, 100%). 
 
5.5.3 X-ray crystallographic studies  
Crystal data for 16a: C23H31NO3Si, M = 397.58, colorless block, 0.15 x 0.08 x 0.05 mm3, 
monoclinic, space group P21/c (No. 14), a = 12.368(12), b = 13.474(14), c = 13.097(13) Å, β 
= 102.866(17)°, V = 2128(4) Å3, Z = 4, Dc = 1.241 g/cm3, F000 = 856, CCD Area Detector, 
MoKα radiation, γ = 0.71073 Å,  T = 294(2)K, 2θmax = 50.0º, 19940 reflections collected, 
3744 unique (Rint = 0.0237).  Final GooF = 1.033, R1 = 0.0506, wR2 = 0.1381, R indices 
based on 3243 reflections with I>2σ(I) (refinement on F2), 259 parameters, 0 restraints, µ = 
0.134 mm-1. CCDC 909838 contains the supplementary crystallographic data for this paper. 
These data can be obtained free of charge at www.ccdc.cam.ac.uk/conts/retrieving.html [or 
from the Cambridge Crystallographic Data Centre (CCDC), 12 Union Road, Cambridge CB2 
1EZ, UK; fax: +44(0) 1223 336 033; email: deposit@ccdc.cam.ac.uk]. 
 
5.5.4 Pharmacology methods   
Materials and Methods: 
Wild type Zebrafish (Danio rerio) were maintained as per the procedure mentioned in 
Zebrafish Book. 25 The studies on anxiety assessment using the light/dark box paradigm were 
conducted based on a published protocol. 21 Drug administration was carried out by a 
procedure reported earlier. 26 Clonidine, an anxiolytic agent was used as a positive control to 
ascertain the validity of the experiments. 
 
5.5.5 Molecular docking studies: 
Till date, the complete crystal structure of the transient receptor potential vanilloid subtype 
1 (TRPV1) is not reported. However, many homology modeling studies were performed to 
explore the three dimensional structure of TRPV1. 24, 27 As reported earlier by Autiero et al., 
the modeling of transmembrane regions (that accommodates capsaicin binding site) of rat 
TRPV1 (rTRPV1) was performed using MODELLER programme. 28, 29 This model was used 
to perform molecular docking studies of the synthesised molecules by using Surflex-dock 
module implemented in the Sybyl program. 30 
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5.5.5.1 Homology modeling of catalytic site of rat TRPV1 receptor: The homology 
modeling of catalytic site of rTRPV1 was performed as discussed earlier. 27 The amino acid 
sequence of rTRPV1 (Uniprot ID: O35433) was obtained from Uniprot protein 
knowledgebase. The sequence corresponding to the six transmembrane regions (431-690) 
were considered and a three dimensional model was developed based on the procedure 
reported previously. 27 As TRPV1 belongs to class of voltage gated ion channels, the 
sequence similarity of its transmembrane regions is compared with the other ion gated 
channels under the same class. With the criteria of the presence of crystallized structure 
voltage-dependent shaker family K+ channel (PDB ID: 2R9R) was chosen as a template. 31 
The sequences are aligned by CLUSTALW2 algorithm as specified in the reference article 
(Figure 16). MODELLER version 9.11 28, 29 was used to build homology models based on 
specified sequence alignment and template.  
Homology modeling studies: The homology model of rTRPV1 containing all the six 
transmembrane regions was developed by employing the procedure as reported earlier by Lee 
et al. 27 The sequence alignment of rTRPV1 with 2R9R was copied as represented in figure 1. 
and 10 models of the rTRPV1 were developed using MODELLER 9v11. 28, 29 The best model 
with lowest PDF score was selected for further optimization and validation studies. The 
stereochemical quality of the final model was assessed by PDBsum, a web based tool for 
Procheck. 32 The homology model shows 85% residues are in most favoured region which 
could be taken as a parameter to perform further docking studies (Figure 17).  
 
Figure 16: Sequence alignment of rat TRPV1 and the voltage dependent shaker family K+ channel (PDBID: 
2R9R). 
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The final monomer model was duplicated in to four entries and superimposed with the 
reported tetramer model. 24 The generated tetramer model was energy minimized with the 
gradient convergence of 0.05 K. cal. To check the clashes from atom contacts, the quality of 
tetramer structure was evaluated through MolProbity.33 Molprobity evaluates the 
stereochemical quality of the model and provides a clash score from the all atom (including 
Hydrogen) contact analysis. The final model has a very least clash score of 1.49 and occupies 
99th percentile for PDB structures with same resolution. Molprobity also determines 
backbone bonds and angles, for which our tetramer model has none of them. The molprobity 
results are detailed in Table 3.  
 
 
Figure 17. Ramachandran plot of the φ–ψ distribution of rTRPV1 produced by PROCHECK after homology 
modeling. Red [A, B, L] most favored regions; Dark yellow [a, b, l, p] additional allowed regions; Light yellow 
[~ a, ~ b, ~ l, ~ p] generously allowed regions; white areas are disallowed regions. 
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Table 3: Molprobity results of the rTRPV1 homology model 
Model Favored
a
 Outliers
b
 Cβ-dev.
c
 Bond length
d
 Bond angle
e
 Clash-score
f
 Percentile
g
 
rTRPV1 85.6 1.07 10 0 0 1.5 99 
 
a percentage of residues in favourable region of Ramachandran plot 
b percentage of residues in disallowed region of Ramachandran plot. 
c Number of residues with Cβ deviation ≥0.25 Å 
d Percentage of backbone bond lengths >4 standard deviations from the accepted values  
e Percentage of backbone bond angles >4 standard deviations from the accepted value 
f Number of atomic clashes per 1000 atoms. 
g Percentile rank compared to structures in the PDB within a similar resolution range 
  
5.5.5.2 Docking Procedure:  
The docking analysis of molecules was performed using Sybyl, version 1.3 implemented from 
Tripos package. Synthesized compounds were sketched in 3D format using build module and 
minimized with gradient convergence of 0.001 K. cal. The protomol (grid) for molecular 
docking was generated from the centroid of aminoacids accomodating vanilloid (capsaicin) 
binding site. Molecules were docked using Surflex-dock module. 30 The ligands were kept 
flexible by producing the ring conformations and by penalizing non-polar amide bond 
conformations, whereas the receptor was kept rigid throughout the docking studies. The most 
stable pose was selected and the ligand interactions with target protein were determined. 
Based on the mutational studies at the vanilloid binding site- LEU515, THR550, SER512, 
TYR511, MET547, PHE543 and LYS571 are reported as key amino acid residues. 27 From 
the centroid of these aminoacids to 10 angstroms surrounding was considered as a grid for 
docking studies. To understand the binding mode of the compounds synthesized, molecular 
docking studies were performed using Surflex-Dock (SFXC) programme of Sybyl software. 
The docking results for capsaicin were in close relevance with the earlier reported docking 
studies. As reported earlier the vanillyl moiety of capsaicin occupied the deep pocket 
surrounded by Tyr511, Tyr565, and Lys571. 27 The hydrophobic tail region occupied the 
upper hydrophobic pocket formed at the interface of two monomers Figure 3. Using the 
above docking parameters we performed a docking study of synthesized compounds 23, 
24and 35.  
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2. Design, synthesis & pharmacological evolution of dehydro shikimate 
analogues as potential antitubercular agents 
1H & 13C NMR of Selected Compounds: 
Ethyl -3-cyano-2-oxo-1,2,5,6,7,8,9,10-octahydrocycloocta[b]pyridine-4-carboxylate 
(11d): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CD3OD) 
N
H
O
COOC2H5
NC
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2-Oxo-1,2,5,6,7,8,9,10-octahydrocycloocta[b]pyridine-4-carboxylic acid (12d): 
 
1H NMR (300 MHz, DMSO-d6) 
 
 
13C NMR (75 MHz, CD3OD) 
 
N
H
O
COOH
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Methyl 2-chloro-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine-4-carboxylate (13d): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
NCl
COOCH2CH3
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2-Chloro-4 (methoxycarbonyl)-6-methylpyridine-1-oxides (14a): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
 
NCl
COOCH3
O
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2-Chloro-4-(methoxycarbonyl)-6,7-dihydro-5H-cyclopenta[b]pyridine1-oxide(14b): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
 
 
NCl
COOCH3
O
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2-Chloro-4-(methoxycarbonyl)-5,6,7,8-tetrahydroquinoline-1-oxide (14c): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
NCl
COOCH3
O
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2-Chloro-4-(methoxycarbonyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine1-oxide 
(14d): 
 
1H NMR (300 MHz, CDCl3) 
 
 
13C NMR (75 MHz, CDCl3) 
NCl
COOCH3
O
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Methyl-1-hydroxy-6-methyl-2-oxo-1,2-dihydropyridine-4-carboxylate (15a): 
 
1H NMR (300 MHz, CDCl3) 
 
 
13C NMR (75 MHz, CDCl3) 
NO
COOCH3
OH
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4-Carboxy-2-ethoxy-6,7-dihydro-5H-cyclopenta[b]pyridine-1-oxide (15b): 
1H NMR  (300 Hz, CD3OD) 
 
 
13C NMR (75 MHz, CD3OD) 
 
 
NO
COOH
O
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4-Carboxy-2-ethoxy-5,6,7,8-tetrahydroquinoline-1-oxide (15c): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
 
NO
COOH
O
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1-Hydroxy-6-methyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid (16): 
 
1H NMR  (300 Hz, CD3OD) 
 
 
13C NMR (75 MHz, CD3OD) 
 
NO
COOH
OH
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1-Hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b] pyridine-4-carboxylic acid (17a):
 
1H NMR  (300 Hz, CD3OD) 
 
 
13C NMR  (75 Hz, CD3OD) 
1-Hydroxy-2-oxo-1,2,5,6,7,8-hexahydroquinoline-4-carboxylic acid (7b): 
NO
COOH
OH
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1H NMR  (300 Hz, CD3OD) 
 
13C NMR  (75 Hz, CD3OD) 
NO
COOH
OH
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4-Carboxy-2,6-diethoxypyridine-1-oxide (20): 
 
1H NMR  (300 Hz, CD3OD) 
 
13C NMR  (75 Hz, CD3OD) 
 
N
COOH
O O
O
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2-Chloro-4 (ethoxycarbonyl quinoline 1-oxides (25a): 
 
1H NMR (300 MHz, CDCl3) 
 
 
13C NMR (75 MHz, CDCl3) 
N Cl
COOC2H5
O
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2-Chloro-4 (ethoxycarbonyl)-6-methylquinoline 1-oxides (25b):   
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
 
N
COOC2H5
Cl
O
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2-Chloro-6-fluoro-4-(ethoxycarbonyl) quinoline 1-oxide (25c): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
 
N
COOCH2CH3
Cl
F
O
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1-Hydroxy-2-oxo-1,2-dihydroquinoline-4-carboxylic acid (26a): 
1H NMR  (300 Hz, CD3OD) 
 
13C NMR  (75 Hz, CD3OD) 
 
 
NO
OH
COOH
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1-Hydroxy-6-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylic acid (26b): 
 
1H NMR  (300 Hz, CD3OD) 
 
 
13C NMR  (75 Hz, CD3OD) 
N
COOH
O
OH
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6-Fluoro-1-hydroxy-2-oxo-1,2-dihydroquinoline-4-carboxylic acid (26c): 
 
1H NMR  (300 Hz, CD3OD) 
 
13C NMR  (75 Hz, CD3OD) 
 
N
COOH
O
F
OH
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Methyl -7-chloro-2,4-dioxo-1-propyl-1,2,3,4-tetrahydropyrido [2, 3-d] pyrimidine-5-
carboxylate (36a): 
 
1H NMR (300 MHz, DMSO-d6) 
 
 
13C NMR (75 MHz, DMSO-d6) 
 
HN
N NO
COOCH3
Cl
O
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7-Chloro-2,4-dioxo-1-propyl-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-5-carboxylic 
acid (36c): 
 
1H NMR (300 MHz, DMSO-d6) 
 
 
13C NMR (75 MHz, DMSO-d6) 
HN
N NO
COOH
Cl
O
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3. Novel synthesis of 2H-benzo[b][1,4]oxazines via sequential C-N and C-O 
bond formation in single pot & their pharmacological evaluation as anti 
inflammatory agents 
Methyl 2-(allyloxy)-5-formyl-6-hydroxy-2H-benzo[b][1,4]oxazine-3-carboxylate (68):                       
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
N
O
COOCH3HO
CHO
O
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Methyl 5-formyl-6-hydroxy-2-(1H-indol-3-yl)-2H-benzo[b][1,4]oxazine-3-carboxylate 
(69):  
                                                 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
N
O
COOCH3HO
CHO
NH
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Methyl 5-formyl-6-hydroxy-2-phenyl-2H-benzo[b][1,4]oxazine-3-carboxylate (70):   
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
 
 
N
O
COOCH3HO
CHO
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Methyl 5-formyl-6-hydroxy-2-(4-methoxyphenyl)-2H-benzo[b][1,4]oxazine-3-
carboxylate (71):  
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
 
N
O
COOCH3HO
CHO
OCH3
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Methyl 2-(4-(benzyloxy) phenyl)-5-formyl-6-hydroxy-2H-benzo[b][1,4]oxazine-3- 
carboxylate (72):  
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
 
N
O
COOCH3HO
CHO
O
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Methyl2-(4-(benzoyloxy)phenyl)-5-formyl-6-hydroxy-2H-benzo[b][1,4]oxazine-3-
carboxylate (73): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
N
O
COOCH3HO
CHO
O
O
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Methyl2-(4-bromophenyl)-5-formyl-6-hydroxy-2H-benzo[b][1,4]oxazine-3-carboxylate 
(74): 
1H NMR (300 MHz, CDCl3)                                                                             
13C NMR (75 MHz, CDCl3) 
 
N
O
COOCH3HO
CHO
Br
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Methyl2-(4-fluorophenyl)-5-formyl-6-hydroxy-2H-benzo[b][1,4]oxazine-3 carboxylate 
(75):  
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
 
N
O
COOCH3HO
CHO
F
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Ethyl 5-formyl-6-hydroxy-2-p-tolyl-2H-benzo[b][1,4]oxazine-3-carboxylate (76):   
1H NMR (300 MHz, CDCl3) 
 
DMSO-d6                             
 
1H NMR (300 MHz, DMSO-d6) 
 
 
N
O
COOCH2CH3HO
CHO
CH3
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DMSO-d6 + D2O 
 
 
 
13C NMR (75 MHz, CDCl3) 
 
N
O
COOCH2CH3HO
CHO
CH3
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Methyl 5-formyl-6-hydroxy-2-(naphthalen-2-yl)-2H-benzo[b][1,4]oxazine-3 carboxylate 
(77) 
1H NMR (300 MHz, CDCl3) 
            
    
13C NMR (75 MHz, CDCl3) 
 
N
O
COOCH3HO
CHO
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Ethyl 5-formyl-6-hydroxy-2-(4-isopropylphenyl)-2H-benzo[b][1,4]oxazine-3-carboxylate 
(78): 
1H NMR (300 MHz, CDCl3) 
 
1h after the addition of CD3OD         
 
1H NMR (300 MHz, CD3OD) 
N
O
COOCH2CH3HO
CHO
N
O
COOCH2CH3HO
CHO
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72 h after the addition of CD3OD: 
                                                                                        1H NMR (300 MHz, CD3OD)    
            
    
13C NMR (75 MHz, CDCl3) 
 
N
O
COOCH2CH3HO
CHO
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Ethyl 2-(di phenyl methylene amino)-3-(4-isopropylphenyl)propanoate (81):    
                                                                                        1H NMR (300 MHz, CDCl3) 
 
Ethyl 2-amino-3-(4-isopropylphenyl)propanoate (82): 
1H NMR (300 MHz, CDCl3) 
H2N COOC2H5
N COOC2H5
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4. Synthesis & pharmacological evolution of substituted phenyl oxazoles as 
a novel class  of  LSD1 inhibitors with anti-proliferative properties  
Methyl 4-(methylthio)-2-(3-nitrobenzamido)butanoate (2a): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
O
N
H
S
O
OCH3
NO2
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(S)-Methyl 2-(2-chloro-5-nitrobenzamido)-4-(methylthio)butanoate (2b): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
 
O
N
H
S
O
OCH3
NO2
Cl
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(S)-Methyl 2-(3,5-dinitrobenzamido)-4-(methylthio)butanoate (2c): 
 
1H NMR (300 MHz, CDCl3) 
 
 
13C NMR (75 MHz, CDCl3) 
O
N
H
S
O
OCH3
NO2
O2N
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4-(Methylthio)-2-(3-nitrobenzamido)butanoic acid  (3a):  
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
O
N
H
S
O
OH
NO2
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(S)-2-(2-chloro-5-nitrobenzamido)-4-(methylthio)butanoic acid  (3b): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
O
N
H
S
O
OH
NO2
Cl
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(S)-2-(3, 5-dinitrobenzamido)-4-(methylthio)butanoic acid (3c): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
O
N
H
S
O
OH
NO2
O2N
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N-(1-(Methylthio)-4-oxopentan-3-yl)-3-nitrobenzamide(4a): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
O
N
H
S
O
NO2
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(S)-2-chloro-N-(1-(methylthio)-4-oxopentan-3-yl)-5-nitrobenzamide (4b): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
 
O
N
H
S
O
NO2
Cl
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(S)-N-(1-(methylthio)-4-oxopentan-3-yl)-3,5-dinitrobenzamide (4c): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
 
O
N
H
S
O
NO2
O2N
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5-Methyl-4-(2-(methylthio) ethyl)-2-(3-nitrophenyl) oxazole (5a): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
 
NO2
N
O
S
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2-(2-chloro-5-nitrophenyl)-5-methyl-4-(2-(methyl thio) ethyl oxazole (5b): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
NO2
N
O
S
Cl
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2-(3,5-dinitrophenyl)-5-methyl-4-(2-(methylthio) ethyl) oxazole (5c): 
 
1H NMR (300 MHz, CDCl3) 
 
 
13C NMR (75 MHz, CDCl3) 
 
N
O
S
O2N
NO2
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3-(5-Methyl-4-(2-(methylthio) ethyl) oxazol-2-yl) aniline (6a): 
 
1H NMR (300 MHz, CDCl3) 
 
 
13C NMR (75 MHz, CDCl3) 
NH2
N
O
S
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4-chloro-3-(5-methyl-4-(2-(methylthio)ethyl)oxazol-2-yl)aniline (6b): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
NH2
N
O
S
Cl
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5-(5-methyl-4-(2-(methyl thio) ethyl) oxazol-2-yl)benzene-1,3-diamine (6c): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
N
O
S
H2N
NH2
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(E)-tert-butyl (tert-butoxycarbonylamino) (3-(5-methyl-4-(2-(methylthio)ethyl)oxazol-2-
yl)phenylamino)methylenecarbamate ( 8a): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
NH
N
O
S
N
H
N
O
O
O
O
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(E)-tert-butyl (tert-butoxycarbonylamino)(4-chloro-3-(5-methyl-4-(2-(methylthio) ethyl) 
oxazol-2-yl) phenyl amino) methylene carbamate (8b): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
NH
N
O
S
Cl
N
H
N
O
O
O
O
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Tert-butyl (5-(5-methyl-4-(2-(methylthio) ethyl) oxazol-2-yl)-1, 3-phenylene) bis 
(azanediyl) bis ((tert-butoxycarbonylamino) methan-1-yl-1-ylidene) dicarbamate (8c): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
NH
N
O
S
N
H
N
O
O
O
O
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O
O
O O
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1-(3-(5-Methyl-4-(2-(methylthio) ethyl) oxazol-2-yl) phenyl) guanidine (9a): 
 
1H NMR (300 MHz, CD3OD) 
 
 
13C NMR (75 MHz, CD3OD) 
NH
N
O
S
NH
H2N
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1-(4-chloro-3-(5-methyl-4-(2-(methyl thio) ethyl) oxazol-2-yl) phenyl) guanidine (9b): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
NH
N
O
S
Cl
NH
H2N
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1,1'-(5-(5-methyl-4-(2-(methylthio) ethyl) oxazol-2-yl)-1,3-phenylene) diguanidine (9c): 
 
1H NMR (300 MHz, CD3OD) 
 
13C NMR (75 MHz, CD3OD) 
 
NH
N
O
S
NH
H2N
HN
HN NH2
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N-(4-chloro-3-(5-methyl-4-(2-(methylthio) ethyl) oxazol-2-yl) phenyl) acetamide (10): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
 
HN
N
O
S
Cl
O
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N-(4-chloro-3-(5-methyl-4-(2-(methylthio)ethyl)oxazol-2-yl)phenyl)benzamide (11): 
 
1H NMR (300 MHz, CDCl3) 
 
 
13C NMR (75 MHz, CDCl3) 
Cl
N
O
HN
S
O
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N-(4-chloro-3-(5-methyl-4-(2-(methylthio)ethyl)oxazol-2-yl)phenyl)methanesulfonamide 
(12) 
 
1H NMR (300 MHz, CDCl3) 
 
  
13C NMR (75 MHz, CDCl3) 
Cl
N
O
HN
S
S
O
O
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N-(4-chloro-3-(5-methyl-4-(2-(methyl thio) ethyl) oxazol-2-yl) phenyl)-4-methyl benzene 
sulphonamide (13): 
 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
Cl
NH
N
O
S
S
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O
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4-chloro-N,N-dimethyl-3-(5-methyl-4-(2-(methylthio) ethyl)oxazol-2-yl)aniline (14): 
 
1H NMR (300 MHz, CDCl3) 
 
 
13C NMR (75 MHz, CDCl3) 
Cl
N
N
O
S
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5. Design, synthesis & pharmacological evolution of isovanillin derived 
Isoxazolidines as potential vanilloid receptors 
2-Allyl-3-(tert-butyldimethylsilyloxy)-4-methoxybenzaldehyde (9a): 
 
1H NMR (400 MHz, CDCl3) 
 
 
13CNMR (100 MHz, CDCl3)  
OTBS
H3CO
O
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(E)-Ethyl 4-(2-(tert-butyldimethylsilyloxy)-6-formyl-3-methoxyphenyl)but-2-enoate (9b): 
 
1H NMR (400 MHz, CDCl3) 
13C NMR (100 MHz, CDCl3) 
 
OTBS
H3CO
O
O
OCH2CH3
6. Appendix                                                 NMR Spectra – Chapter 5 
B.Dulla, PhD thesis (2013) Page 220 
 
(E)-2-allyl-3-(tert-butyldimethylsilyloxy)-4-methoxybenzaldehyde oxime (10): 
 
1H NMR (400 MHz, CDCl3) 
 
 
13C NMR (100 MHz, CDCl3) 
OTBS
H3CO
N
OH
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5-(tert-butyldimethylsilyloxy)-3-(2-ethoxy-2-oxoethyl)-6-methoxy-3,4 dihydro isoquinoline 
2-oxide (11): 
 
1H NMR (400 MHz, CDCl3) 
 
13C NMR (100 MHz, CDCl3) 
OTBS
H3CO
N
COOC2H5
O
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Ethyl7-(tert-butyldimethylsilyloxy)-5-(2-ethoxy-2-oxoethyl)-8-methoxy-2,5,6,10b-
tetrahydro-1H-isoxazolo [3,2-a] isoquinoline-1-carboxylate (12a): 
 
1H NMR (400 MHz, CDCl3) 
 
13C NMR (100 MHz, CDCl3) 
OTBS
H3CO
N
COOC2H5
O
C2H5OOC
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Expansion of 1D NOE of Compound 12a 
Ethyl7-(tert-butyldimethylsilyloxy)-5-(2-ethoxy-2-oxoethyl)-8-methoxy-2,5,6,10b-
tetrahydro-1H-isoxazolo[3,2-a] isoquinoline-2-carboxylate (12b): 
 
1H NMR (400 MHz, CDCl3) 
OTBS
H3CO
N
COOC2H5
O
COOC2H5
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13C NMR (100 MHz, CDCl3) 
 
1H- 1H COSY NMR of Compound 12b 
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Ethyl-2-(5-(tert-butyldimethylsilyloxy)-6-methoxy-1,2,3,4 tetrahydroisoquinolin-3-yl) 
acetate (13): 
 
1H NMR (400 MHz, CDCl3)   
 
                                                                                                 13C NMR (100 MHz, CDCl3)  
 
 
OTBS
H3CO
NH
COOC2H5
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(E)-N-(2-allyl-3-(tert-butyldimethylsilyloxy)-4-methoxybenzylidene)-2-cyanoaniline 
oxide (15e): 
 
1H NMR (400 MHz, CDCl3) 
 
 
13C NMR (100 MHz, CDCl3)  
 
N
OTBS
H3CO
O
CN
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5-(tert-butyldimethylsilyloxy)-6-methoxy-1-phenyl-3,3a,4,8b-tetrahydro-1H-indeno [1, 
2-c] isoxazole (16a): 
 
1H NMR (400 MHz, CDCl3) 
 
13C NMR (100 MHz, CDCl3) 
ON
OTBS
H3CO
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1H- 1H COSY NMR of Compound 16a 
 
 
 
 
 
 
 
 
 
Expansion of 1H- 1H COSY NMR of Compound 16a 
 
 
 
 
ON
OTBS
H3CO
Ha
Hb
Ha: 5.36 ppm Hc: 4.18 ppm
Hb: 3.45 ppm Hd: 3.89 ppmHc
Hd
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5-(tert-butyldimethylsilyloxy)-6-methoxy-1-p-tolyl-3,3a,4,8b-tetrahydro-1H-indeno[1,2-
c] isoxazole (16b): 
 
1H NMR (400 MHz, CDCl3) 
 
13C NMR (100 MHz, CDCl3) 
ON
OTBS
H3CO
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4-(5-(tert-butyldimethylsilyloxy)-6-methoxy-3,3a,4,8b-tetrahydro-1H-indeno [1,2-c] 
isoxazol-1-yl) benzonitrile (16c): 
 
                                                                                                 1H NMR (400 MHz, CDCl3) 
                                                                    
13C NMR (100 MHz, CDCl3) 
 
ON
OTBS
H3CO
NC
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N-(3-(5-(tert-butyldimethylsilyloxy)-6-methoxy-3,3a,4,8b-tetrahydro-1H-indeno[1,2-c] 
isoxazol-1-yl) phenyl) methanesulfonamide (16d): 
 
                           
1H NMR (400 MHz, CDCl3) 
 
                                                                                                  13 CNMR (100 MHz, CDCl3)  
 
ON
OTBS
H3CO
NH
S
O
O
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Ethyl 5-(tert-butyldimethylsilyloxy)-6-methoxy-1-phenyl-3,3a,4,8b-tetrahydro-1H-
indeno[1,2-c]isoxazole-3-carboxylate (16f): 
 
 
1H NMR (400 MHz, CDCl3) 
 
 
13C NMR (100 MHz, CDCl3) 
ON
OTBS
H3CO
COOC2H5
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2D NOESY of Compound 16f 
 
  
 
 
 
 
 
 
 
 
 
 
Compound 16f 
 
 
 
Compound 17a: 
ON
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H3CO
COOCH2CH3
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-ve noe between
Ha and Hb
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1H NMR (400 MHz, CDCl3) 
 
 
13C NMR (100 MHz, CDCl3) 
 
ON
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1H- 1H COSY NMR of Compound 17a 
 
 
 
 
 
 
 
 
 
 
Expansion of 1H- 1H COSY NMR of Compound 17a 
 
 
 
 
ON
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Ha: 5.12 ppm Hc: 3.09 ppm
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Compound (17b): 
 
1H NMR (400 MHz, CDCl3) 
 
 
                                                                                                        13C NMR (100 MHz, CDCl3) 
 
 
ON
OTBS
H3CO
6. Appendix                                                 NMR Spectra – Chapter 5 
B.Dulla, PhD thesis (2013) Page 239 
 
Compound (17c):  
 
                                                                                                1H NMR (400 MHz, CDCl3) 
 
 
                                                                                                 13 C NMR (100 MHz, CDCl3) 
 
 
 
ON
OTBS
H3CO
NC
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Compound (17d): 
 
1H NMR (400 MHz, CDCl3) 
 
 
13C NMR (100 MHz, CDCl3) 
 
ON
OTBS
H3CO
NHSO2CH3
6. Appendix                                                 NMR Spectra – Chapter 5 
B.Dulla, PhD thesis (2013) Page 241 
 
Ethyl 5-(tert-butyldimethylsilyloxy)-1-(2-cyanophenylamino)-3-hydroxy-6-methoxy-1,2, 
3,4-tetrahydronaphthalene-2-carboxylate (18): 
  
1H NMR (400 MHz, CDCl3) 
    
13 C NMR (100 MHz, CDCl3) CDCl3) 
 
OTBS
H3CO
O
OCH2CH3
OH
NH
CN
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                  NMR Spectra 
2D NOESY of Compound 18 
 
 
 
Expansion of 2D NOESY of Compound 
– Chapter 5 
Page 242 
 
 
 
10 
6. Appendix                                                 NMR Spectra – Chapter 5 
B.Dulla, PhD thesis (2013) Page 243 
 
Ethyl2-(4-(tert-butyldimethylsilyloxy)-5-methoxy-1-(phenylamino)-2,3-dihydro-1H-
inden-2-yl)-2-hydroxyacetate (19): 
 
1H NMR (400 MHz, CDCl3) 
 
13C NMR (100 MHz, CDCl3) 
 
NH
OTBS
H3CO
OH
COOEt
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(5-(tert-butyldimethylsilyloxy)-3-hydroxy-6-methoxy-1-phenyl-1,3a,4,8b-
tetrahydroindeno[1,2-b]pyrrol-2(3H)-one (20): 
 
                                                                                                1H NMR (400 MHz, CDCl3) 
 
 
                                                                                                   13C NMR (100 MHz, CDCl3) 
 
N
OTBS
H3CO
OH
O
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(4-(tert-butyldimethylsilyloxy)-5-methoxy-1-(phenylamino)-2,3-dihydro-1H-inden-2-yl) 
methanol (21): 
 
1H NMR (400 MHz, CDCl3) 
 
 
13C NMR (100 MHz, CDCl3) 
NH
OTBS
H3CO
OH
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7-(tert-butyldimethylsilyloxy)-8-methoxy-1-phenyl-5,5a,6,10b-tetrahydro-1H-
indeno[1,2-e][1,4]oxazepin-2(3H)-one (22): 
 
1H NMR (400 MHz, CDCl3) 
 
13C NMR (100 MHz, CDCl3) 
N
OTBS
H3CO
O
O
6. Appendix                                                 NMR Spectra – Chapter 5 
B.Dulla, PhD thesis (2013) Page 247 
 
4-(5-Hydroxy-6-methoxy-3,3a,4,8b-tetrahydro-1H-indeno[1,2-c] isoxazol-1-yl) 
benzonitrile (23): 
 
1H NMR (400 MHz, CDCl3) 
 
13C NMR (100 MHz, CDCl3) 
ON
OH
H3CO
NC
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 (24): 
 
 
O
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Compound 26:  
 
1H NMR (400 MHz, CDCl3) 
 
13C NMR (100 MHz, CDCl3) 
 
ON
OH
H3CO
CN
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Ethyl 5-hydroxy-6-methoxy-1-phenyl-3,3a,4,8b-tetrahydro-1H-indeno[1,2-c]isoxazole-3-
carboxylate (30): 
 
1H NMR (400 MHz, CDCl3) 
13C NMR (100 MHz, CDCl3) 
ON
OH
H3CO
COOC2H5
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7-hydroxy-8-methoxy-1-phenyl-5,5a,6,10b-tetrahydro-1H-indeno[1,2-e][1,4]oxazepin-
2(3H)-one (34): 
 
1H NMR (400 MHz, CDCl3) 
 
 
13C NMR (100 MHz, CDCl3) 
N
OH
H3CO
O
O
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3,5-dihydroxy-6-methoxy-1-phenyl-1,3a,4,8b-tetrahydroindeno[1,2-b]pyrrol-2(3H)-one 
(35): 
 
1H NMR (400 MHz, CDCl3) 
                                                      
13C NMR (100 MHz, CDCl3)     
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